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Abstract 
A large body of evidence supports the role of activated stromal cells in the 
persistence of inflammation. The switch from resting to pathogenic stroma 
appears to be associated with the development of tertiary lymphoid organs 
(TLOs) within sites of chronic inflammation. However little is known about the 
immunological function of the stromal component.  
We utilised a murine model of inducible TLO formation in inflamed salivary 
glands to investigate the role of activated stromal cells characterised by the 
expression of gp38 and FAP during TLO development. 
We demonstrated that during inflammation, stroma-derived ICOSL engages 
ICOS on T cells, necessary for the release of lymphotoxin α and consequent 
TLO formation. Whilst dissecting the role of stromal cells in this context, we 
demonstrate that gp38 expression is required for the upregulation of adhesion 
molecules involved in cell clustering. Depletion of gp38+FAP+ stromal cells 
led to a significant reduction in lymphoid chemokine production, a decreased 
number of infiltrating lymphocytes and severely compromised TLO formation. 
Collectively, we provide evidence that activated stromal cells express FAP, 
provide co-stimulatory signals, and are necessary for the establishment of 
viral-induced TLOs, highlighting a potential novel therapeutic target in TLO-
associated autoimmune diseases. 
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Chapter 1 
INTRODUCTION 
1.1. Tertiary Lymphoid Organs and their association 
with inflammation 
Chronic inflammation is defined by two major features: persistence of the 
inflammatory process and specificity for certain anatomical sites (Buckley, 
2011). Stromal cells (non-hematopoetic, non-epitelial and non-endothelial 
cells), namely fibroblasts, have been suggested as key effector cells involved 
in the switch to persistence of inflammation (Buckley et al., 2004, Barone et 
al., 2012). An important feature of inflammation is the communication between 
stromal and immune cells. In chronically inflamed tissue, activated tissue 
resident fibroblasts are essential in the homing of immune cells and 
maintaining inflammatory infiltrates through the inappropriate secretion of 
survival and retentive factors, therefore controlling recruitment, activation and 
survival of leukocytes (Pitzalis et al., 2014, Naylor et al., 2013).  
Under specific conditions, infiltrating immune cells can cluster in chronically 
inflamed tissue and form structures histologically similar to secondary 
lymphoid organs (SLOs) (Pitzalis et al., 2014). Whilst the “specific conditions” 
required are still largely unknown, it has been shown that such structures are 
also functionally active and have been termed tertiary lymphoid organs 
(TLOs), ectopic lymphoid structures (ELSs) or tertiary lymphoid tissues (TLTs) 
(Pitzalis et al., 2014).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
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The transient formation of TLOs has been shown in physiological settings, for 
example, the development of gut isolated lymphoid follicles (ILFs), in 
response to intestinal flora, characterised by single B cell follicles surrounded 
by dendritic cells (DCs) (Buckley et al., 2015, Eberl and Lochner, 2009, 
Lochner et al., 2011, Constantinovits et al., 2012). ILFs seem to be critical for 
immune homeostasis and normal colonic mucosal regeneration (Buckley et 
al., 2015, Eberl and Lochner, 2009, Lochner et al., 2011, Constantinovits et 
al., 2012). Nevertheless, TLO formation is more classically associated with 
chronic inflammation, autoimmunity and cancer (Buckley et al., 2015). Within 
the target tissues of human autoimmune diseases, TLO formation is 
associated with the persistence of the inflammatory process and associated 
with a poor prognosis (Theander et al., 2011, Weyand and Goronzy, 2003). 
The events that generate highly specialized SLOs and transient hubs for 
autoreactive cell proliferation in TLOs are different. Still, in both settings the 
resident mesenchyme undergoes critical changes, in SLOs during embryonic 
life and postnatally in TLOs (Buckley et al., 2015).  
 
1.1.1. Development of TLOs 
Numerous signals have been implicated in the formation of TLO structures 
and these have been extensively investigated. Lymphotoxin (LT) signals are 
directly associated with increased expression of chemokine (C-X-C motif) 
ligand 13 (CXCL13), chemokine (C-C motif) ligand 19 (CCL19) and ligand 21 
(CCL21), leading for example to recruitment of cluster of differentiation (CD) 
62L+ T cells (Pitzalis et al., 2014). Lymphotoxin-alpha (LTα)-deficiency results 
in a complete absence of peripheral lymphoid organs (De Togni et al., 1994) 
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and combined overexpression of Lta and Ltb results in more prominent TLO 
formation compared with Lta overexpression on its own (Drayton et al., 2003). 
Even though there is still ongoing research on this aspect, some cell subsets 
have been implicated in TLO formation, including: lymphoid tissue inducer 
cells (LTi cells), lymphoid tissue organizer cells (LTo cells), interleukin (IL)-17 
secreting CD4+ T cells and T follicular helper cells (TFH cells) (Pitzalis et al., 
2014). 
CD4+CD3-CD45+ LTi cells accumulate in the early stages of lymph node 
development, and their recruitment, activation and survival is controlled by 
expression of CXCL13, receptor activator of NF-B ligand (RANKL) and (IL-7) 
(Pitzalis et al., 2014). These cells also express C-X-C chemokine receptor 
type 5 (CXCR5) and IL-7 receptor and interact with LTo cells, characterised 
by expression of vascular adhesion molecule 1 (VCAM-1), intercellular 
adhesion molecule 1 (ICAM-1) and the mucosal addressin cell adhesion 
molecule 1 (MAdCAM-1) (Mebius et al., 1997, Yoshida et al., 1999, Honda et 
al., 2001, Finke et al., 2002). Such cascade of events leads to homeostatic 
chemokine release and vascularization by high endothelial venules (HEVs) 
(Pitzalis et al., 2014). In the context of chronic inflammation-associated 
ectopic lymphoid structures, it has been hypothesized that stromal cells found 
in close relationship with TLOs may acquire lymphoid tissue organizer-like 
properties (Sato et al., 2011, Rangel-Moreno et al., 2007). 
The hypothesis that, in chronic inflammation, stromal cells acquire lymphoid 
tissue organizer-like properties is consistent with the observation that adoptive 
transfer of adult LTi cells into Cxcr5-/- mice induces the formation of intestinal 
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lymphoid tissues and suggests that innate adult cells also play a role in TLO 
formation (Schmutz et al., 2009). Ectopic tissues that develop in response to 
transgenic overexpression of the Il7 gene also require LTi cells (Meier et al., 
2007). Adult LTi cells express the transcriptional regulator retinoic acid 
receptor-related orphan receptor-t (RORt) and can produce IL-17, a cytokine 
that is characteristic of group 3 innate lymphoid cells (ILCs) (Artis and Spits, 
2015, Pitt et al., 2012, Powell et al., 2012). IL-17 and T helper (TH) 17 cells 
have now been linked with ectopic lymphoid neogenesis, where they have a 
role in chronic allograft rejection, experimental autoimmune encephalomyelitis 
(EAE) and the development of inducible bronchus-associated lymphoid tissue 
(iBALT) (Deteix et al., 2010, Peters et al., 2011, Rangel-Moreno et al., 2011).  
 
1.1.2. Cell organization within TLOs 
In human pathology, TLOs are mainly characterised by the presence of 
organised B cell follicles, which can develop into germinal centres (GC) in the 
presence of activation-induced cytidine deaminase (AID) enzyme, B cell class 
switching and follicular dendritic cells network (FDCs) (Buckley et al., 2015, 
Neyt et al., 2012). In some pathologies, such as Sjögren’s syndrome (SS) and 
primary biliary cirrhosis, T cell areas and stromal cell networks can also be 
identified (Buckley et al., 2015, Link et al., 2011). 
Within TLOs, vessels resembling HEVs can also be found in the T cell zones 
and their expression of peripheral node addressins (PNAd) or MECA79 allows 
the recruitment of C-C chemokine receptor type (CCR)7+L-selectin+ T cells 
(Buckley et al., 2015, Neyt et al., 2012). 
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1.1.3. Function of TLOs 
TLOs share a number of structural and functional features with SLOs, 
including: lymphocyte segregation into distinct areas (T and B cell area), local 
differentiation of FDCs and modification of the endothelium with acquisition of 
a plump morphology and expression of lymphoid associated addressins 
(PNAD or MAdCAM). Ectopic expression of lymphoid or homeostatic 
chemokines, known to regulate naïve and central memory T margination, 
CCL21 and CCL19, and B cell organization in follicles and germinal centres, 
CXCL13 and CXCL12, are also found in TLOs (Manzo et al., 2007, Amft et al., 
2001). 
During chronic inflammation, TLOs with different degrees of organization have 
been identified in the target tissues of human autoimmune disease, such as 
pancreas (Type I diabetes), thyroid tissue (during both Hashimoto’s thyroiditis 
and, to a lesser extent, Grave’s disease), in the thymus (during myasthenia 
gravis) and in the salivary glands (during SS) (Pitzalis et al., 2014). 
The preferential formation of TLOs in association with epithelial tissue has 
been noted, with the exception of the formation in the synovial membrane (a 
non-epithelial organ) of patients affected by rheumatoid arthritis (RA). TLOs 
formation has been reported less frequently in the inflamed synovial 
membrane, being observed in only 25% of patients with RA (Klimiuk et al., 
1997). Despite the observation that these structures have an inferior degree of 
organization as compared to the thyroid or the salivary glands they are 
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functional and capable of producing pathogenic disease specific 
autoantibodies (Klimiuk et al., 1997).  
Allograft rejection and response to foreign bodies (metal hip implants) can 
also give rise to the formation of local TLOs and is believed to be involved in 
the pathogenic process of rejection (Mittal et al., 2013). 
TLOs have also been reported to transiently form at sites of localized 
infections, influenza and microbacterial infections (Moyron-Quiroz et al., 2004, 
GeurtsvanKessel et al., 2009, Neyt et al., 2012, Carragher et al., 2008). 
During infection, TLOs are believed to represent an attempt to favour 
lymphocyte interaction at the site of antigen presentation without the need to 
spread the response to the SLOs (Buckley et al., 2015). Formal proof of this 
latter functional aspect has not yet been provided (Maglione et al., 2007, 
Buckley et al., 2015). 
TLO formation during inflammation is associated with a higher degree of 
humoral immune response and in some cases systemic involvement, 
suggesting that TLOs might provide an additional hub (as compared to SLOs) 
for the production of autoantibodies. The direct correlation between TLO 
detection and certain clinical features, such as levels of immunoglobulins, 
systemic detection of autoantibodies, diffuse disease manifestations and 
tissue damage has been largely supported (Klimiuk et al., 1997, Weyand et 
al., 1998, Takemura et al., 2001, Weyand and Goronzy, 2003, Bugatti et al., 
2005). 
The products of TLO organization such as elevated serum levels of CXCL13 
in the blood of patients with RA have also been associated with increased 
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disease severity and persistence of subclinical synovitis (Bugatti et al., 2012). 
TLO detection has been more recently considered a prognostic biomarker, for 
example in SS TLO detection (that occurs in up to 25% of the patients) has 
been associated with an increased risk of non-Hodgkin B cell lymphoma of the 
salivary glands (Theander et al., 2011). 
 
1.1.4. Cytokines and chemokines in TLO formation 
In chronic inflammatory settings, the pathways involved in TLO formation 
overlap with some of the pathways necessary for lymphoid organogenesis 
(Neyt et al., 2012). 
Persistent antigenic stimulation and the presence of pro-inflammatory 
cytokines enable the conversion of stromal cells into a lymphoid tissue-like 
cell phenotype (Peduto et al., 2009). This lymphoid-like stroma is one of the 
key drivers of TLO organization (Barone et al., 2015b) and expression of 
cytokines (LTα, LTβ) and lymphoid chemokines (CXCL13, CCL21, CCL19, 
CXCL12) are linked to organisation of lymphoid aggregates and TLO size, 
with high expression of LTα, CXCL13 and CCL19 associated with highly 
organized follicles (Aloisi and Pujol-Borrell, 2006, Amft et al., 2001, Barone et 
al., 2005, Manzo et al., 2005). 
While, CXCL13 and CCL21 control the segregation of B and T cells (Luther et 
al., 2002, Luther et al., 2000), CCL19 and CXCL12 promote lymphocyte 
infiltration and the positioning of DCs, B cells and plasma cells within these 
aggregates (Luther et al., 2002). Overexpression of CXCL13 led to TLO 
formation characterised by highly organised T and B cell zones, presence of 
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DCs and a BP3+ stromal cell network (Luther et al., 2000, Link et al., 2011). 
Similarly, rat insulin promoter (RIP)-CCL21 Tg mice and ectopic expression of 
CCL21 in thyroid presented similar organised lymphoid structures to that 
observed in RIP-CXCL13 Tg mice (Chen et al., 2002, Fan et al., 2000, Lira, 
2005), however overexpression of CCL21 under the RIP promoter alone does 
not seem sufficient to induce full lymphoid neogenesis since no formation of 
CD35+ FDCs or CXCL13+ cells were observed (Chen et al., 2002, Fan et al., 
2000). Indeed, there is some evidence that CXCL13 and LTβ expression 
might predict the development of ectopic GCs in patients with RA and SS 
(Barone et al., 2005, Carragher et al., 2008, Weyand and Goronzy, 2003, 
Salomonsson et al., 2002). 
On the other hand, in the absence or blockade of CXCL13, CXCR5, CCR7 or 
LTα TLO formation is critically impaired (Furtado et al., 2007, Gatumu et al., 
2009, Grabner et al., 2009, Rangel-Moreno et al., 2007, Wengner et al., 2007, 
Winter et al., 2010). 
Ruddle’s work has elucidated the importance of LTα in TLO formation (Sacca 
et al., 1995, Kratz et al., 1996). Overexpression of LTα under the control of 
RIP resulted in TLO formation in both pancreas and kidney with segregated T 
and B cell areas, FDCs, stromal cell networks and HEVs (Sacca et al., 1995, 
Kratz et al., 1996). Moreover, LTα signalling through tumour necrosis factor 
receptor I (TNFRI) seemed to trigger TLO formation by inducing the secretion 
of CXCL13 and CCL21 (Sacca et al., 1995, Kratz et al., 1996). LTα seems to 
be crucial for the development of stromal cells into FDCs and HEVs (Drayton 
et al., 2003).  
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Mice deficient in IL-7, a homeostatic cytokine, completely lack lymph nodes 
and Peyer’s Patches (PP), since it seems to be directly involved in T cell 
survival and activation of LTi cells (von Freeden-Jeffry et al., 1995). 
 
1.1.5. Stromal cells in TLO formation and function 
The function of the Immune system relies on numerous interactions between 
various cell populations. Stroma is an important tissue that consists of 
extracellular matrix (ECM) and mesenchymal cells, known for providing a 
structural scaffold and conduit for blood and lymphatic vessels, nerves and 
leukocytes (Barone et al., 2012). Non-hematopoietic stromal cells are 
recognized as essential counterparts to leucocytes in pathogenicity, as they 
have been shown to be actively involved in migration, activation and survival 
of immune cells in persistent inflammatory conditions (Barone et al., 2012, 
Chang et al., 2002). 
Fibroblasts, traditionally described by their spindle shaped morphology and 
their ability to adhere to tissue culture plastic in vitro, are the most abundant 
cells of the stroma. Fibroblasts comprise a heterogeneous population of 
distinctly differentiated cell types involved in the synthesis of ECM and form 
the structural framework characteristic of stromal tissue (Chang et al., 2002, 
Tarin and Croft, 1969, Filer et al., 2007). Fibroblasts are thought to 
differentiate from at least three sources: primary mesenchyme, local epithelial-
mesenchymal transition, and bone marrow-derived precursors (Bucala et al., 
1994, Chesney and Bucala, 1997, Iwano et al., 2002, Kalluri and Neilson, 
2003, Parsonage et al., 2005). Fibroblasts are responsible for the synthesis of 
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ECM components, type I, III and V collagen and fibronectin, and also proteins 
involved in the formation (type IV collagen and laminin) and degradation of 
basement membrane (metalloproteinases) (Marinkovich et al., 1993, Sabatelli 
et al., 2001, Tomita et al., 2002). 
A particular type of stromal cells termed FDCs represents a critical cell type in 
SLOs and provides antigen presentation and survival factors to the expanding 
B cell population leading to affinity maturation (Aguzzi et al., 2014). The 
maturation of FDCs is dependent on the expression of tumour necrosis factor 
alpha (TNFα) and LT by GC B cells. Mice deficient in the expression of TNFα 
and LT or of their downstream signalling pathways are unable to develop 
FDCs and GCs within their SLOs (Allen and Cyster, 2008, Tumanov et al., 
2004). In the periphery, FDC networks form only within large TLOs, when a 
critical number of B cells are clustered in the tissue (Barone et al., 2005). 
Interestingly, not all tissues, and only a minority of TLOs form mature FDC 
networks (Pitzalis et al., 2014), suggesting that while the stimulus for FDC 
differentiation might be the same as that observed in SLO (TNF and LT), it 
is possible that the threshold required for FDC formation in peripheral tissue is 
higher than in SLOs. Whether the phenotype, origin and function of FDCs in 
peripheral TLOs are different from FDCs in SLO is not known, neither is their 
dependency on LT or LT-inducing pathways. 
The biology of stromal cells is still to be fully understood but it appears that 
activated fibroblasts are intimately involved in the switch from resolving to 
persistent inflammation, for example providing retention and survival factors to 
infiltrating immune cells within non-lymphoid organs (Buckley, 2011, Filer et 
al., 2007, Naylor et al., 2013). 
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Pathogenic stromal cells have also been associated with the formation of 
TLOs and their persistence is thought to be mainly related to an inappropriate 
expression by activated stromal cells of adhesion molecules, survival factors, 
such as B-cell activating factor (BAFF) and IL-7, inflammatory and 
homeostatic chemokines and their receptors, CXCL8, CCL5, CXCL1, 
CXCL12, CXCL13, CCL19, CCL21 and CCL17 (Mueller and Germain, 2009, 
Buckley, 2011). Consistent with these observations, under appropriate 
conditions, tissue resident fibroblasts can mature into glycoprotein 38 (gp38)+ 
lymphoid-like stromal cells both in cancer and inflammation (Peduto et al., 
2009).  
A model of stromal cell differentiation is illustrated in Figure 1.1. 
 
 
 
Cupedo et al. have shown that intradermal injections of new-born lymph node-
derived cells into adult mice induce the ectopic formation of lymph node-like 
Figure 1.1. Model of stromal cell differentiation during the switch to chronic 
inflammation. In response to inflammatory cytokines, resident stromal cells produce 
inflammatory chemokines upon stimuli. In cases of chronic inflammation stromal cells acquire a 
lymphoid-like phenotype and taking part in the formation of TLOs (Buckley et al., 2015). 
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structures and highly organised TLOs, in which lymphoid-like stromal cells 
recruit host lymphocytes (Cupedo et al., 2004). In the absence of additional 
stimuli, injections of adult lymph node-derived cells did not result in formation 
of such structures (Cupedo et al., 2004). Similarly, Suematsu and Watanabe 
demonstrated that transplantation of stromal cells under the kidney capsule of 
adult mice was sufficient to trigger the development of lymphoid-like tissue  
(Suematsu and Watanabe, 2004).  
Recently, Pikor and colleagues have demonstrated that a cytokine- and 
chemokine-producing stromal cell network forms in the meninges of mice 
during EAE and that LTαβ-expressing TH17 cells and LTβR expressed by 
local resident cells, cooperate in the development of TLOs (Pikor et al., 2015). 
In summary, there is compelling evidence that the cross talk between both the 
stromal and hematopoietic compartments is necessary for the development of 
TLOs (Nishikawa et al., 2000, Mebius, 2007, Buckley et al., 2015, Peters et 
al., 2011, Pikor et al., 2015). 
The following sections will describe a co-stimulatory pathway in the context of 
inflammation and autoimmunity and two distinct proteins discretely expressed 
by stromal cells in resting conditions but overexpressed during inflammation. 
These proteins, namely gp38/podoplanin (PDPN) and fibroblast activation 
protein α (FAP) can not only be used to identify subtypes of stromal cells but 
are also believed to play a functional role in chronic inflammation. 
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1.2. Co-stimulatory molecules  
Antigens processed by antigen-presenting cells (APCs) are presented to the T 
cell receptor (TCR) via major histocompatibility complex (MHC); consequently 
this interaction induces T cell activation. However, T cell activation, tolerance 
and secretion of most lymphokines only occur upon the engagement of 
signals in addition to TCR stimulation. Indeed, other co-stimulatory molecules, 
often described as ‘signal 2’, expressed by both T cells and APCs are 
necessary to further enhance T cell activation and proliferation (Stuart and 
Racke, 2002, Sharpe and Freeman, 2002). Some of the most studied and 
better understood co-stimulatory molecules include CD80 (B7-1), CD86 (B7-
2), CD28, cytotoxic T lymphocyte antigen 4 (CTLA-4), inducible co-stimulator 
(ICOS), programmed death 1 (PD-1), OX40 and CD40 ligand (CD40L) (Stuart 
and Racke, 2002). CD28, ICOS, OX40 and CD40L promote T cell activation; 
from these molecules, CD28, which binds to CD80 and CD86, targets naïve T 
cells and leads to IL-2 secretion (Hara and Fu, 1985, Lucas et al., 1995, 
Lenschow et al., 1996, Thompson et al., 1989). On the other hand, CTLA-4 
and PD-1 are considered inhibitory co-stimulatory molecules (Stuart and 
Racke, 2002). 
It is now believed that such co-stimulatory pathways have a critical role in 
regulating and shaping the character and magnitude of T cell responses (Ford 
et al., 2014). Therefore, co-stimulatory pathways have become a very 
appealing therapeutic target in cancer and in autoimmune diseases since its 
manipulation can determine the fate of immune responses (Stuart and Racke, 
2002).  
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1.2.1. ICOS and ICOSL 
1.2.1.1 Structure  
ICOS was firstly described by Hutloff et al. as a member of the CD28 family 
(Hutloff et al., 1999). Immunoprecipitation of ICOS revealed a disulphide-
linked homodimer in which each chain has a molecular weight that can vary 
between 27K and 29K, depending on post-translational modifications (Hutloff 
et al., 1999). ICOS is a type-I transmembrane molecule, containing an 
immunoglobulin V-like domain, a transmembrane region of 23 amino acids 
and a cytoplasmic tail of 35 amino acids. It also comprises a Src-homology 
SH2 and SH3 domains that can be found in intracellular signal-transducing 
proteins (Stuart and Racke, 2002). This predicted structure unveiled an 
obvious structural resemblance with CD28 and CTLA-4 (Hutloff et al., 1999). 
The amino acid sequence shows 39% similarity with CD28 and CTLA-4 in 
which the residue allegedly responsible for the disulphide bridge formed 
between the two dimers in CD28 and CTLA-4 is also conserved in the ICOS 
molecule (Hutloff et al., 1999, Brunet et al., 1987). However, the motif 
MYPPPY that is critically involved in binding of CD28 and CTLA-4 to their 
receptors B7-1 and B7-2 is not present in ICOS, suggesting that ICOS binds 
to a different receptor (Hutloff et al., 1999, Peach et al., 1994, Truneh et al., 
1996). Human and murine ICOS amino acid sequences have 69% homology 
(Yoshinaga et al., 1999). 
ICOS ligand (ICOSL or B7RP-1), a member of the B7 family, is the only 
known ligand to ICOS and it does not bind proteins in the CD28 or CTLA-4 co-
stimulatory pathways (Swallow et al., 1999, Yoshinaga et al., 2000). There is 
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41% amino acid identity between the human and murine ICOSL (Yoshinaga et 
al., 2000). The protein consists of 302 amino acids and structurally resembles 
CD80 and CD86, being a type I transmembrane protein with a main domain, 
two extracellular immunoglobulin-like domains, a transmembrane region and a 
short cytoplasmic tail (Yoshinaga et al., 2000, Swallow et al., 1999). 
 
1.2.1.2. Expression 
ICOS was firstly identified in activated CD4+ and CD8+ T cells (post TCR 
stimulation) and proliferation induced by ICOS signalling was equally as 
potent to that observed after CD28 co-stimulation (Hutloff et al., 1999).  ICOS 
is also expressed by TH1, TH2, TH17, TFH and regulatory T cells (Treg) (Tan et 
al., 2008, Nakae et al., 2007, Burmeister et al., 2008, Akiba et al., 2005). 
In contrast to CD28 co-stimulation, ICOS signalling does not induce secretion 
of IL-2 but rather promotes upregulation of IL-4, IL-5, interferon gamma (IFN-
γ), TNFα and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
and greatly induces IL-10 secretion, a cytokine implicated in the generation of 
B cell memory and plasma cells (Hutloff et al., 1999, van Berkel and 
Oosterwegel, 2006). But similarly to CD28 signalling, ICOS also induces 
expression of CD69, CD25, CD71 and CD40L (CD154 or TRAP), the latter 
being a key ligand for CD40 on B cells and a prerequisite for isotype switching 
and synthesis of immunoglobulin (Ig) G, IgA and IgE by B cells  (Hutloff et al., 
1999, Kroczek et al., 1994).  
Indeed, with monoclonal antibodies F44 (anti-ICOS) and 9.3 (anti-CD28), it 
was shown that co-stimulation via either ICOS or CD28 enhances Ig 
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production by B cells (Hutloff et al., 1999). High levels of ICOS expression 
were found in 50 to 70% of tonsillar T cells which were mostly all also positive 
for CD28 and CD45RO, an established marker for memory T cells (Hutloff et 
al., 1999, Merkenschlager and Beverley, 1989). ICOS upregulation was also 
described in most T cells post stimulation with PMA and ionomycin 
(Yoshinaga et al., 2000). Interestingly, nearly all TFH cells in GC, a subset of T 
cells that has been appointed as the main T cell help towards Ig production by 
GC B cells via induction of AID synthesis and class switch recombination, are 
also ICOS+ (Hutloff et al., 1999, Dong et al., 2001a, Kim et al., 2005, Liang et 
al., 2002). 
Accordingly, in tonsil, ICOS+ T cells are mainly confined to GCs, particularly 
in the apical light zone where TFH cells can be found and where the 
differentiation from B cells into antibody-secreting plasma cells takes place 
(Hutloff et al., 1999, Vinuesa et al., 2005). Studies in ICOS deficient mice 
have unveiled a key role for TFH cells in B cell differentiation and generation of 
autoantibodies in autoimmune disease (Hu et al., 2009). 
In mice, ICOS expression was first described in T cells, isolated from the 
inguinal lymph nodes of mice with inflammatory colitis, however only low 
levels of ICOS are detectable in the lymph nodes of resting mice (Yoshinaga 
et al., 1999, Boirivant et al., 1998). ICOS is also expressed de novo in 
activated CD4+ and CD8+ T cells (Yoshinaga et al., 1999). In aged mice, a 
significant number of splenic ICOS+ T cells also express high levels of CD44 
and low levels of expression of CD45RB, consistent with the observation of 
ICOS expression in human memory T cells (Yoshinaga et al., 1999). 
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ICOSL was first found in B cells in murine lymph nodes, both in resting 
conditions and experimental colitis, in the splenic marginal zone, PP follicles 
and thymus medulla (Yoshinaga et al., 1999). 
ICOSL is also expressed by other murine APCs such as macrophages, DCs 
and also by their human counterparts (Yoshinaga et al., 1999, Yoshinaga et 
al., 2000). In vitro treatment with TNFα efficiently induced ICOSL upregulation 
in B cells and monocytes but it had the opposite effect on DCs (Yoshinaga et 
al., 2000). 
An in vitro study has shown that ICOSL expression in fibroblasts can be 
induced by TNFα stimulation via activation of the NF-B/Rel family of 
transcription factors, known to control immune and inflammatory responses 
and to be persistently activated in chronic inflammatory conditions (Swallow et 
al., 1999, Pena and Penate, 2002, Satoh et al., 2007, Oikonomidou et al., 
2006, Greetham et al., 2007). Accordingly, in mice challenged with 
lypopolyssacharide (LPS), non-lymphoid tissues upregulated ICOSL (Swallow 
et al., 1999). However to date, there is no in vivo evidence of ICOSL 
expression in non-hematopoietic cells. In the absence of ICOS or ICOSL, T 
cell development is not affected and GC structure was normal in resting mice. 
However, due to abrogated levels of IL-2 secreted by ICOS-/- CD4+ T cells, T 
cell activation and proliferation are defective in ICOS knockout mice (KO) 
(Dong et al., 2001a, Wong et al., 2003, Dong et al., 2001b).  
In PP, part of the mucosa-associated lymphoid tissues (MALT), the ICOS 
pathway has been implicated in their development, but not organogenesis. 
ICOS deficiency does not affect the number of GC in PP nor their cellular 
composition; however, ICOS-/- PP are significantly smaller and lack peanut 
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agglutinin binding (PNA)+ B cells (Iiyama et al., 2003). Similar findings were 
observed in the ICOS-YF mice, a knock-in strain with a modified 
cytoplasmatic tail that prevents ICOS binding to phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) (Gigoux et al., 2009). Consistent with previous 
findings, the proportion of IgA- and IgG-producing cells, but not IgM, was 
significantly reduced in ICOS-/- (Iiyama et al., 2003). In summary, ICOS 
signalling seems to be necessary for the complete establishment of GC within 
PP. 
 
1.2.1.3. Regulation 
At a transcriptional level, ICOS is regulated by molecules downstream of TCR 
engagement, such as Src kinase Fyn and MAP kinase ERK (Zamoyska et al., 
2003, Tan et al., 2006). Src kinase Fyn seems to be directly involved in 
NFATc2 dephosphorylation and nuclear translocation, which can as well as 
ERK bind to the ICOS promoter (Simpson et al., 2010). Accordingly, in vitro 
upregulation of ICOS by mouse T cells is regulated by NFATc2 and ERK (Tan 
et al., 2006, Simpson et al., 2010).  
Post-transcriptionally, ICOS expression can also be suppressed by Roquin, a 
member of the RING-type ubiquitin ligase family, which induces degradation 
of Icos mRNA when micro RNA-101 binds to the 3’ UTR region (Vinuesa et 
al., 2005, Yu et al., 2007). In fact, Yu and colleagues have described the 
development of a lupus-like autoimmune condition in sanroque mice. This 
transgenic strain contains a mutation of one amino acid substitution of the 
Roquin ROQ domain leading to ICOS overexpression by T cells, increased 
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development of GC, uncontrolled differentiation of TFH cells and IL-21 
production (Yu et al., 2007, Vinuesa et al., 2005, Bertossi et al., 2011). Roquin 
knockout mice are lethal shortly after birth (Bertossi et al., 2011). 
In TH1 cells, ICOS upregulation is dependent on the interaction of NFATc2 
and T-bet to its promoter; furthermore, IRF4 has also been shown to bind to 
the ICOS promoter in Tregs (Tan et al., 2008, Zheng et al., 2009). On the 
other hand, ICOS expression levels in Th2 cells rely on the binding of NFATc2 
and GATA-3 to the untranslated 3’ UTR region of Icos mRNA (Tan et al., 
2008, Simpson et al., 2010). 
ICOS signalling occurs through PI3K, which contains a catalytic p85 and 
regulatory p50α subunits (Fos et al., 2008). This particular form of PI3K shows 
greater lipid kinase activity leading to increased production of 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and consequently elevated 
levels of the kinase Akt (Fos et al., 2008, Parry et al., 2003). Akt is one of the 
most important signalling molecules downstream of PIP3 and has been 
described as a key modulator of T cell survival and proliferation factors 
(Fruman, 2004, Song et al., 2005). Indeed, in a study from 2009, PP of ICOS-
YF mice were challenged, resulting in decreased secretion of Th2- and TFH-
derived cytokines (IL-4, IL-10, IL-21), compromised generation and 
development of TFH and impaired GC formation and Ab class switching 
(Gigoux et al., 2009) 
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1.2.1.4. Role in T cell responses 
The ICOS-ICOSL interaction provides a further co-stimulatory signal to 
previously activated T cells (Swallow et al., 1999, Yoshinaga et al., 1999). 
When ICOS-/- mice are immunized with an adjuvant known to induce a TH2 
response the draining lymph nodes from the knockout mouse are smaller, 
total cell number is reduced to half of what is observed in the controls and IL-4 
production is completely abrogated in ICOS-/- T cells, suggesting defective 
TH2 function and cytokine production (Dong et al., 2001b).  
Accordingly, immunization with sheep red blood cells, which induces splenic T 
cell dependent immune response, leads to the formation of smaller GC in an 
ICOS-/- spleen and reduced numbers of IgG1+ GC, a process dependent on 
TH2 cytokines (Dong et al., 2001a, Dong et al., 2001b). However, ICOS was 
absolutely necessary to mount a secondary immune response post re-
challenge (Dong et al., 2001b). Using the same immunization model in ICOS 
deficient or in anti-ICOSL treated mice, Akiba et al. reported defective 
development of CXCR5+ TFH cells in both spleen and lymph nodes in the 
absence of ICOS (Akiba et al., 2005). 
Similarly, ICOSL-/- showed defective T cell-dependent but not T cell-
independent immune responses, and Ag-specific B cells were absent from the 
follicles of immunized spleens (Wong et al., 2003). Such impairment in GC 
formation has been hypothesized to be due to the lack of communication 
between T and B cells in the T cell areas of SLOs via ICOS-ICOSL signalling, 
which prevents B cell migration to form GCs (Wong et al., 2003). More 
recently, Hamel and colleagues have shown that in the spleen of ICOSL-/- 
mice post immunization the percentage of GC is drastically reduced and so 
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are the numbers of CD4+CXCR5+CD62LlowPD-1+ICOS+ cells (Hamel et al., 
2014). 
ICOS is now considered a key player in TFH development in both mice and 
humans and in fact ICOS-/- mice have fewer TFH cells and these secrete 
reduced levels of IL-21, IL-23R and transcription factor c-Maf; all of which are 
involved in TFH development (Warnatz et al., 2006, Akiba et al., 2005, 
Bossaller et al., 2006, Bauquet et al., 2009, Simpson et al., 2010). 
In a mouse model of airway hyper-responsiveness, ICOS deficient lungs are 
infiltrated by similar numbers of leukocytes and re-challenged cells from 
draining lymph nodes secreted reduced levels of two relevant TH2 cytokines, 
IL-13 and IL-4 (Dong et al., 2001a). 
 
1.2.1.5. Role in autoimmunity 
ICOS-/- mice are significantly more susceptible to EAE, with greater infiltrates 
found in the brain and higher numbers of CD4+ T cells in general and 
increased proportion of interferon gamma (IFNγ)-producing T cells (Dong et 
al., 2001a, Sporici et al., 2001). It has been suggested that the deficient 
production of IL-13 by ICOS-/- T cells could explain the increased severity of 
murine EAE model as disease was ameliorated by administration of IL-13 in 
rats (Dong et al., 2001a, Cash et al., 1994). In this particular study, ICOS 
seems to act as a negative regulator of inflammation. In contrast, Sporici and 
colleagues described an improvement in clinical score when EAE mice with 
ongoing disease were treated with ICOS-Fc (Sporici et al., 2001). ICOSL 
expression was detected in B cells and macrophages from the brain of EAE 
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mice (Sporici et al., 2001).  ICOS-Ig treatment decreased production of IL-10 
and IFN-γ and increased T cell apoptosis (Sporici et al., 2001). 
Iwai et al. first explored the potential role of ICOS-ICOSL interaction in the 
pathogenesis of autoimmune arthritis by using an anti-ICOSL monoclonal Ab 
in a model of collagen-induced arthritis (CIA) (Iwai et al., 2002). ICOS was 
found in T cells and ICOSL in B cells, macrophages and DCs of inflamed 
synovium (Iwai et al., 2002). Both therapeutic and prophylactic blockade 
resulted in significant improvement in disease clinical score, lymphocytic 
infiltration, hyperplasia of the synovium and bone erosion (Iwai et al., 2002). 
Furthermore, blockade of this interaction significantly reduced the expression 
of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 (Iwai et al., 2002). 
Another study investigated the role of ICOS in the pathogenesis of arthritis 
and found that ICOS deficient mice are protected against CIA, with normal 
histological appearance and greatly reduced anti-collagen IgM and IgG2a 
levels (Nurieva, 2005). Hu et al. used the same approach of ICOS-ICOSL 
blockade and reported reduced numbers of TFH and GC B cells in CIA and 
mouse model of systemic lupus erythematosus (SLE) (Hu et al., 2009). 
Moreover, recently Hamel et al. described that ICOSL deficient mice are fully 
protected when challenged with the cartilage proteoglycan-induced arthritis 
model and confirmed other reported results such as suppression of pro-
inflammatory cytokines IL-17, IL-10, IL-4, IL-21 and IFN-γ (Hamel et al., 
2014). Furthermore, a similar degree of protection towards the development of 
arthritis was found when the same group generated B-cell specific ICOSL-/- 
chimeric mice (Hamel et al., 2014). In patients with RA, analysis of both 
peripheral blood and synovial fibroblasts revealed increased expression of 
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ICOS by T cells from patients when compared to controls (Okamoto et al., 
2003). SLE patients with active disease also have higher numbers of ICOS+ T 
cells and following in vitro ICOS co-stimulation T cells from SLE patients 
produced elevated amounts of IFN-γ (Kawamoto et al., 2006). 
Anti-ICOS treatment was reported to suppress the development of 
autoimmune diabetes in non-obese diabetic (NOD) mice, following treatment 
administered to 1 and 10 weeks old mice (Nanji et al., 2006, Ansari et al., 
2008). NOD mice spontaneously develop type 1 (insulin dependent) diabetes, 
an autoimmune T cell mediated response that characterized by leukocyte 
infiltration around the insulin-producing islet  cells ultimately leading to its 
destruction (Atkinson and Leiter, 1999, Delovitch and Singh, 1997). T cell 
accumulation can also be found in the salivary glands of NOD mice, in lesions 
that resemble SS lesions (Bach, 1994), but the effect of ICOS blockade in 
NOD salivary glands has not yet been reported. 
In the context of TLO formation, this pathway has not been extensively 
explored but a recent study has reported that blockade of ICOS/ICOSL 
interaction suppresses the formation of ectopic lymphoid structures in a 
mouse model of atherosclerotic plaque development (Clement et al., 2015). 
The observed impairment was associated with a disrupted TFH - GC B cell 
axis as TFH cells are known to express ICOS and were shown to take an 
active part in GC reaction within TLOs in diseased arteries (Clement et al., 
2015). 
ICOS null patients showed similar phenotypes of defective class switch 
recombination and GC formation as these patients fail to generate and 
maintain memory B cells and Ig levels (McAdam et al., 2001, Mak et al., 2003, 
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Grimbacher et al., 2003). Takahashi et al. reported the case of two ICOS 
deficient siblings with reduced numbers of CD4+ central and effector memory 
T cells, the latter one associated with deficient upregulation of T-bet, GATA3 
and MAF and retinoic acid-related orphan nuclear hormone receptor (RORC) 
(Takahashi et al., 2009). Confirming what was reported in ICOS deficient 
mice, CD4+ T cells from these patients also secrete poor levels of TH1, TH2 
and TH17 cytokines (Takahashi et al., 2009).  
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1.3. Stromal cell markers 
1.3.1. Podoplanin 
Gp38 or PDPN was first identified by Farr et al. (1992) in stromal cells of 
peripheral lymphoid tissues (Farr et al., 1992), including in lymph node 
fibroblastic reticular cells (FRCs). More than 2 decades later, despite the fact 
that gp38 expression has been extensively characterised in tissues under 
both physiological and pathological conditions little is known regarding its 
functional role under these conditions.  
 
1.3.1.1. Structure 
Gp38 is a 43 kDa protein and its cloning revealed a 172 amino acid sequence. 
Gp38 is a mucin-like type I integral membrane protein with an extracellular 
domain rich in both Serine and Threonine residues, containing one potential 
N-linked glycosylation site, six O-glycosylation sites, a hydrophobic 
transmembrane domain, and a short cytoplasmic domain with two potential 
phosphorylation sites (Farr et al., 1992, Breiteneder-Geleff et al., 1997). 
 
1.3.1.2. Regulation 
Gp38 is expressed by lymphatic endothelial cells (LEC), where it is regulated 
by the gene Prox1 (Hong et al., 2002). IL-3 stimulation has been shown to 
control expression of both Prox-1 and gp38 in LEC (Groger et al., 2004, 
Schacht et al., 2003). Moreover, IL-3 presence in culture medium induces 
differentiation of blood endothelial cells (BEC) into LEC (Groger et al., 2004). 
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The authors further demonstrated that TNFα/IFN-γ stimulation also induces 
gp38 expression by LEC via IL-3 (Groger et al., 2004). 
Splenic expression of gp38 is dependent on the secretion of LTα by B cells 
(Ngo et al., 2001). Also in spleen, lack of gp38 expression has been linked to 
impaired B and T cell segregation (Bekiaris et al., 2007). 
The only known endogenous ligand/receptor for gp38 is CLEC-2, a C-type 
lectin receptor mainly expressed on platelets and DCs (Acton et al., 2014, 
Astarita et al., 2015), and its expression is linked to thrombosis, tumour 
metastasis and lymphangiogenesis (Suzuki-Inoue et al., 2010). 
 
1.3.1.3. Expression during embryogenesis and post natal 
During embryonic development the expression of gp38 is both temporally and 
spatially regulated. At embryonic day 9 (E9) gp38 is expressed in the central 
nervous system and foregut (Rishi et al., 1995, Ramirez et al., 2003). At 
embryonic day 11 (E11.0) its expression becomes restricted to lymphatic 
progenitor cells (Schacht et al., 2003) and by E11.5 and E12.5, gp38 can be 
found in all endothelial cells of the cardinal vein (Schacht et al., 2003). 
Moreover, gp38 expression has also been reported in the developing 
mammalian kidney, choroid plexus, intestine and oesophagus (Williams et al., 
1996). 
After birth, gp38 expression is mostly confined to lymphatic endothelial cells 
and FRCs in lymphoid organs, mature osteoblasts, alveolar type I cells and a 
subset of F4/80+ macrophages induced following zymosan peritonitis 
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(Wetterwald et al., 1996, Williams et al., 1996, Hou et al., 2010, Schacht et al., 
2003).  
 
Both in the lymph node and spleen, gp38+ cells are found in close association 
with T cell areas (Farr et al., 1992). Kidney glomerular epithelial cells, also 
called podocytes, express gp38 on their cell membranes and epithelial cells of 
Bowman’s capsule express gp38 at the luminal surfaces in resting conditions 
but not in a model of rat nephropathy (Breiteneder-Geleff et al., 1997). 
Gp38 is also expressed by LEC, myoepithelial cells, subsets of lymphocytes 
and DCs (Yazisiz et al., 2013, Jones et al., 2015). 
 
1.3.1.4. Expression in pathology 
Gp38 expression is induced in epidermal carcinogenesis and in skin 
remodelling processes (Scholl et al., 1999). 
In the salivary glands of patients with SS, both gp38 expression in 
myoepithelial cells and the number of lymphatic vessels are increased 
(Yazisiz et al., 2013). In healthy synovium gp38 seems to be absent but it is 
significantly upregulated in the inflamed synovium of patients with RA (Ekwall 
et al., 2011). Concordantly, cultured synoviocytes upregulate gp38 after 
stimulation with IL-1β, TNF-α and transforming growth factor beta (TGF-β) 
(Ekwall et al., 2011). 
In EAE, TH17 cells that express gp38 were directly involved in the formation of 
ectopic lymphoid aggregates in the central nervous system, particularly with 
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the microarchitecture of T cell zones (Peters et al., 2011, Link et al., 2011, 
Pitzalis et al., 2014, Pikor et al., 2015).  
 
1.3.1.5. Function of gp38 
PDPN-/- mice die at birth due to respiratory failure and exhibit critical defects in 
lymphatic structure and organization, but not in blood vessel formation. Such 
defects include impaired lymphatic transport, lymphedema and dilation of 
lymphatic vessels (Bertozzi et al., 2010, Finney et al., 2012, Herzog et al., 
2013, Suzuki-Inoue et al., 2010, Watson et al., 2010, Schacht et al., 2003). In 
contrast to what happens in Prox1-/- mice in which lymphatic vasculature is 
completely absent, the fact that lymphatic vessels still develop in PDPN-/- mice 
suggests that gp38 might play a role at later stages of lymphatic development 
(Schacht et al., 2003).  
Similarly, CLEC-2 deficient mice are also lethal at neonatal stages with blood-
filled lymphatic vessels and edema, both features also observed in PDPN-/- 
mice (Suzuki-Inoue et al., 2010). Interaction between gp38+ lymphatic 
endothelial cells with circulating platelets during development has been shown 
to be critical for the separation of the lymphatic from the blood system (Uhrin 
et al., 2010). In lymph nodes, gp38+ FRCs engage with CLEC-2+ DCs 
inducing cytoskeleton rearrangement and consequent cell migration across 
stromal cell areas (Acton et al., 2012). Indeed, gp38-CLEC-2 interaction plays 
a role in lymph node elasticity and the absence of CLEC-2 in DCs significantly 
affects lymph node expansion (Acton et al., 2014). 
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Interaction between gp38 and CLEC-2 is also crucial for HEVs integrity where 
lack of gp38 leads to bleeding in draining lymph nodes post immunization 
(Herzog et al., 2013). 
Gp38 has been identified in actin-rich microvilli and plasma membrane 
projections and its overexpression in keratinocyte cell lines leads to the 
acquisition of a fibroblast-like shape with augmented membrane projections, 
reorganization of the cytoskeleton and increased motility (Scholl et al., 1999, 
Schacht et al., 2003). In lymphatic endothelial cells, gp38 expression is 
associated with increased cell adhesion and migration (Schacht et al., 2003). 
Peduto et al. have demonstrated that, during inflammation, resting stromal 
cells can upregulate the expression of gp38 and acquire a lymphoid-like 
phenotype similar to that observed in secondary lymphoid organs (Peduto et 
al., 2009). Gp38+ cells also upregulate the expression of adhesion molecules, 
chemokines and cytokines known to be involved in the development of 
lymphoid tissues (Mebius, 2003, Kratz et al., 1996).  
 
1.3.2. Fibroblast Activation Protein   
FAP, also designated as seprase, was first described as a cell surface antigen 
identified with a monoclonal antibody F19 on human astrocytoma and 
sarcoma cell lines in vitro (Garin-Chesa et al., 1990a). Fap gene expression is 
significantly upregulated in activated fibroblasts in pathological sites, including 
cancer, wound healing and chronic inflammation (Dolznig et al., 2005, Bauer 
et al., 2006, Garin-Chesa et al., 1990b, Levy et al., 1999). Evidence of FAP 
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expression in these tissues may indicate possible roles in promoting cell 
invasion.  
 
1.3.2.1. Structure 
FAP is a 170kDa type II cell surface glycoprotein and a member of the serine 
prolyl oligopeptidase family, a type-II transmembrane serine protease 
(Ayoama and Chen, 1990, Niedermeyer et al., 1997, Garin-Chesa et al., 
1990b, Scanlan et al., 1994). Homodimerisation is essential for its catalytic 
function and the active FAP enzyme is constituted of two 97kDa subunits on 
the cell surface (Pineiro-Sanchez et al., 1997). It comprises of a large COOH- 
terminal extracellular domain, a hydrophobic transmembrane segment of 
approximately 20 amino acids and a short cytoplasmic domain only 6 amino 
acids long. The extra cellular domain contains six potential N-glycosylation 
sites, 13 cysteine residues and three highly conserved catalytic domains 
(Scanlan et al., 1994). FAP belongs to the family of post prolyl amino 
peptidases that are capable of cleaving the –NH2-terminal dipeptides from 
polypeptides with penultimate L-prolines or L-alanines (Niedermeyer et al., 
1998). 
In both human and mouse, the Fap gene is located on chromosome 2 and 
89% of the amino acid sequence is shared between the two species, including 
a perfectly conserved catalytic domain (Niedermeyer et al., 1998). FAP shares 
61% nucleotide sequence and 48% amino acid sequence identity with its 
closest family member dipeptidyl-peptidase IV (DPPIV), a T cell activation 
antigen, also known as CD26 (Mathew et al., 1995, Park et al., 1999, Scanlan 
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et al., 1994). FAP and DPPIV have an identical domain structure and 70% 
identity in the catalytic domain (Goldstein et al., 1997, Pineiro-Sanchez et al., 
1997, Scanlan et al., 1994). Under physiological conditions, DPPIV is 
ubiquitously expressed and has been shown to play a role in various 
processes such as T cell co-stimulation, chemokine biology, glucose 
metabolism and cancer (Van Damme et al., 1999, Drucker, 2003). 
 
1.3.2.2. Regulation 
The active FAP protein is a 170 kDa homodimer of two N-glycosylated 97 kDa 
subunits (Pineiro-Sanchez et al., 1997). Dimerization and post-translation 
glycosylation of FAP subunits are required for its catalytic function (Park et al., 
1999, Sun et al., 2002). Interestingly, FAP can also form an active 
heterodimer with DPPIV and other proteases on the surface of migratory 
connective tissue cells, promoting cell migration during connective tissue 
repair (Ghersi et al., 2002, Scanlan et al., 1994). The assembly of the FAP 
homo and heterodimers is reported to occur in endoplasmic reticulum and the 
golgi apparatus (Kelly et al., 1994). 
Milner et al. described upregulation of Fap gene expression when cultured 
chondrocytes were stimulated with IL-1 and oncostatin, both pro-inflammatory 
molecules known to promote cartilage resorption (Milner et al., 2006). Also, 
Chen et al. demonstrated that cancer cells activate stromal fibroblasts through 
IL-1 and TGF- by inducing FAP expression (Chen et al., 2009).  
A role for transcription factor EGR1 in regulating FAP expression has been 
proposed (Zhang et al., 2010). EGR1 is known to control a variety of genes, 
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including growth factors (TGFβ, PDGFβ), cytokines (IL-2), cell cycle 
regulators (cyclinD1) and matrix proteins (collagen and fibronectin) (Baron et 
al., 2006, Khachigian, 2006). Similar to FAP, EGR1 is also involved in wound 
healing and tumorigenesis (Abdulkadir, 2005, Baron et al., 2006). 
 
1.3.2.3. Expression during embryogenesis 
In wild-type mouse embryos, FAP was found to be expressed in the primitive 
mesenchymal tissue adjacent to the eye and to the cartilaginous primordial of 
bones (Niedermeyer et al., 2000). In a FAP-/- mouse model generated to also 
express -galactosidase under the control of the endogenous Fap promoter, 
-galactosidase was firstly detected at embryonic day 10.5 (E10.5) within the 
somites with a similar expression pattern  at E11.5 and E12.5 (Niedermeyer et 
al., 2001). The protein was also identified in developing myotubes (11.5 
d.p.c.), paravertebral regions (12.5 d.p.c.), and in  peri-chondral mesenchymal 
cells from the primitive cartilage of the ribs and intercostal muscle fibers and 
also in dermal fibroblasts (Niedermeyer et al., 2001). The physiological role of 
FAP during embryogenesis appears to be mainly related to tissue remodelling 
and angiogenesis activity. 
 
1.3.2.4. Expression in resting tissues 
In adult tissues, FAP is considered to be selectively expressed by activated 
fibroblasts in areas undergoing tissue remodelling, such as embryonic 
mesenchyme, wound healing, gravid uterus and reactive stroma of epithelial 
cancers (Niedermeyer et al., 2000). A more recent analysis, carried out by 
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Dolznig et al. showed that normal tissues generally present low FAP 
expression, with the exception of transient expression in uterus and cervix 
(Dolznig et al., 2005).  
 
1.3.2.5. Expression in pathology 
FAP was first identified as an inducible antigen by the F19 monoclonal 
antibody expressed on reactive mesenchyme of various tumours and 
transformed cell lines and granulation tissue of wound healing (Rettig et al., 
1986, Rettig et al., 1988, Garin-Chesa et al., 1990b, Aoyama and Chen, 1990, 
Kelly et al., 1994, Monsky et al., 1994). 
Activated fibroblasts present in tumour associated stroma, granulation tissue 
of healing wounds and chronic inflammatory conditions differ from resting 
fibroblasts by a characteristic gene expression, which includes fap 
upregulation (Scanlan et al., 1994).  
Epithelial cancers induce the formation of new blood vessels to secure an 
efficient blood supply to the malignant tissue, and allow the recruitment of 
activated fibroblasts, lymphoid and phagocytic infiltrates, as well as facilitating 
the release of peptide mediators and proteases (Scanlan et al., 1994). These 
events lead to the production of a transformed ECM. FAP-expressing 
activated fibroblasts, as well as FAP positive pericytes, can be found closely 
associated with tumour capillaries, forming a separate compartment between 
the tumour capillary endothelium and the basal portion of malignant epithelial 
cell clusters (Welt et al., 1994, Scanlan et al., 1994, Rettig et al., 1993). 
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Benign and premalignant epithelial cancers generally consist of very low or 
moderate FAP-expressing stromal cells. However, FAP positive cells are a 
common feature of reactive tumour mesenchyme of several types of epithelial 
cancers, including more than 90% of breast, lung, colorectal and pancreatic 
carcinomas (Garin-Chesa et al., 1990b). Furthermore, high FAP expression 
has also been shown in a large proportion of bone and soft tissue sarcomas 
(Rettig et al., 1986, Dohi et al., 2009, Aoyama and Chen, 1990, Monsky et al., 
1994). Particularly, in pancreatic ductal adenocarcinoma an association 
between FAP expression and tumour size, fibrotic focus, perineural invasion 
and worse prognosis has been established (Shi et al., 2012). Similarly, in 
colon cancers increased stromal FAP staining is positively correlated with 
disease prognosis and development of metastases (Henry et al., 2007). 
Despite these studies, the role of FAP in the tumour microenvironment is 
unclear. However, the most compelling evidence suggests a key role for 
FAP+ cells in cancer invasion, tumour angiogenesis and subsequent growth 
and metastases (Mori et al., 2004, Iwasa et al., 2005, Kelly et al., 1998, 
Kraman et al., 2010). 
Apart from cancer associated fibroblasts, FAP expression is also reported in 
activated fibroblasts at the tissue remodelling interface of healing wounds, 
cirrhotic liver and in the fibrotic interstitial space in lungs from patients 
suffering from idiopathic pulmonary fibrosis (Garin-Chesa et al., 1990a, Levy 
et al., 1999, Acharya et al., 2006).  
In synovial biopsy samples from patients with RA, FAP is highly expressed 
throughout the synovium but also in synovial fibroblasts (Waldele et al., 2015). 
FAP-expressing fibroblast-like synoviocytes (FLSs) were predominantly found 
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in the lining layer of the synovium, co-localised with metalloproteinases (MMP-
1 and MMP-13) as well as CD44, molecules known to be involved in ECM 
degradation in the synovial membranes of diseased joints (Bauer et al., 2006). 
In mouse models of arthritis, gene expression profiles displayed a seven-fold 
increase in Fap and DPPIV transcripts in inflamed paws when compared to 
non-inflamed counterparts (McIndoe et al., 1999) and, based on FAP-/- mice, it 
has been suggested that in the context of chronic inflammation in arthritic 
joints FAP might be involved in cartilage and bone damage (Waldele et al., 
2015). 
FAP expression, induced by macrophage-derived TNFα, was also detected in 
human aortic atherosclerotic plaques, in smooth muscle cells, where it 
contributes to type I collagen degradation (Brokopp et al., 2011). 
 
1.3.2.6. Function  
FAP exhibits both prolyl dipeptidyl peptidase, which overlaps with that of 
DPPIV, and collagenolytic activity capable of degrading gelatin and type 1 
collagen, which distinguishes FAP from DPPIV (Levy et al., 1999). Both 
functions utilise the common active serine 624 in FAP (Park et al., 1999). 
However, not much is known about its natural substrate and the significance 
of its peptidase activity in vivo (Park et al., 1999). In vitro exposure of a 
metastatic ovarian cancer cell line to different FAP doses demonstrated 
increased invasion, migration and proliferation ability in a dose-dependent 
manner (Chen et al., 2009). Due to its enzymatic activity FAP is known to 
denature collagen, playing a role in the degradation of ECM; thus, acting in 
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physiological tissue repair and remodelling (Milner et al., 2006, Niedermeyer 
et al., 2001). This is particularly evident during tadpole metamorphosis in 
Xenopus laevis in which FAP activity has been reported (Brown et al., 1996). 
Interestingly, according to Niedermeyer et al., FAP-/- mice are viable, fertile 
and show no development effects or structural abnormalities when compared 
to wildtype mice (Niedermeyer et al., 2000).  
When overexpressed in epithelial and fibroblastic cell lines, FAP significantly 
affects cell adhesion, migration, proliferation and apoptosis and also tumour 
invasion (Wang et al., 2005, Lee et al., 2011). Inhibition of FAP proteolytic 
activity with blocking antibodies or antisense strategies suppress its function, 
reducing tumour growth (Cheng et al., 2002, Santos et al., 2009, Goodman et 
al., 2003). Furthermore, overexpression of FAP upregulates MMP2 and CD44 
and downregulates integrin-β1, the latter known to connect the cytoskeleton to 
the ECM thereby facilitating tumour cell migration (Wang et al., 2005). 
Recently, Waldele et al. showed that FAP-/- crossed with hTNFtg mice were 
less affected by cartilage degradation and their synovial fibroblasts exhibited 
reduced capability to adhere to cartilage (Waldele et al., 2015). Therefore, in 
the context of chronic inflammatory arthritis FAP seems to be involved in the 
loss of proteoglycans and consequent cartilage degradation (Waldele et al., 
2015). 
 
1.3.2.7. Inducible depletion of FAP+ cells: the FAP-DTR transgenic 
mouse 
In this project, a FAP-DTR Tg mouse model, a kind gift from Prof Douglas 
Fearon, was used to clarify the role of FAP in the context of TLO formation. In 
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this model the Fap gene has been modified by insertion of a cassette 
encoding the primate diphtheria toxin receptor (DTR), not expressed in mice. 
Administration of Diphtheria Toxin (DTx) to mice via injection induces specific 
deletion of the FAP-expressing cells. This model has been previously used by 
our collaborators to address the role of FAP+ cell in cancer biology, where 
deletion of the FAP+ cell caused growth arrest of immunogenic tumours 
through hypoxic necrosis of both cancer and stromal cells (Kraman et al., 
2010). 
According to Schreiber and Rowley, the ablation of FAP-expressing 
fibroblasts and pericytes damages the blood supply to the tumour causing 
death to some cancer cells. The resulting signals released by cancer cells 
undergoing cell death activate circulating T cells, which in turn, secrete the 
pro-inflammatory cytokines IFN and TNF, leading to an immune response 
against the remaining tumour (Schreiber and Rowley, 2010). This model has 
therefore suggested an immunosuppressive role for FAP+ cells in cancer 
biology raising the intriguing possibility that a similar role might be played by 
FAP in physiological conditions and linked to immunosuppression during 
autoimmunity and inflammation.  
More recently, the same model has been used to deplete lymph node FRCs 
(which express FAP) leading to loss of T, B and dendritic cells, disrupting 
normal lymph node homeostasis (Denton et al., 2014). Furthermore, in a 
mouse model of influenza infection mice lacking FAP+ cells mounted 
diminished immune responses characterised by reduced numbers of GC B 
cells, plasma B cells and TFH cells (Denton et al., 2014). This work has 
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established FAP expressing FRCs in the lymph node as a key cell type in the 
retention of naïve lymphocytes and initiation of immune responses.  
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1.4. Sjögren’s syndrome 
1.4.1. Clinical features  
SS is an inflammatory disease of autoimmune aetiology characterised by 
chronic focal lymphocytic infiltration of exocrine glands, predominately the 
lachrymal and salivary glands. Chronic sialadenitis results in progressive 
tissue damage with loss of secretory gland function leading to the primary 
clinical features of keratoconjunctivitis sicca (dry eyes) and xerostomia (dry 
mouth). The inflammatory process can progress to involve almost any organ 
system resulting in systemic manifestations of disease (Fox, 2005, Ramos-
Casals et al., 2008). In addition, patients with primary disease are at 
increased risk of B cell lymphomas compared to the general population 
(Theander et al., 2006).  
The disorder was first described both clinically and histologically in 1933 by 
the Swedish ophthalmologist Henry Sjögren. The organ specific pathology is 
caused by local inflammation and progressive loss of the glandular 
parenchyma (Chisholm and Mason, 1968). In 50-60% of cases this disorder is 
associated with other systemic autoimmune diseases, such as RA or SLE 
where it is considered to be a secondary, rather than primary disease process 
(Chisholm and Mason, 1968, Moutsopoulos, 1994).  
Primary SS (pSS), which occurs in the absence of other conditions, has a 
higher frequency in female patients (9:1) and a prevalence of 0.5% in the 
general population, making SS one of the three most frequent autoimmune 
diseases (Bowman et al., 2004, Chisholm and Mason, 1968, Fox et al., 1999, 
Pillemer et al., 2001). 
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Compelling evidence now suggests that several biological processes are 
involved in pSS and contribute to the establishment of salivary gland 
pathology. Those encompass pathways of activation belonging to both the 
innate and acquired immune systems, such as IFN activation (Brkic et al., 
2013), defective regulatory T cell activity (Christodoulou et al., 2008), an 
increased number and function of TH17 cells (Katsifis et al., 2009) and 
excessive co-stimulation (Dimitriou et al., 2002, Gong, 2012). 
Lymphoneogenesis with GC formation and clonal expansion of malignant B 
cells is ascribed to the aberrant B cell activation that characterises a subset of 
patients with high serum titres of autoantibodies and systemic manifestations 
of the disease.  These patients also have an increased risk of the 
development of lymphoma (Theander et al., 2011).  
PSS is characterized by, but not limited to, secretory dysfunction. One third of 
patients exhibit systemic extra-glandular manifestations, whose development 
and onset varies during the disease progression (Moutsopoulos, 1994, 
Shiboski et al., 2012). As a result, clinical management of the disease 
requires a multi-disciplinary approach including input from rheumatologists, 
ophthalmologists and oral medicine specialists.  
The extra-glandular manifestations include cutaneous vasculitis 
(leucocytoclastic vasculitis), peripheral neuropathy, polyarthralgia and 
synovitis, fatigue, renal tubular acidosis, interstitial lung disease, 
lymphoproliferative disease and immunological abnormalities, such as 
lymphopenia, anaemia or thrombocytopenia (Anaya et al., 2006, Ramos-
Casals et al., 2008). Immunological findings are also observed in pSS, such 
as the presence of anti-Sjögren’s-syndrome-related antigen A and B 
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autoantibodies (antiSSA/Ro and SSB/La), hyper-gammaglobulinaemia and 
low complement  levels (C4) (Malladi et al., 2012).  
Approximately 5% patients with pSS develop lymphoma, conferring a higher 
mortality risk in pSS as compared to the normal population (Moutsopoulos 
and Manoussakis, 1998). Patients with pSS have a 16 to 44 times increased 
risk of developing lymphoma. Histologically, the malignancy is predominantly 
a MALT non-Hodgkin’s lymphoma that forms in extra-nodal sites, mainly 
within the acquired MALT present in affected major salivary glands (Theander 
et al., 2006, Voulgarelis et al., 1999). However other forms of B cell 
lymphoma, such as diffuse large B cell lymphoma, are also observed. 
 
1.4.2. Histological findings in the salivary glands from Sjögren’s 
syndrome patients 
Salivary glands are classified as exocrine glands, which secrete saliva 
through a duct system from a secretory structure called the salivary acinus 
(Holsinger and Bui, 2007). There are three main types of acini: serous, 
mucous and mixed (Holsinger and Bui, 2007). Between the epithelial cells and 
basal lamina of the acinus, flat myoepithelial cells form a latticework and 
possess cytoplasmic filaments on their basal side to aid in contraction, and 
thus forced secretion, of the acini. Spindle shaped myoepithelial cells are also 
observed around the intercalated ducts (Holsinger and Bui, 2007, Dawes et 
al., 2012). 
The formation of small lymphocytic foci around the intra-lobular and inter-
lobular ducts represents the typical histological lesion in pSS (Chisholm and 
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Mason, 1968, Greenspan et al., 1974, Christodoulou et al., 2010). PSS is 
characterized by the formation of peri-epithelial mononuclear cell infiltrates, 
which preferentially form in the exocrine glands: salivary glands, lachrymal 
glands and exocrine pancreas. The histological lesions characteristic of SS 
occurs both in major and in minor salivary glands. Nonetheless, it has to be 
acknowledged the predominance of lympho-epithelial lesions (LESA, areas of 
lymphocytic infiltration of the duct that result in atrophy of the columnar ductal 
epithelium and proliferation of the basal epithelial cells) and the detection of 
better-organized GCs in major but not minor salivary glands (Carbone et al., 
2000, Barone et al., 2005, Bombardieri et al., 2007). 
In the early stages of the disease, CD4+ T cells and DCs mainly inhabit initial 
aggregates and progressive B cell infiltration is often observed during the 
disease course. The large diffuse infiltrate then spreads into the parenchyma, 
resulting in the loss of tissue architecture and atrophic involution of the acini 
(Gonzalez et al., 2011). Parenchymal and ductal alterations can be observed 
in the affected glands including atrophic involution of the acini and hyperplasia 
of the lining cells of the intra-glandular ducts (Chisholm and Mason, 1968, 
Greenspan et al., 1974, Christodoulou et al., 2010, Gonzalez et al., 2011). 
Accumulation of hyaline material is also found in the lumen of altered ducts 
and around blood vessels (Gonzalez et al., 2011, Greenspan et al., 1974). 
Small foci consist predominantly of plasma cells with a smaller lymphocytic 
component that is distributed throughout the foci. Larger foci are mainly 
composed of lymphocytes with fewer macrophages and plasma cells. A 
discrete plasma cell component can be observed at the periphery of the larger 
foci (Greenspan et al., 1974).  
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Activated CD4+ T cells predominate in small aggregates and decrease in 
severe lesions; on the other hand, B cell infiltration predominates in the larger 
foci (Christodoulou et al., 2008, Christodoulou et al., 2010). Accordingly, the 
T/B cell ratio is negatively associated with the degree of inflammation 
(Christodoulou et al., 2010). Instead, the percentage of CD8+ T cells and 
natural killer (NK) cells does not significantly change with lesion severity 
(Christodoulou et al., 2010). Higher numbers of Tregs have been found in 
patients with pSS as compared to patients with secondary SS or connective 
tissue disease patients without SS (Furuzawa-Carballeda et al., 2014). Sarigul 
et al. also described a higher percentage of FoxP3-expressing CD4+ T cells in 
the salivary glands of pSS patients, even though similar numbers were found 
in peripheral blood of patients with either pSS or RA and healthy controls 
(Sarigul et al., 2010). The frequency of regulatory T cell detection appears to 
correlate with lesion severity (Sarigul et al., 2010). Plasmacytoid DCs, 
CD123+BDCA-2+ cells are the main source of IFN-α, and have also been 
identified in all pSS salivary gland biopsies analysed by Gottenberg et al. 
(Gottenberg et al., 2006, Fitzgerald-Bocarsly et al., 2008). Circulatory 
plasmacytoid DCs are more activated in pSS patients with a higher 
expression of CD40 (Wildenberg et al., 2008). 
Infiltrating lymphocytes in the ducts can give rise to the formation of LESA, 
such areas of lymphocytic infiltration (mainly B cells) can lead to atrophy of 
the columnar ductal epithelium and proliferation of the basal epithelial cells 
(Carbone et al., 2000). B cells represent the predominant infiltrating cell type, 
often acquiring monocytoid features or centrocyte-like morphology frequently 
accompanied by immunoblasts, plasmacytoid lymphocytes and plasma cell 
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differentiation (Greaves and Wang, 2011). In up to 50 % of cases clonal intra 
epithelial B cell infiltration is present (Carbone et al., 2000) and, in some 
cases it is possible to observe, either by in situ hybridization or 
immunohistochemistry, kappa or lambda light chain excess production in the  
infiltrating cells (Harris, 1999). 
 
1.4.3. Germinal centre detection in biopsies from Sjögren’s 
syndrome 
In approximately 20-25% of patients with SS salivary gland aggregates are 
organized into segregated T and B cell areas, and are characterised by the 
formation of areas of active B cell proliferation and FDC networks within 
defined GC-like structures (Figure 1.2) (Salomonsson et al., 2003).  
In GCs within SLOs the process of antigen selection is tightly regulated; in 
contrast, it is believed that in ectopic GCs, chronic antigen stimulation may 
contribute to persistent activation of innate and adaptive immune cells (Berg 
et al., 1986, Vinuesa et al., 2009, Aloisi and Pujol-Borrell, 2006). Indeed, the 
chronic antigenic stimulation together with the local ectopic expression of B 
and T cell survival factors are likely to provide the ideal microenvironment for 
the development of hyperactive B cell clones (Pitzalis et al., 2014). 
A large body of literature has highlighted the potential role for the GC-like 
structures present in the salivary glands in sustaining the process of B cell 
affinity maturation of autoreactive clones. GCs are mainly composed of B 
lymphocytes but also macrophages, DCs, FDCs and T cells. DCs play a key 
role in ectopic GC formation and persistence supporting antigen presentation 
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and producing key cytokines for B cell maturation and proliferation (Aguzzi et 
al., 2014). Structurally, a dark zone that is inhabited by highly proliferating 
centroblasts and a light zone, populated by FDCs and centrocytes, form GCs 
(MacLennan, 1994). While the dark zone represents the area where the B cell 
clones undergo expansion; the light zone is the site of antigen presentation 
and affinity maturation of the B cell compartment (MacLennan, 1994).  
Indeed, the local expression of AID, the enzyme instrumental for B cell affinity 
maturation, is associated with the presence of inflammatory aggregates 
(Barone et al., 2005, Bombardieri et al., 2007). Moreover a positive correlation 
between the persistence of the GC-like structures and the development of B 
cell lymphoma has been suggested (Barone et al., 2008).  
Salivary gland lymphoid organization and GC formation is accompanied by 
the ectopic production of  lymphoid chemokines CXCL13, CCL21 and 
CXCL12, that localize, within the aggregates, in discrete areas resembling the 
lymphoid organization observed in secondary lymphoid organs (Barone et al., 
2005, Bombardieri et al., 2007, Ansel et al., 2000, Luther et al., 2000, Luther 
et al., 2002, Mebius, 2003). Increased local and systemic (serum and saliva) 
levels of CXCL13 correlates with xerostomia and it has been previously 
demonstrated that in lymphoid aggregates the level of CXCL13 or CCL21 
correlates with the degree of organization of the foci (Kramer et al., 2013, 
Barone et al., 2005, Bombardieri et al., 2007). 
During the disease course the detection of GCs in salivary gland biopsy has 
been associated with more aggressive disease development both 
serologically and clinically (Risselada et al., 2013b). The presence of 
histologically detectable GCs in approximately 25% of pSS patients has been 
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found to correlate with the presence of a higher focus score (1.25 points 
higher) (Risselada et al., 2013b). Specifically, the presence of a positive RF or 
anti-Ro/SSA and anti-La/SSB antibodies is much higher in patients with GCs 
than in patients without, suggesting a possible contribution of these structures 
in the local production of autoantibodies (Risselada et al., 2013b). In terms of 
autoantibody production and inflammatory cytokine release, no significant 
differences have been observed between SS patients with positive or negative 
biopsies for presence of GC (Szodoray et al., 2005, Jonsson et al., 2005). 
 
 
Figure 1.2. Germinal centres in TLOs in Sjögren’s syndrome salivary gland biopsies. 
Hematoxylin and eosin staining of SS salivary gland (A and C) and immunohistological staining 
anti-CD21 in germinal centre B cell area. (Barone et al., 2015a) 
A 
C 
B 
D 
Figure 1.2 
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1.4.4. Classification criteria  
The large spectrum of manifestations typical of SS has provided a major 
challenge for the definition and validation of unifying classification criteria 
(Shiboski et al., 2012). In 1993 the European Study Group On Diagnostic 
Criteria for SS proposed a set of 6 items including 2 subjective and 4 objective 
criteria (Vitali et al., 1996). These items included: ocular symptoms; oral 
symptoms; ocular signs; presence of focal lymphocytic sialoadenitis; 
instrumental evidence of salivary gland involvement; and presence of 
autoantibodies (anti-SSA/Ro and/or anti-SSB/La). According to these 
guidelines, the presence of any four of the above mentioned criteria were 
indicative of pSS, in the absence of any other associated autoimmune disease 
(Vitali et al., 1996). The main criticism raised to these criteria was the potential 
inclusion of patients with no evidence of sialoadenitis or presence of 
autoantibodies as long as they fulfilled the remaining four criteria (Vitali et al., 
2002). In 2002 Vitali et al. revised these criteria, making the presence of a 
histological diagnosis of SS or the presence in the serum of anti-SSA/Ro 
and/or anti-SSB/La antibodies mandatory for the diagnosis of pSS (Vitali et 
al., 2002).  
More recently, in 2012 the Sjögren’s International Collaborative Clinical 
Alliance (SICCA) published the first set of criteria approved by the American 
College of Rheumatology. According to these guidelines, the classification of 
an individual as having pSS is based exclusively on the presence of objective 
criteria which include the detection of serum anti-Ro/SSA and/or anti-La/SSB 
antibodies, or positive rheumatoid factor and antinuclear antibody (ANA); a 
positive salivary gland biopsy exhibiting a focal lymphocytic sialoadenitis with 
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a focus score ≥ 1 or the presence of keratoconjuctivitis sicca (Shiboski et al., 
2012). Two out of three of those criteria are required for disease diagnosis. 
Several criticisms of these proposed new criteria have been made (Bowman 
and Fox, 2014); however, Rasmussen et al. have recently demonstrated 
concordance between the AECG and ACR sets of classification criteria when 
applied to the same cohort (Rasmussen et al., 2014).  
Whilst the classification criteria have been designed for clinical studies and 
trials, they are often used in the clinical practice to support the diagnostic 
process. In this context, the performance of a salivary gland biopsy and the 
relative histological examination is critical for a number of patients that present 
with negative ANA antibodies (Giovelli et al., 2015). In those cases the 
positivity of the histological assessment is required to substantiate the clinical 
diagnosis of pSS (Vitali et al., 2002).  
 
1.4.5. Histological evaluation of the salivary gland biopsy 
The classical method to score SS biopsy relies on the Chisholm and Mason 
criteria (1968). This grading system (4 grades) relies on the detection in the 
gland of focal lymphocytic and/or diffuse lymphocytic infiltration. The presence 
of more than 50 periductal lymphocytes (histiocytes and plasma cells) in 
4mm2 square of salivary gland tissue is used as criteria for the definition of a 
focus (Chisholm and Mason, 1968). 
Greenspan elaborated the focus score in 1974 as an extension of the 
Chisholm and Mason classification. According to its definition the identification 
of focal lymphocytic sialoadenitis is followed by the quantification of the 
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number of foci per 4mm2 of tissue section adjacent to normal parenchyma 
(Greenspan et al., 1974).  
The focus score has been validated as a histologic index of severity of the 
salivary gland involvement in pSS. A series of manuscripts have correlated 
the presence of high focus scores with indices of local or systemic disease 
activity. The presence of a higher focus score has been found to correlate with 
acinar damage (Greenspan et al., 1974), presence of anti-SSA/B serology (12 
times higher among those with focus score ≥ 1 than among those with focus 
score < 1 or without focal lymphocytic sialoadenitis (95% CI: 9.3; 15.5) and 
the presence of specific extraglandular features, such as Raynaud’s 
phenomenon (reduced blood flow), vasculitis, lymph node or spleen 
enlargement and leucopenia (Gerli et al., 1997). A focus score ≥ 1 has also 
been found to correlate with positive RF serology, high ANA titres and IgG 
concentrations, the presence of keratoconjunctivitis sicca and low 
unstimulated salivary flow rates (Daniels et al., 2011, Haldorsen et al., 2008). 
More recently, Risselada et al. (2013) established that a high focus score (≥ 3) 
has a significant predictive value for the development of non-Hodgkin B cell 
lymphoma (Risselada et al., 2013a).  
The focus score, whilst giving an idea of the extent of the cellular infiltrate, 
fails to provide discrete data on the foci size and its organization (Greenspan 
et al., 1974). The focus score does not require quantification of the presence 
of GC-like structures or the evaluation of the aggregation of lymphocytes in 
segregated T and B cells areas. The introduction of additional measurements 
such as average of focus area, area of lymphocytic infiltration and evaluation 
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of the degree of organization is currently debated in the SS community to 
integrate the information provided by the simple focus score.   
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1.5. A murine model of viral-induced TLO formation 
Salivary gland inflammation can be induced by the delivery of a replication-
deficient adenovirus-5 in submandibular glands of wild type mice through 
retrograde excretory duct cannulation (Bombardieri et al., 2012).  
This inflammatory process leads to the formation of viral-induced lymphoid 
aggregates that organise into TLOs resembling the histological lesions that 
can be found in approximately 20-40% of SS salivary glands (Barone et al., 
2005). TLOs form progressively over 2 weeks in the infected gland and are 
characterised by organized B and T cell zones, ectopic expression of 
lymphoid chemokines (CXCL13, CCL19, CCL21), lymphoid associated 
cytokines (such as LT), FDC network formation and expression of PNAd on 
HEVs (Bombardieri et al., 2012). 
The model is a useful tool to study the molecular and cellular mechanisms 
involved in TLO formation (Bombardieri et al., 2012).  
Indeed, our group has previously shown that expansion of a gp38+ stromal 
population occurs in this model, starting at 3 hours post cannulation (p.c.) with 
replication-deficient adenovirus. This population secretes CXCL13 and CCL19 
and expresses lymphoid-associated stromal markers VCAM-1 and ICAM-1, 
RANKL and MadCAM (Saba Nayar, unpublished data). Therefore, we believe 
that gp38+ stromal cells (CD45-EpCAM-CD31-gp38+), termed lymphoid-like 
stromal cells (LLSc), actively participate in the formation of TLOs in inflamed 
SG. 
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1.6. Project hypothesis 
We have previously demonstrated that critical changes occur to tissue 
resident stromal cells during the establishment of TLOs, including: the 
upregulation of adhesion molecules, expression of lymphoid chemokines and 
upregulation of gp38 and FAP, two stromal cell markers associated with 
lymphoid stromal cells in secondary lymphoid organs and in target tissues of 
inflammation.  
We hypothesize that those markers and the stromal cells identified by their 
expression play a functional role in the establishment and homeostasis of 
TLOs. To test this hypothesis we aim to delete Pdpn and FAP+ cells and 
evaluate the downstream effects on TLO formation. 
 
1.7. Project aims 
 Identify the potential signals provided by lymphoid-like stromal cells in 
the phase of recruitment, activation and retention of leukocytes in 
inflamed salivary glands. 
 Dissect the role of gp38+ activated lymphoid-like stromal cells in the 
development of TLOs in murine salivary glands.  
 Evaluate the consequences of depleting salivary gland activated 
stromal cells in the formation of TLOs, taking advantage of the 
expression of FAP on activated gp38+ lymphoid-like stromal cells.  
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Chapter 2 
MATERIALS AND METHODS 
2.1. Mice 
Conditional KO of the Pdpn gene, C57BL/6-Pdpntm2418Arte (PDPNfl/fl) was 
generated by Taconic Biosciences (NY, USA) for Prof Christopher Buckley 
and Prof Steve Watson (University of Birmingham), in which the Pdpn exon 3 
was flanked by loxP sites. B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J 
(Rosa26+/CreER), were purchased from The Jackson Laboratory (ME, USA) 
(Stock Number: 008463). To generate this strain, a conditional Cre-ERT2 (Cre 
recombinase – estrogen receptor T2) cassette was introduced to the gene. 
The ERT2 retains the Cre recombinase in the cytoplasm until tamoxifen 
administration releases this inhibition, thus permitting the recombination of 
genomic loxP sites. Rosa26CreER mice were bred with the PDPNfl/fl mice in 
order to enable temporal control of Pdpn gene expression by tamoxifen 
induction in vivo. Cre-mediated recombination leads to deletion of the Pdpn 
exon 3 and consequent loss of function of the Pdpn gene by generating a 
frameshift from exon 2 to all downstream exons (premature Stop codon in 
exon 5). Homozygous mice for both the floxed Pdpn gene and the Cre allele 
were used for experiments. 
FAP-DTR transgenic (Tg) embryos were a kind gift from Prof Douglas Fearon 
(University of Cambridge). FAP-DTR mice were generated to express the 
DTR, luciferase reporter (Luc2) and mCherry under the murine fap promoter, 
by insertion of a 206kb BAC clone (RP23-16A15) (Roberts, 2013). FAP-DTR+ 
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mice were bred with albino C57BL/6 females (C57BL/6J-Tyrc-2J) and 
heterozygous animals were used for experiments.  
Colony of ICOSL-/- mice was established by Dr Francesca Barone (University 
of Birmingham) with homozygous breeding pairs donated by Dr David Withers 
(University of Birmingham). 
Lta-/- and tnfr-/- (p55/75) mice were provided by Dr J. Caamaño (University of 
Birmingham) and CD3ε-/- mice by Prof Peter Lane (University of Birmingham). 
C57BL/6 and C57BL/6J-Tyrc-2J were purchased from Harlan or Charles River. 
All mice were bred at the Biomedical Services Unit (BMSU), University of 
Birmingham, and kept under pathogen-free conditions according to Home 
Office regulations. 
Experiments were carried out at the University of Birmingham, UK (project 
licence number 30/2796) following strict guidelines governed by the UK 
Animal (Scientific Procedures) Act 1986 and approved by the local ethics 
committee (BERSC: Birmingham Ethical Review Subcommittee). Mice used in 
this study were housed in individually ventilated cages in groups of 3-6 
individuals on a 12-hour light-dark cycle. 
 
2.1.1. Tamoxifen-mediated conditional KO of Pdpn gene 
Pdpnfl/flRosa26+/CreER female mice, between 26 and 30 days old, were treated 
with 2mg of tamoxifen (Sigma Aldrich) or vehicle control, corn oil, for 5 
consecutive days via intraperitoneal (i.p.) injections. Animals were then left for 
a tamoxifen washout period of 35 days prior to any further experimental 
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procedures, to rule out previously reported anti-inflammatory properties of 
tamoxifen (Wu et al., 2000, Dayan et al., 1997). 
 
2.1.2. Diphtheria Toxin-mediated deletion of FAP+ cells 
DTx (List Biological Laboratories, USA) was administered by i.p. injection to 8 
week old FAP-DTR female mice at a dose of 25ng/g at day 0 and day 2, twice 
a day. Further experimental procedures were performed at day 7 after the first 
DTx i.p. injection. 
 
2.1.3. Generation of Bone Marrow Chimeric Mice 
ICOSLKO and C57BL/6 females, 8-10 weeks old, were given Baytril for 7 
days in drinking water prior to two doses of irradiation of 475rad, with an 
interval of 3 hours. One hour after the second dose of irradiation, ICOSLKO 
mice were intravenously (i.v.) injected with 1x107 bone marrow cells from 
C57BL/6 animals to reconstitute their immune system and C57BL/6 mice were 
transplanted with 1x107 ICOSLKO bone marrow cells. Mice were kept on 
Baytril after irradiation and, 6 weeks later, the salivary glands were cannulated 
with replication-deficient adenovirus. 
 
2.1.4. Anti-ICOS treatment 
C57BL/6 female mice were injected i.p. with 10mg/kg with an anti-mouse 
ICOS blocking antibody (J51HG1-TM) or isotype control (R347-TM) (Yusuf et 
al., 2014) every 4 days starting from day 0 post cannulation. 
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2.2. Salivary Gland Cannulation  
Submandibular salivary glands of anaesthetised mice were cannulated 
through the excretory duct with 1x108 – 1x109 plaque-forming units of 
replication-deficient adenovirus type 5, encoding the luciferase gene 
(Bombardieri et al., 2012). 
 
2.2.1. Adenovirus Preparation 
HEK 293 cells were cultured in 150x25mm tissue culture petri dishes and, 
when 80% confluency was reached, these cells were infected with 2ml of 
adenovirus supernatant and incubated for 2 to 3 days until massive 
detachment was observed. Cells were then harvested, centrifuged and 
resuspended in 100mM Tris pH8 and put through three cycles of freeze-thaw 
to ensure lysis of infected cells and release of virus particles in the 
supernantant. After centrifugation, the supernatant containing the viral 
particles was purified using a discontinuous CsCl gradient, 1.4g/ml and 
1.25g/ml. The resulting band formed of appropriately packaged viral particles 
was collected and purified further with 1.3g/ml CsCl. Once again, the resulting 
band was collected, inserted into a 3500MWCO dialysis cassette (Thermo 
Scientific) and dialysed against 2L of a 1mM MgCl2, 10mM Tris (pH7.4) and 
150mM NaCl with 10% glycerol solution for 24h. 
After dialysis, the AdV particles were titrated using an Adeno-X Rapid Titer Kit 
(Clontech), according to manufacturer’s instructions in which serial dilutions of 
the resulting AdV solution was prepared and seeded with HEK 293 cells in a 
57 
 
12 well plate, incubated for 48 hours at 37°C. Infected cells were then fixed 
with ice cold 100% methanol for 10min at -20°C and incubated with an anti-
hexon antibody, followed by a HRP-conjugated antibody. Chromogenic 
staining was revealed with DAB, the substrate for HRP. Positive infected cells 
were counted and infectious units were calculated according to 
manufacturer’s instructions. 
 
2.2.2. Intrasalivary gland delivery of Adenovirus 
Animals to be cannulated were administered buprenorphine (0.03mg/kg) 
subcutaneously, at least 30 minutes before the start of the procedure. Mice 
were anaesthetised with ketamine (76mg/kg) and domitor (1mg/kg) (i.p.) and 
using a heat-drawn glass gas chromatography tubing (0.1mm internal 
diameter; Sigma Aldrich) 1x108 – 1x109 plaque forming units of replication-
deficient adenovirus which carries Luciferase gene was delivered to the 
submandibular salivary glands via the excretory duct. After delivery of virus, 
cannula was removed and mice were given antipamezole (0.075mg/mouse) to 
reverse anaesthesia. 
 
2.2.3. Luciferase Assay 
Luciferase assay was used to assess the efficiency of the salivary gland 
cannulation. After gland dissection, a piece of each salivary gland was kept in 
RNAlater (Qiagen) at -20°C. Samples were thawed at room temperature, 
transferred into bijoux containing 350µl of Glo Lysis Buffer (Promega) and 
homogenised with a tissue homogeniser. Lysates were then centrifuged at 
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13000rpm for 5 minutes and 25µl of supernatant was added to a flat-bottomed 
96 well plate and incubated with 25µl of Luciferase Assay Substrate 
(Promega, UK) for 5 minutes at room temperature. Plates were run in a 
Berthold Technologies CentroLB 960 using MikroWin software. 
 
2.3. Human salivary gland biopsies from Sjögren’s 
Syndrome patients 
Minor salivary gland samples were obtained from Human Biomaterials 
Resource Centre at the University of Birmingham under ethics number 10-
018. Specimens were selected among samples presenting the histological 
criteria for the diagnosis of SS. 
 
2.4. Flow Cytometry 
2.4.1. Stromal tissue digestion 
For flow cytometric analysis, salivary glands and lymph nodes were dissected 
and collected in 2ml of RPMI-1640 (+2% FCS) on ice. Tissues were 
transferred into 1.5ml of Digestion Buffer 1 – RPMI-1640 (Sigma Aldrich) 
(+2% FCS) containing 0.1g/ml Collagenase D (Roche) and 0.01g/ml of DNase 
I (Sigma Aldrich) – and gently pierced with fine forceps. Samples were 
incubated at 37°C in a water bath for 40 minutes with stirring and centrifuged 
at 1800rpm for 4 minutes. Fresh Digestion Buffer 2, 1.5ml RPMI-1640 (Sigma 
Aldrich) (+2% FCS) containing 0.1g/ml Collagenase Dispase (Roche) and 
0.01g/ml DNase I (Sigma Aldrich), was added to the samples and contents 
59 
 
were gently mixed and incubated at 37°C for 20 minutes with magnetic 
stirring. Finally, 15µl of 0.5M EDTA (Sigma Aldrich) was added to the samples 
followed by incubation at 37°C for 5 minutes. Cell suspensions were filtered 
through 70µm cell strainers into a 50ml falcon tube containing RPMI-1640 
(Sigma Aldrich) (+2% FCS) and resulting contents centrifuged at 1800rpm for 
4 minutes at 4°C. Cell pellets were resuspended in MACS Buffer, 0.25g BSA 
(Sigma Aldrich) and 0.5M EDTA in PBS (Thermo Fisher Scientific), for 
subsequent staining. 
 
2.4.2. Leukocyte digestion 
For flow cytometric analysis salivary glands were transferred into 2ml of 
Digestion Buffer, comprised of 0.1g/ml Collagenase Dispase and 0.01g/ml of 
DNase I, and pierced with fine forceps. Samples in digestion buffer were 
transferred into 5ml falcon tubes (BD biosciences) and incubated for 20 
minutes at 37°C with stirring. 40µl of 0.5M EDTA (Sigma Aldrich) was added 
to the solution and incubated at 37°C for another 5 minutes. Cell suspensions 
were filtered through a 70µm cell strainer into a 50ml falcon tube containing 
2ml of RPMI-1640 (Sigma Aldrich) (+2% FCS) and resulting contents 
centrifuged at 1800rpm for 4 minutes at 4°C. Cell pellet was resuspended in 
MACS Buffer for staining.  
 
2.4.3. Collagenase P Digestion 
Collagenase P digestion protocol was an alternative protocol optimised in 
order to enable staining for both stromal and leukocyte markers in samples 
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that have undergone the same digestion protocol. Since this is a milder 
technique most of the leukocyte markers are not cleaved by the enzymes. 
Salivary glands were transferred into 5ml falcon tubes (BD biosciences) with 
2ml of Digestion Buffer, containing RPMI-1640 (Sigma Aldrich) (+2% FCS), 
0.8mg/ml Dispase (Roche), 0.2mg/ml Collagenase P (Roche) and 0.1mg/ml 
DNase I (Sigma Aldrich), cut with scissors and incubated at 37°C with 
magnetic stirrers. After 20 minutes, samples were taken out of the water bath 
and left for 30 seconds for large fragments to settle. Enzyme mix was 
collected and added to 15ml of ice-cold MACS Buffer in a 50ml falcon tube. 
2ml of new Digestion Buffer was added to the samples, mixed by pipetting 
and incubated for a further 10min. All enzyme mix was collected, transferred 
once again into the 50ml falcon tubes, strained through a 70µm cell strainer 
(BD biosciences) and centrifuged at 300g for 4 minutes at 4°C. Cell pellet was 
resuspended in MACS Buffer for staining.  
 
2.4.4. Staining 
Cells were incubated with 100µl (50µl for lymph node stromal cells) of diluted 
primary antibodies for 30 minutes in MACS Buffer. Cells were washed with 
MACS Buffer followed by fixation with Fixing solution (eBioscience) and 
further washing with Fixation/Permeabilization Wash Buffer (eBioscience).  
For FAP staining, cells were incubated with Fc block for 15 minutes prior to 
incubation with sheep anti-FAP and biotinylated mouse anti-sheep/goat 
antibodies.  
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Intracellular staining for cytokine production was performed (BD 
Cytofix/Cytoperm) according to the manufactures protocol. In brief, following 
surface staining with cocktails of desired antibodies, cells were washed in 
PBS (with 0.5% BSA and 2mM EDTA), re-suspended in 150 µl 
Cytofix/Cytoperm (BD Pharmingen) and incubated overnight at 4°C. Cells 
were washed twice with the BD Perm/Wash Buffer and subsequently intra-
cellular LTα (Geneway) antibody was added and incubated at 4°C for 30–40 
minutes, the LTα was detected by secondary antibody. Afterwards cells were 
washed twice, resuspended and then analyzed using a CyAnTM ADP Analyzer 
(Beckman Coulter) with forward/side scatter gates set to exclude non-viable 
cells. Data were analyzed with FlowJo software (Tree Star). For cell sorting, 
stained cells were sorted using MoFlo-XDP (Beckman Coulter Inc). The purity 
of sorted stromal populations routinely exceeded 96%. 
A list of antibodies used for flow cytometry can be found in Table 2.1. 
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Antibody 
specificity 
Isotype Clone Format Supplier Dilution 
used 
CD45  
 
Rat IgG2b 30-F11 PERCPCy5.5 
PECy7 
APC-Cy7 
ebiosciences 1:300 
1:500 
1:800 
Podoplanin 
(gp38) 
Hamster 
IgG 
ebio8.1.1 PE ebiosciences 1:200 
CD31 
(PECAM-1) 
Rat IgG2a 390 FITC/PECy7 ebiosciences 1:200 
CD326 
(EpCAM) 
Rat IgG2b G8.8 PECy7 ebiosciences 1:500 
CD54 
(ICAM-1) 
Rat IgG2b YN1/1.7.4 PE ebiosciences 1:200 
CD106 
(VCAM-1) 
Rat IgG2a 429 
(MVCAM.A) 
PERCPCy5.5 Biolegend 1:50 
Ki67 Mouse 
IgG1 
B56 Alexa-
Fluor647 
BD 
biosciences 
1:50 
CD3e Hamster 
IgG 
145-2C11 PECy7 BD 
biosciences 
1:100 
B220 
(CD45R) 
Rat IgG2a RA3-6B2 APCCy7 BD 
biosciences 
1:100 
CD4 Rat IgG2a RM4-5 efluor 450 ebiosciences 1:50 
CD8α Rat IgG2a 53-6.7 PE-TexasRed BD 
biosciences 
1:200 
CD19 Rat IgG2a eBio1D3 
(1D3) 
APC ebiosciences 1:100 
LTα Mouse 
IgG2b 
AT15 A3 unconjugated GenWay 1:50 
CD278 
(ICOS) 
Hamster 
IgG 
C398.4A PE ebiosciences 1:100 
CD275 
(ICOSL) 
Rat IgG2a HK5.3 biotin ebiosciences 1:50 
FAP Polyclonal 
Sheep IgG 
-  unconjugated R&D 
Systems 
1:50 
Anti-
goat/sheep 
Mouse 
IgG1 
GT-34 biotin Sigma 1:1000 
Streptavidin -  -  APC ebiosciences 1:600 
Table 2.1. Antibodies for flow cytometry staining.  
   
2.4.5. In vitro LTα cytokine stimulation assay  
Isolated stromal cells or dendritic cells were re-suspended at the same cell 
density in 500µl of DMEM (with 10% FCS, 1%GPS, 1% NEAA, 1%HEPES 
and 50µM β-mercaptoethanol) for in vitro LTα cytokine stimulation assay in 48 
well plates. T cells isolated from spleen of wt mice were incubated with 
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50ng/ml PMA (Phorbol-12-Myristate-13-Acetate), 750ng/ml Ionomycin and 
10ul of 108-109 p.f.u. of adenovirus for 4 h at 37°C. Stimulated cells T cells 
were then added at 1:4 ratios to 48 well plates with stromal cells and dendritic 
cells (DCs) with or without virus. DCs were FACS sorted from inflamed 
salivary glands (day 5 p.c.). Cells were harvested after 24 hours and taken for 
quantitative PCR analysis. 
 
2.5. Histology 
2.5.1. Tissue Harvesting 
After dissection, a portion of the cannulated salivary gland was saved for 
histology analysis. Freshly dissected tissue was placed in a cryomold (Sakura 
Finetek), embedded in OCT compound (Sakura Finetek) and frozen in dry ice 
and stored at -80°C. 
 
2.5.2. Cryosectioning 
Tissues were sectioned (5-7µm) using a Leica cryostat at -20°C. Slides were 
left to dry overnight; on the following day, were covered in foil and kept at -
80°C until use. 
Sectioning for mRNA isolation was carried out in the same cryostat, however 
extra care was taken to keep surfaces as clean as possible. Five to seven 
thick sections of 15µm were collected in an RNase-free eppendorf tubes 
(StarLab), using a sterile needle. Tubes were kept at -80°C until further use. 
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2.5.3. Immunofluorescence 
Stored slides were defrosted and fixed for 20 minutes in acetone (Sigma 
Aldrich). PFA fixed slides were incubated with Dako Target Antigen Retrieval 
Solution in a water bath at 95°C for 10 minutes. Slides were left to cool in the 
Target Antigen Retrieval Solution followed by wash in PBS. In order to block 
endogenous biotin, sections were incubated with avidin (1:20, Sigma Aldrich) 
and biotin (1:4, Sigma Aldrich) both for 15 minutes and with 5 minute washes 
with PBS in between. Finally, sections were blocked with 10% horse serum 
(Sigma Aldrich) for 10 minutes and incubated for 1 hour with primary 
antibodies diluted in PBS (1% BSA); followed by 10 minutes washing in PBS 
and incubation with secondary antibodies for 30 minutes. Secondary 
antibodies had been previously cross-adsorbed with 10% mouse serum 
(Sigma Aldrich) in a total volume of 100µl of PBS (1% BSA). Slides were 
washed again and stained with tertiary antibodies with nuclear yellow Hoechst 
(Invitrogen) for further 30 minutes. Slides were washed in PBS for 10 minutes 
and mounted using ProLong® Gold Antifade Reagent (Invitrogen) and stored 
at -20°C. Images were acquired using a Zeiss LSM 780 confocal microscope 
and processed using ZEN software. 
A list of primary and secondary antibodies used for immunofluorescence can 
be found in Tables 2.2 and 2.3, respectively.  
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Antibody Clone Format Supplier Dilution 
Used 
Hamster anti-
mouse gp38 
8.1.1 unconjugated ebiosciences 1:100 
Goat anti-
mouse 
CCL21 
AF457 unconjugated R&D Systems 1:100 
Hamster anti-
mouse CD3ε 
eBio500A2 
(500A2) 
biotin ebiosciences 1:50 
Hamster anti-
mouse CD3ε 
eBio500A2 
(500A2) 
FITC ebiosciences 1:100 
Rat anti-
mouse CD19 
eBio1D3 (1D3) eFluor660 ebiosciences 1:50 
Rat anti-
mouse CD45 
30-F11 APC ebiosciences 1:50 
Rat anti-
mouse CD4 
GK1.5 eFluor660 ebiosciences 1:50 
Rabbit anti-
mouse Lyve-
1 
polyclonal unconjugated Abcam 1:400 
Rabbit anti-
mouse FAP 
polyclonal unconjugated Abcam 1:50 
Table 2.2. Primary antibodies for immunofluorescence staining.  
 
Antibody Format Supplier Dilution Used 
Goat anti-
hamster 
biotin Biolegend 1:100 
Goat anti-
rabbit  
Alexa-Fluor488 Invitrogen 1:100 
Rabbit anti-
FITC 
unconjugated Invitrogen 1:200 
Donkey anti-
goat 
FITC Jackson 
Immunoresearch 
Laboratoies Inc. 
1:100 
Donkey anti-
rabbit 
Alexa-Fluor647  
Invitrogen 
1:100 
Streptavidin 555 Invitrogen 1:500 
Streptavidin 647 Invitrogen 1:300 
Table 2.3. Secondary antibodies for immunofluorescence staining.  
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2.5.4. Image analysis of immunofluorescence staining 
In order to quantify the size of the lymphocytic infiltrates in cannulated murine 
salivary glands, frozen salivary gland sections were stained with anti-CD3 and 
anti-CD19 and tile scans were acquired on a Zeiss LSM 780 confocal 
microscope. Using the ZEN software, a region of interest was drawn around 
the aggregates and total area of salivary gland tissue. Volume fraction of 
lymphoid follicles and average follicle area were calculated according to the 
formulas below. 
𝑉𝑜𝑙𝑢𝑚𝑒 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 (µ𝑚2) =  
𝑇𝑜𝑡𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑙𝑦𝑚𝑝ℎ𝑜𝑖𝑑 𝑓𝑜𝑙𝑙𝑖𝑐𝑙𝑒𝑠
𝑇𝑜𝑡𝑎𝑙 𝑡𝑖𝑠𝑠𝑢𝑒 𝑎𝑟𝑒𝑎
 
 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑙𝑦𝑚𝑝ℎ𝑜𝑖𝑑 𝑓𝑜𝑙𝑙𝑖𝑐𝑙𝑒 𝑎𝑟𝑒𝑎 (µ𝑚2)  =  
𝑇𝑜𝑡𝑎𝑙 𝑓𝑜𝑙𝑙𝑖𝑐𝑙𝑒 𝑎𝑟𝑒𝑎
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑓𝑜𝑙𝑙𝑖𝑐𝑙𝑒𝑠
 
 
2.5.5. Immunohistochemistry 
Formalin-fixed paraffin-embedded labial salivary gland biopsies from 
Sjögren’s syndrome patients were dewaxed in xylene three times (10 minutes, 
10minutes, 5minutes) and hydrated through decreasing ethanol 
concentrations (100%, 95%, 80%, 75%, 50%) for 2 minutes each. Slides were 
then washed in distilled water three times for 2 minutes each and incubated 
with Dako Target Antigen Retrieval Solution (Dako) for 35 minutes at 96°C. 
When finished, the slides were left to cool in the plastic jar at room 
temperature or at 4°C. Once the Target Antigen Retrieval Solution became 
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clear, slides were washed in TBS and sections were bordered with 
hydrophobic PAP pen for immunostaining (Sigma Aldrich). 
For incubation of primary antibodies, amplification methods and chromogens, 
the EnVisionTM G|2 Doublestain System, Rabbit/Mouse (DAB+/Permanent 
Red) (Dako) was used according to manufacturer’s instructions. This system 
allows the simultaneous detection of two different antigens in one section; the 
first antigen is identified with peroxidase (HRP) and DAB as the chromogen, 
and the second with alkaline phosphatase (AP) and Permanent Red. In brief, 
sections were blocked with Dual Endogenous Enzyme Block for 5 minutes, 
washed in TBS and the first primary antibody, diluted in TBS (+ 1% BSA) was 
incubated for 1 hour at room temperature. The secondary antibody with 
Polymer/HRP was incubated for 10 minutes and slides washed twice with 
TBS. Incubation with DAB took place under the light microscope and the 
reaction was stopped with distilled water when optimal brown staining was 
achieved. Followed by a blocking step with Doublestain Block reagent (3 
minutes), the sections were incubated with the second diluted primary 
antibody for 1 hour. The following step was the Rabbit/Mouse (LINK) for 10 
minutes and then another 10 minutes with Polymer/AP. The second reaction 
was then developed with Permanent Red and once again it took place under 
the light microscope until optimal red staining was achieved.  
Sections were dehydrated in increasing concentrations of ethanol (80%, 95% 
and 100%) and placed in xylene for five minutes, twice. Finally, slides were 
mounted with Mouting Medium DPX (Sigma Aldrich) and scanned using a 
Zeiss AxioScan.Z1 slide scanner. 
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A list of primary antibodies used for immunohistochemistry can be found in 
Tables 2.4.  
 
Antibody Clone Format Supplier Dilution Used 
CD3 Polyclonal unconjugated Dako 1:80 
CD20 L26 unconjugated Dako 1:20 
CD11c 5D11 unconjugated Leica 1:10 
Gp38 D2-40 unconjugated AbD serotec 1:10 
ICOS SP98 unconjugated Novus 
Biologicals 
1:10 
ICOSL N/A unconjugated LSBio 1:10 
Table 2.4. Primary antibodies for immunohistochemistry staining.  
 
2.6. Relative Quantification of Gene Expression 
2.6.1. RNA extraction 
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) as appropriate 
and following the manufacturer’s instructions. Salivary gland specimens were 
sectioned in the cryostat as mentioned above and, once thawed, lysed in 
200µl RLT Buffer (Qiagen) with 10% of β-mercaptoethanol (Sigma Aldrich). 
Samples were vortexed and centrifuged for 1 minute at 13000rpm, followed by 
200µl of ice-cold 70% ethanol (ratio 1:1 to RLT Buffer). After mixing by 
pipetting, samples were transferred to RNeasy mini spin columns and 
centrifuged for 2 minutes at 13000rpm. Solution in collection tube was 
discarded and 350µl of Buffer RW1 was added and centrifuged once again. 
80µl of DNase I (previously prepared with 10µl of DNase I to 70µl of Buffer 
RDD) was added directly to the column membrane and incubated for 15 
69 
 
minutes at room temperature. After DNase I incubation, centrifugation with 
350µl of Buffer RW1 was repeated, followed by 500µl of Wash Buffer RPE 
and a 1 minute spin, twice. The collection tube was discarded; pink columns 
were placed in new 2ml collection tubes and centrifuged for 5 minutes at 
13000rpm in order to dry the membrane. Columns were then placed in new 
1.5ml collection tubes and 12.5µl of RNase-free water was directly added to 
the membrane, twice, in order to elute the extracted RNA. 
To isolate total RNA from sorted cells the RNeasy Micro Kit (Qiagen) was 
used according to manufacturer’s instructions. In brief, there were three key 
differences to the protocol of RNA extraction from tissues. After adding 200µl 
of RLT Buffer to each sample, a 19G needle and a 2ml syringe was used to 
break up the cells further. Secondly, instead of a second wash with Wash 
Buffer RPE, 500µl of ice-cold 80% ethanol was added and centrifuged at 
13000rpm for 2 minutes. Lastly, at first RNA was eluted with 12.5µl of RNase-
free water and after centrifugation the eluted 12.5µl of RNA were put through 
the membrane again to ensure a higher concentration of RNA. 
 
2.6.2. cDNA Reverse Transcription 
cDNA was synthesized from total RNA on the same day as the RNA isolation, 
using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) in 
a 96 well plate (Applied Biosystems). A mix comprising 10X RT Buffer (5µl), 
10X Random Primers (5µl), 100nM dNTPs Mix (2µl), reverse transcriptase 
enzyme (2.5µl) and RNase-free water (10.5µl) was added to the RNA sample 
in a ratio 1:1. The plate was sealed with a MicroAmp™ Clear Adhesive Film 
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(Applied Biosystems) and spun for 2 minutes at 1200rpm. Reaction was 
carried out on a Techne TC-Plus thermal cycler with the following protocol: 
25°C for 10 minutes, 37°C for 2 hours and 85°C for 5 minutes. Once the 
reaction was completed, cDNA was diluted with 50µl of RNase-free whater 
(ratio 1:1) and kept at -20°C. 
 
2.6.3. Quantitative Real-Time PCR 
Following cDNA synthesis, quantitative real-time PCR (qRT-PCR) was 
performed on a 7900HT Real-Time PCR System (Applied Biosystems), using 
TaqMan® Gene Expression Master Mix (Applied Biosystems). Primers/probes 
(Applied Biosystems) were diluted in Master Mix at their reported optimal 
concentration and pre-labelled with 6-FAM™. Master Mix with primers/probes 
(2.6µl) and cDNA (2.3µl) were loaded into a 384-well plate (Applied 
Biosystems) in duplicate in a final volume 5.1µl. The plate was sealed with a 
MicroAmp™ Clear Adhesive Film (Applied Biosystems) and spun for 2 
minutes at 1200rpm. As mentioned above, the reaction took place on a 
7900HT Real-Time PCR System with standard thermal cycling conditions, 40 
cycles of: 2 minutes at 50°C for UNG activation; 10 minutes at 95°C for Taq 
polymerase enzyme activation; denaturation for 15 seconds at 95°C; and 1 
minute at 60°C for annealing. Results were analysed with RQ Manager 1.2 
software and Ct values were determined within the logarithmic phase of the 
PCR reaction, which correspond to the cycle number at which the 
amplification plot crosses the defined fluorescence threshold. The mean of the 
two technical replicates of the Ct values was calculated for each sample and 
gene, for both endogenous controls (β-actin and PDGFRβ) and targets. ΔCt 
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was determined by subtracting the endogenous control Ct value to the gene of 
interest Ct value and the relative amount was calculated as 2-ΔCt. All target 
genes were normalised to β-actin, except for stromal cell dependent genes 
that were normalised to PDGFRβ to account for possible differences in 
percentage of infiltrating cells. 
Relative quantity expression (RQ) of the target gene as compared to the 
endogenous control was calculated as 2-ΔΔCt, in which ΔΔCt corresponds to 
the difference between Ct values of genes in cannulated salivary glands (or 
sorted cells for cannulated glands) and Ct values from resting non-cannulated 
salivary glands (or from sorted cells from day 0 salivary glands).  
A list of primers used for qRT-PCR can be found in Table 2.5. 
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Gene  mRNA Accession 
number 
Assay ID Source 
Mouse β-
actin 
NM_007393.3 Mm01205647_g1 Applied Biosystems 
Mouse 
Pdgfrβ 
 
NM_001146268.1 
NM_008809.2 
 
Mm00435546_m1 Applied Biosystems 
Mouse 
CXCL13 
NM_018866 Mm00444533_m1 Applied Biosystems 
Mouse 
CXCR5 
NM_007551 Mm00432086_m1 Applied Biosystems 
Mouse 
CCL19 
NM_011888 Mm00839967_g1 Applied Biosystems 
Mouse CCR7 NM_007719 Mm01301785_m1 Applied Biosystems 
Mouse FAP NM_007986.3 Mm01329175_m1 Applied Biosystems 
Mouse ICOS NM_017480.2 Mm00497600_m1 Applied Biosystems 
Mouse ICOSL NM_015790.3 Mm00497237_m1 Applied Biosystems 
Mouse LTβ NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse LTα NM_007986 Mm00484254_m1 Applied Biosystems 
Mouse Pdpn NM_001290822.1 
NM_010329.3 
Mm01348912_g1 Applied Biosystems 
Mouse TNFα NM_013693 Mm00443258_m1 Applied Biosystems 
Mouse TNFR NM_011609.4 Mm00441883_g1 Applied Biosystems 
Table 2.5. Primers used for qRT-PCR.  
  
2.7. Statistical Analysis 
Statistical analysis was performed using GraphPad Prism and difference 
between groups assessed by student’s t test or, where appropriate and as 
indicated in relevant sections, one-way ANOVA. Significance was accepted at 
p ≤ 0.05. All graphs are presented as mean (SD). 
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Chapter 3  
ICOSL EXPRESSION BY LYMPHOID-LIKE STROMAL 
CELLS CONTRIBUTES TO T CELL ACTIVATION AND 
RELEASE OF LYMPHOTOXIN ALPHA THAT ENABLE 
CHEMOKINE PRODUCTION AND TLO 
ESTABLISHMENT 
3.1. Introduction 
Complex aggregates of lymphocytes are often found at sites of chronic 
inflammation (Pitzalis et al., 2014). These structures, namely TLOs, 
recapitulate in form and function the lymphoid follicles found in spleen and 
lymph nodes (Buckley et al., 2015). The stromal cell component of TLOs 
largely overlaps with that of SLOs and gp38+ICAM+VCAM+ stromal cell 
network (Link et al., 2011), FDCs and high endothelial cell formation have 
been described in TLOs (Barone et al., 2005).  
While SLOs are known to house mainly naïve lymphocytes, TLOs are 
prevalently inhabited by activated, memory T and B cells (Pitzalis et al., 2014). 
Formation of GCs with polyclonal B cell proliferation, class-switching 
recombination and somatic hypermutation has been observed in TLOs and 
believed to contribute to local expansion of auto-reactive B cell clones 
(Buckley et al., 2015). TLO assembly and GC formation are dependent on the 
expression of lymphoid chemokines that regulates lymphocyte organization in 
discrete areas (Allen et al., 2004, Ansel et al., 2000, Luther et al., 2002, 
Barone et al., 2005, Manzo et al., 2007). While in SLOs this phenomenon is 
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strictly dependent on LT (Cupedo and Mebius, 2005), several evidence 
suggests that in the periphery, lymphoid chemokine expression by resident 
stromal cells can be, at least in part, regulated by pro-inflammatory cytokines 
(Barone et al., 2015b, Fleige et al., 2014). 
Co-stimulatory signals provided by CD4+/bcl-6+/CXCR5+ TFH cells are also 
required for the establishment of GC, cytokine production, B cell differentiation 
and expansion (Schaerli et al., 2000, Haynes et al., 2007, Fazilleau et al., 
2009). Among those, ICOS (inducible co-stimulatory molecule), a member of 
the CD28 family, expressed on activated T cells (Hutloff et al., 1999) is critical 
for TFH differentiation and generation of the GC reaction (Dong et al., 2001a, 
Dong et al., 2001b, Wong et al., 2003). ICOSL is expressed on APCs, B cells 
and other non-hematopoietic cells, its expression can be enhanced in 
inflammatory conditions by exposure to IFN-γ and TNFα (Swallow et al., 
1999).  
ICOS/ICOSL interaction enhances basic T-cell responses to a foreign antigen 
support B cells antibody secretion (Hutloff et al., 1999), memory B cells and 
plasma cell differentiation (Hutloff et al., 1999, van Berkel and Oosterwegel, 
2006). Pharmacological or genetic interference with the ICOS pathway 
prevents the development of spontaneous disease in pre-diabetic NOD mice 
(Ansari et al., 2008), ameliorates collagen-induced arthritis and systemic lupus 
erythematous (Hu et al., 2009, Iwai et al., 2002). Treatment with anti-ICOSL 
blocking antibodies is currently the subject of clinical trials in autoimmune 
diseases characterized by TLO formation (http://www.clinicaltrials.gov; 
NCT00774943); however the mechanism of action of these molecules in TLO 
assembly is not fully understood. 
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In this chapter we explored the role of ICOS/ICOSL interaction in the 
formation of tertiary lymphoid organs during inflammation. We have 
investigated the expression of both co-stimulatory molecules in salivary gland 
biopsies from SS patients, and further examined their role and pathways 
involved in our murine model of TLO formation. 
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3.2. Results 
3.2.1. ICOS-ICOSL interaction influences chemokine expression on 
gp38+ stromal cells 
In order to dissect the potential changes occurring to the lymphoid aggregates 
in mice treated prophylactically with an anti-ICOS blocking antibody, 
immunofluorescence staining for T and B cells was performed on salivary 
gland sections obtained from mice at day 5 and 8 p.c.. Consistent with our 
previous findings both untreated and isotype-treated wild-type (wt) animals 
developed a significant number of salivary gland lymphoid aggregates, 
characterized initially by predominant T cell infiltration followed by B cell 
aggregation leading to the development of segregated and organized ectopic 
lymphoid structures (Figure 3.1A). In anti-ICOS treated mice a defect in TLO 
formation was observed with fewer T cells and minimal B cell influx (Figure 
3.1A). Accordingly, the transcript level of CCL19, the chemokine known to 
enable T cell recruitment in the early phases of TLO aggregation, was 
significantly reduced in anti-ICOS treated mice as compared to wt controls 
(Figure 3.1B). CXCL13 production, on the contrary, was not significantly 
affected by ICOS blockade (Figure 3.1C).  
Percentage of LLSc, a population of gp38+ stromal cells, was assessed by 
flow cytometry staining (Figure 3.1D) and the results between untreated wt 
and anti-ICOS treated mice were matched at days 2 and 5 p.c. (Figure 3.1E). 
At day 8 p.c., anti-ICOS treated salivary glands presented a significantly 
higher percentage of activated stromal cells (Figure 3.1E).
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Figure 3.1 (cont.) 
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Figure 3.1. In vivo blockade of ICOS results in an unexpected defect in TLO 
formation. (A) Wt mice were left untreated (i, iv) or treated with anti-ICOS blocking 
antibody (ii, v), isotype control (iii, vi) from day 0 post salivary gland cannulation and 
sacrificed at days 5 and 8 p.c. (post cannulation). Representative microphotographs of 
salivary glands examined by immunofluorescence for CD3ε (red) and CD19 (blue) 
showing lymphocytic infiltration. Original magnification 25X. (B-C) Quantitative RT-
PCR analysis of mRNA obtained from salivary glands at day 5 and 8 p.c. showing 
lymphoid chemokine ccl19 (B) and cxcl13 (C) in anti-ICOS treated wt mice (white bars) 
in comparison to their wt untreated (black bars) and isotype treated (grey bars) 
counterparts. ccl19 and cxcl13 mRNA transcripts were normalised to pdgfrβ mRNA 
and results are presented as relative quantitation (RQ). * p < 0.05; *** p < 0.001, 
unpaired t test. Data are representated as mean  (SD) of two independent 
experiments with at least four glands analysed per group. (D) Representative gating 
strategy of flow cytometry identification of CD45-EpCAM-CD31-gp38+ lymphoid-like 
stromal cells (LLSc), double negative cells (DN) and blood endothelial cells (BEC) in 
enzymatically digested salivary glands. (E) Time course analysis, following enzymatic 
digestion of dissected salivary glands, of the percentage of CD45-EpCAM-CD31-
gp38+ (LLSc) after cannulation assessed by flow cytometry in cannulated untreated 
(black bars) and anti-ICOS treated (white bars) wt mice. Data presented as mean (SD) 
of two independent experiments with two to six glands analysed per group. *** p < 
0.001, unpaired t test.  
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3.2.2. ICOSL is expressed by salivary gland activated stromal cells 
upon inflammation 
ICOSL is highly expressed on hematopoietic antigen presenting cells and 
ICOSL expression has been shown to be inducible in non-hematopoietic cells. 
In SLOs, gp38+ FRCs produce CCL19, in order to investigate whether the 
decrease in CCL19 was directly mediated due to a defect in the stromal cells 
or via interaction of other cell type, we sorted LLSc from inflamed murine 
salivary glands and in wt mice we demonstrated up-regulation of ICOSL on 
both gp38+ stromal cells and on hematopoietic cells (CD11c+ cells from 
inflamed salivary glands), both at mRNA and protein level post cannulation 
(Figure 3.2A-B).  
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Figure 3.2. ICOSL is expressed by activated stromal cells upon salivary gland 
inflammation. (A)  Icosl expression in FACS sorted CD45-EpCAM-CD31-gp38+ (LLSc) 
(black bars), CD45-EpCAM-CD31-gp38- (DN) (grey bars), activated CD11c+ dendritic 
cells (white bars). mRNA transcripts were assessed by qRT-PCR and normalised to 
housekeeping gene β-actin. RQ values calculated with calibrator day 0 DN cells. Data 
showed as mean (SD) of two independent experiments with at least two salivary glands 
per group. * p < 0.001; *** p < 0.001, one-way ANOVA. (B) Histogram showing flow 
cytometry staining for ICOSL expression in wt mice at day 0 p.c. (black line), wt mice at 
day 5 p.c. (blue line) and ICOSLKO mice at day 5 p.c. (grey line).  
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3.2.3. ICOSL-/- mice display impaired TLO formation, but normal 
numbers of LLSc upon salivary gland cannulation 
Consistent with our observations in anti-ICOS treated animals, ICOSLKO 
mice showed aberrant T cell recruitment and aborted TLO formation when 
compared to wt control mice (Figure 3.3A). In SLOs, FRCs provide the 
largest source of CCL19 (Link et al., 2007) and we previously demonstrated 
that, in TLOs, gp38+ cells express CXCL13 but not CXCL12 (Barone et al., 
2015b). Evaluation of (CD31-EpCAM-) gp38+ absolute cell number in 
ICOSLKO mice revealed similar levels to wt control (Figure 3.3B), thus 
suggesting that interfering with the ICOS/ICOSL pathways results in a 
functional rather than numerical impairment of the gp38+ stroma component. 
Sorted gp38+ cells from ICOSLKO mice showed significantly decreased 
CCL19 expression (Figure 3.3Ci); CXCL13 levels were not as affected as 
compared to their wt counterparts (Figure 3.3Cii).  
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Figure 3.3 
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Figure 3.3. ICOSLKO mice display impaired TLO formation, but normal numbers 
of LLSc, upon salivary gland cannulation. (A) Salivary glands from WT and 
ICOSLKO mice were cannulated and mice were sacrificed at days 5 and 8 p.c.. 
Representative microphotographs of salivary glands examined by 
immunofluorescence for CD3ε (red) and CD19 (blue) showing lymphocytic infiltration. 
Original magnification 25X. (B) Absolute numbers of CD45-EpCAM-CD31-gp38+ cells 
(LLSc) were determined by flow cytometry in both wt and ICOSLKO salivary glands at 
day 5 p.c.. ns = non-sgnificant, unpaired t test. Data expressed as mean (SD) of one 
experiment with four glands analysed per group. qRT-PCR analysis of ccl19 (i) and 
cxcl13 (ii) mRNA transcripts in FACS sorted LLSc from wt (black bars) and ICOSLKO 
(white bars) mice at day 5 p.c. Transcripts levels were normalised to β-actin and 
expressed relative to day 0 LLSc results. * p < 0.05; *** p < 0.001, unpaired t test, data 
represented as mean (SD) from two independent experiments with three to seven 
glands analysed per group. 
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3.2.4. T cells are the main source of ICOS in inflamed salivary 
glands 
T cells are known to express ICOS upon activation; accordingly, we detected 
ICOS expression on T cells and NK1.1+ cells infiltrating the cannulated 
salivary glands (Figure 3.4A). In ICOSLKO, ICOS transcript levels were not 
affected (Figure 3.4Ci). In order to investigate the role of T cells in the 
regulation of CCL19 expression we performed salivary gland cannulation of T 
cell deficient mice (cd3ε). Quantification of mRNA transcripts on infected 
salivary glands showed a significant defect in CCL19 expression at different 
time points post cannulation (Figure 3.4Bi) and both LTα and LTβ mRNA 
levels were significantly reduced (Figure 3.4Bii-iii). Interestingly, T cells 
isolated from ICOSL-/- salivary glands post inflammation produced lower levels 
of LTα than the wt controls but expressed normal levels of LTβ and TNFα 
(Figure 3.4Cii-iv).  
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Figure 3.4 
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Figure 3.4. T cells are the main source of ICOS in inflamed salivary glands. (A) 
Representative dot plot showing flow cytometry staining for ICOS expression in wt 
salivary glands at day 5 p.c. by CD3ε+ T cells and NK1.1. (B) qRT-PCR analysis of 
ccl19 (i), lta (ii) and ltb (iii) mRNA transcripts from wt (black bars) and CD3ε-/- (white 
bars) salivary glands at day 5, 8, 15 and 23 p.c.. lta and ltb were normalised to 
housekeeping gene β-actin, ccl19 results to pdgfrb and expressed as RQ values 
relative to day 0 mRNA transcripts results.. * p < 0.05; ** p < 0.01; *** p < 0.001, 
unpaired t test, data represented as mean (SD) from two independent experiments 
with four to six glands analysed per group. (C) qRT-PCR analysis of icos (i), lta (ii), ltb 
(iii) and tnfa (iv) mRNA transcripts in FACS sorted CD3ε+ T cells from wt (black bars) 
and ICOSLKO (white bars) mice at day 5 p.c. Transcripts levels were normalised to β-
actin and expressed relative to day 0 CD45+ cells results. ns = non significant, 
unpaired t test, data represented as mean (SD). from two independent experiments 
with three to four glands analysed per group. 
CD45+ cells CD45+NK1.1+cell
s 
CD45+CD3e+cell
s 
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3.2.5. ICOS activation on T cells induces release of LTα during 
inflammation 
These findings suggest a potential role of ICOS/ICOSL interaction in LTα 
production by T cells during inflammation. In wt cannulated mice, T cells were 
found to represent the predominant source of LTα (Figure 3.5A). Indeed 
ICOSLKO infected salivary glands contain lower T cells number and 
decreased expression of LTα as compared to wt controls (Figure 3.5B), thus 
justifying our finding of reduced CCL19 expression in this strain. Salivary 
glands from LtαKO mice, exhibited, upon cannulation a similar profile of 
chemokine expression as observed in cd3ε mice, showing abrogated levels of 
both CCL19 and CXCL13 (Figure 3.5Ci-ii).  
These findings suggest a novel role for ICOS/ICOSL interaction in the 
regulation of LTα production by activated T cells during TLO formation and a 
stringent dependency of CCL19 expression on local levels of LTα.   
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Figure 3.5. ICOS activation on T cells induces release of LTα during 
inflammation. (A) Representative dot plot of flow cytometry staining for LTα 
expression by T and B cells in wt (i) and LTαKO (iii) salivary glands at day 5 p.c.. 
Isotype control staining for LTα expression (ii). (B) Absolute numbers of T cells (i) 
and LTα-producing T cells (ii) in wt (black bars) and ICOSLKO (white bars) salivary 
glands at day 5p.c.. Results were determined by flow cytometry and presented as 
mean (SD) of two independent experiments with three to eight salivary glands per 
group. * p < 0.05; ** p < 0.01, unpaired t test. (C) qRT-PCR analysis of ccl19 (i) and 
cxcl13 (ii) mRNA transcripts from wt (black bars) and LTαKO (white bars) salivary 
glands at days 5, 8, 15 and 23 p.c.. Transcripts levels were normalised to pdgfrβ 
mRNA and results are presented as relative quantitation (RQ). * p < 0.05; ** p < 
0.01; *** p < 0.001, unpaired t test. Data represented as mean (SD) from two 
independent experiments with three to four glands analysed per group. 
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3.2.6. TNFR mediates the effects of LTα in our model of TLO 
formation 
Since LTα is known to signal through TNFRα to induce chemokine 
expression, we postulated that salivary gland cannulation in TNFRαKO mice 
would mimic the phenotype observed in LTαKO, CD3εKO and ICOSLKO 
mice. Indeed, FRC like (CD31-EpCAM-) gp38+stromal cells isolated from wt 
infected mice express TNFRI and increased this expression post cannulation 
(Figure 3.6C). In TNFRαKO mice, gene expression analysis of cannulated 
salivary glands unveiled a defect both in CCL19 and CXCL13 (Figure 3.6A) 
transcript levels. Accordingly, immunofluorescence staining revealed smaller 
lymphocytic aggregates with reduced T and B cell aggregation (Figure 3.6B).  
These data suggest that early CCL19 expression is regulated by TNFR 
signalling on stromal cells by engagement of ICOS+ T cells with ICOSL. 
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Figure 3.6 
Figure 3.6. TNFR mediates the effects of LTα in our model of salivary gland 
inflammation. (A) qRT-PCR analysis of ccl19 (i) and cxcl13 (ii) mRNA transcripts 
from wt (black bars) and TNFRKO (white bars) salivary glands at day 2, 5, 8 and 15 
p.c.. ccl19 and cxcl13 mRNA transcript results were normalised to pdgfrb. * p < 0.05; 
** p < 0.01; *** p < 0.001, unpaired t test, data represented as mean (SD) from two 
independent experiments with at least two salivary glands analysed per group. (B) 
Immunofluorescence staining in salivary glands from wt and TNFRKO mice for CD3ε 
(red) and CD19 (blue) at day 8 p.c.. Original magnification 25X. (C)  tnfra expression 
in FACS sorted CD45-EpCAM-CD31-gp38+ (LLSc) (black bars) at day 0, 5, 8 and 15 
p.c.. mRNA transcripts were assessed by quantitative real time PCR and normalised 
to housekeeping gene β-actin. Relative quantitation (RQ) values were calculated with 
calibrator day 0 DN cells. Data showed as mean (SD) of two independent experiments 
with two to four salivary glands analysed per group. * p < 0.05; ** p < 0.01, one-way 
ANOVA. 
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3.2.7. Engagement of non-hematopoietic derived ICOSL 
contributes to the expression of LTα by T cells  
ICOSL is highly expressed on hematopoietic APCs and ICOSL expression in 
vitro has been shown to be inducible in non-hematopoietic cells. In order to 
investigate the relevance of stromal cell derived ICOSL in the early 
establishment of TLOs, we generated bone marrow (BM) chimeras of both 
ICOSLKOmice reconstituted with wt BM and wt mice reconstituted with 
ICOSLKO  BM and studied TLO development as well as the regulation of LTα 
on T cells isolated from these mice. Flow cytometry analysis showed reduced 
numbers of infiltrating T cells in both groups of chimeric mice compared to wt 
controls (Figure 3.7Ai). Similarly, the number of LTα-producing T cells was 
also compromised when mice lacked ICOSL in both the hematopoietic and 
non-hematopoietic compartments (Figure 3.7Aii). This defect seen by flow 
cytometry was also confirmed by qRT-PCR analysis, showing decreased 
levels of lta and ccl19 mRNA in BM reconstituted animals (Figure 3.7Bi, ii).  
These findings demonstrated that ICOSL expressed early post inflammation 
by both the hematopoietic and stromal cell compartment is necessary for the 
expression of LTα by T cells.  
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Figure 3.7. Engagement of stroma-derived ICOSL contributes to the expression of 
LTα by T cells. (A) Absolute numbers of T cells (i) and LTα-producing T cells (ii) in wt 
(black bars), ICOSLKO mice reconstituted with wt bone marrow (dark grey bars) and wt 
mice reconstituted with ICOSLKO bone marrow (light grey bars) at day 5 p.c.. Results 
were determined by flow cytometry and presented as mean (SD) of two independent 
experiments with at least four salivary glands per group. * p < 0.05; *** p < 0.001, one-
way ANOVA. (B) Quantitative real time PCR analysis of mRNA transcripts of lta (i) and 
ccl19 (ii) in wt (black bars), ICOSLKO mice reconstituted with wt bone marrow (dark 
grey bars) and wt mice reconstituted with ICOSLKO bone marrow (light grey bars). lta 
mRNA transcripts were normalised to housekeeping gene β-actin and ccl19 results to 
pdgfrβ. ns = non-significant; ** p < 0.01; *** p < 0.001, one-way ANOVA, data presented 
as mean (SD) of two independent experiments with four to seven salivary glands 
analysed per group. 
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3.2.8. ICOSL expression by both activated stromal cells and 
dendritic cells supports the expression of LTα by T cells 
In order to validate these results in vitro, T cells isolated from spleen were co-
cultured with LLSc or DCs from either wt or ICOSLKO salivary glands. Lta 
mRNA signal was substantially decreased when T cells were cultured with 
lymphoid stroma as well as DCs from ICOSLKO, comparatively to when 
cultured with the correspondent wt control (Figure 3.8A).  
Additionally, a trans-well assay in which T cells were cultured in the same 
well, but not in contact with the other cell population, showed no significant 
differences in the expression of LTα by T cells. Of note, in the trans-well 
setting the induction of LTα expression was between 3 to 15 fold lower as 
compared to the direct co-culture experiment (Figure 3.8B).  
Those data suggest that cell-cell interaction is required by either professional 
APC or activated stromal cells to provide ICOSL required to activated newly 
recruited T cells and stimulate LTα production in early TLOs.  
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Figure 3.8. ICOSL expression by both activated stromal cells and dendritic 
cells supports the expression of LTα by T cells. (A) T cells were FACS sorted 
from wt mice and LLSc and DCs were isolated from both wt and ICOSLKO mice 
at day 0 p.c.. wt T cells were co-cultured with either wt or ICOSLKO LLsc or DCs, 
additionally stimulated with adenovirus. Graph presents quantitative real time 
PCR analysis that determined lta mRNA transcripts. qRT-PCR results were 
normalised to the housekeeping gene β-actin mRNA transcripts and results are 
presented as relative quantitation (RQ) values calibrated to unstimulated T cells 
cultured alone. * p < 0.05; ** p < 0.01; *** p < 0.001, one-way ANOVA, data are 
representative as mean (SD) of two independent experiments. (B) T cells were 
FACS sorted from wt mice and LLSc and DCs were isolated from both wt and 
ICOSLKO mice at day 0 p.c.. wt T cells were cultured in trans-wells with either wt 
or ICOSLKO LLsc or DCs, additionally stimulated with adenovirus. Graph 
presents quantitative real time PCR analysis that determined lta mRNA 
transcripts. qRT-PCR results were normalised to the housekeeping gene β-actin 
mRNA transcripts and results are presented as RQ values calibrated to 
unstimulated T cells cultured alone. ns = non-significant, one-way ANOVA, data 
are representative as mean (SD) of two independent experiments. 
Figure 3.8 (cont.) 
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3.2.9. ICOS and ICOSL expression in salivary glands of Sjögren’s 
syndrome patients 
In order investigate the relevance of our findings in human disease we 
investigated the expression of ICOS and ICOSL by immunohistochemistry on 
labial salivary gland biopsies from SS patients. Immunohistochemistry staining 
showed significant expression of ICOS and ICOSL in SS samples, confirming 
engagement of the ICOS-ICOSL pathway in inflamed salivary glands. ICOS 
expression was mainly detected on CD3+ cells (Figure 3.9A). ICOSL 
expression was detected within but not limited to the lymphocyte rich area in 
co-localization with CD20+ cells (Figure 3.9B), CD11c+ cells (Figure 3.9C) 
and on gp38+ cells thus suggesting a similar role for this pathway in human 
disease (Figure 3.9D).  
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Figure 3.9. ICOS and ICOSL expression in salivary glands of Sjögren’s syndrome 
patients. (A-D) Representative microphotographs of human salivary glands examined 
by immunohistochemistry for ICOS (brown, A), ICOSL (brown, B-C; pink, D) CD3 (red; 
A), CD20 (pink; B), CD11c (pink; C) and gp38 (brown, D). Original magnification 25X. 
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3.3. Discussion 
In this chapter we describe a novel role of co-stimulatory molecules ICOS and 
ICOSL in TLO formation and, moreover, activated stromal cells as a 
previously unidentified source of ICOSL during inflammation. 
Co-stimulation via ICOS-ICOSL interaction is critical for the generation of 
functional GCs, maturation of recruited T lymphocytes into cytokine-producing 
cells and production of antibodies. In autoimmunity this pathway is known to 
contribute to the development of autoreactive B cells and autoantibody 
production (Hondowicz et al., 2010). In autoimmune conditions such as SLE, 
RA and SS, higher frequencies of CD4+CXCR5+ICOShi T cells have been 
described (Hutloff et al., 2004, Ma et al., 2012, Simpson et al., 2010, Tangye 
et al., 2013). Furthermore, significantly increased levels of 
CD4+CXCR5+CCR6+ T cells, the TH17-like ‘circulating’ TFH were found in 
blood of SS patients and it was strongly correlated with increased detection of 
anti-Ro/SSA, anti-La/SSB (Jin et al., 2014, Li et al., 2012). Recently, Szabo et 
al. used immunohistochemistry to characterise the inflammatory infiltrates 
regarding their expression of TFH-related markers and found them mostly 
present in biopsies with higher focus score (Szabo et al., 2014). 
While those functions support ICOS-ICOSL targeting in TLO GCs this 
pathway has not been extensively explored but a recent study has reported 
that blockade of ICOS/ICOSL interaction suppresses the formation of ectopic 
lymphoid structures in a mouse model of artherosclerotic plaque development 
(Clement et al., 2015). The observed impairment was associated with a 
disrupted TFH - GC B cell axis as TFH cells are known to express ICOS and 
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were shown to take an active part in GC reaction within TLOs in diseased 
arteries (Clement et al., 2015).  
We previously demonstrated that activated stromal cells at site of TLO 
formation are responsible for chemokine production and early aggregation of 
recruited lymphocytes (Barone et al., 2015b). Here we show that gp38+ LLSc 
are also involved in the functional activation of the locally recruited 
lymphocytes, by up regulating ICOSL on their surface and contributing to the 
production of LTα from locally recruited ICOS+T cells. Indeed, absence of 
ICOSL in genetically modified mice or interference with ICOS/ICOSL 
interaction induced abrogation of TLO formation with significantly decreased 
expression of lymphoid chemokines and defective lymphocyte recruitment. 
Using bone marrow chimeras and co-culture in vitro experiments we 
demonstrated that ICOSL expressed by both the hematopoietic and stromal 
cell compartment contributes to the expression of LTα by T cells. Of note, wt 
controls reconstituted with wt bone marrow are missing from this experiment. 
These would have accounted for possible secondary effects from from 
irradiation and Baytril administration.  
Expression of co-stimulatory molecules on non-hematopoietic stromal cells 
has been previously reported and up regulation of ICOSL has been described 
on FRCs in the lymph node (ImmGen) and on TNFα stimulated fibroblasts 
(Swallow et al., 1999, Yoshinaga et al., 2000). However, to our knowledge this 
is the first report of functional stromal cell derived co-stimulation in the context 
of TLO establishment.  
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During lymph node organogenesis, stromal activation occurs prior and 
independently of lymphocytes. However, lymphocytes are critical in adult 
SLOs for maintenance of lymphoid structures. Evidence suggests that the 
maintenance of homeostatic lymphoid chemokine expression and FDCs in B 
cell follicles is dependent on LTαβ and TNFα expression on mature B cells 
(Endres et al., 1999, Fu et al., 1997b, Randall et al., 2008). It has been 
suggested that lymphocytes can substitute for the inductive function of LTi 
cells within SLOs, particularly when they are activated (Ware et al., 1992, 
Androlewicz et al., 1992, Tumanov et al., 2004, Tumanov et al., 2002, Fu et 
al., 1997a, Endres et al., 1999, Cupedo et al., 2004) and CD4+ T cells have 
been shown to be crucial for development of TLO in the thyroid (Marinkovic et 
al., 2006). TLO dependency on lymphotoxin signalling has been demonstrated 
in mice deficient in LT signaling or treated with anti-LTβR antibody (Columba-
Cabezas et al., 2006, Gatumu et al., 2009, Gommerman et al., 2003, Lee et 
al., 2006, Rangel-Moreno et al., 2011, Boulianne et al., 2012, Grabner et al., 
2009). Accordingly, LTα over-expression under the control of RIP, is able to 
induce TLO formation in a process that is dependent on TNFR1 but not LTβR, 
suggesting that signals through TNFR1, are sufficient to sustain TLO 
development (Sacca et al., 1995, Picarella et al., 1993, Kratz et al., 1996, 
Hjelmstrom, 2001).  
LTα expression is increased in synovium and serum from RA patients (Robak 
et al., 1998, O'Rourke et al., 2008), and interestingly RA patients that did not 
respond to anti-TNFα treatment were additionally treated with anti-TNFR, 
leading to clinical remission (Buch et al., 2004, Calmon-Hamaty et al., 2011). 
An in vitro study has shown that LTα stimulates proliferation and induces 
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secretion of IL-6, IL-8 and MMP3 by RA fibroblast-like synoviocytes (Calmon-
Hamaty et al., 2011). In SS patients, LTα is also increased in both the salivary 
glands and sera (Shen et al., 2010). 
Indeed, in our model, LTα effect was mediated by the activation of TNFRI; 
nonetheless the phenotype observed in the TNFRKO is not as severe as that 
observed in the LTαKO mice, thus suggesting that LTβR signalling 
collaborates with TNFRI for chemokine production by stromal cells. Similarly, 
Frances et al., previously shown that GC B cells from ICOSKO mice express 
lower levels of LTαβ compared with wild-type GC B cells in vivo. Interestingly, 
in that setting administration of agonistic anti-LTβ receptor antibody was 
unable to restore the GC response suggesting that additional input from 
another pathway or engagement of a different receptor is required to 
accomplish GC generation (Vu et al., 2008).  
Interestingly, in our system, CCL19 is more susceptible to the decrease in 
LTα as compared to CXCL13 and the production of the B cell recruiting 
chemokine is only partially dependent on ICOS-dependent T cells activation. 
We have previously shown that CXCL13 expression can be induced by 
cytokines other than lymphotoxin (Barone et al., 2015b). On the contrary, our 
data suggest that CCL19 expression requires the specific activation of a 
lymphoid axis that involves lymphotoxin. Indeed, while CXCL13 expression 
can be found in several infective conditions, not necessarly charaterised by 
lymphoneogenesis, the expression of both B and T cell chemokines in a 
regulated and organised manner is key to TLO formation. In this context, the 
early expression of LTα that regulates CCL19 production by local stromal 
might be critical to establish new TLOs.  
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Therefore, this work provides a relevant new insight to the role of co-
stimulation in TLO formation by establishing a functional connection between 
ICOS/ICOSL interaction, activation of pathogenic stroma and T cell 
importance in TLO development (Figure 3.10), as well as introducing potential 
new therapeutic targets in the context of SS. 
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Figure 3.10. Model of stroma-T cell cross-talk via ICOSL-ICOS interaction that is 
critical for TLO formation. At sites of TLO formation, activated LLSc and DCs 
upregulate ICOSL that interacts with the locally recruited ICOS+T cell stimulating the 
secretion of LTα. Engagement of LTα with TNFR upregulated on the activated stromal 
cells induces chemokine production, in particular CCL19, that in turn contributes to the 
recruitment and organization of further T cells and establishing the feedback loop 
required for TLO formation. 
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Chapter 4 
EARLY DELETION OF GP38 POST SALIVARY GLAND 
INFLAMMATION DOES NOT IMPAIR TLO FORMATION 
 
4.1. Introduction 
During inflammation expression of gp38 is induced on tissue resident 
fibroblasts (Peduto et al., 2009). Up-regulation of gp38 expression by these 
stromal cells is associated with the acquisition of a lymphoid-like cell 
phenotype similar to that observed in secondary lymphoid organs. These cells 
establish a network that supports lymphocyte recruitment and survival (Peduto 
et al., 2009). However, most studies regarding gp38 expression are 
descriptive and fail to establish a functional role for this molecule in pathology. 
Recently, Acton et al. have shown that engagement of gp38 with CLEC-2 on 
dendritic cells is necessary for cytoskeleton rearrangement and the 
consequent cell motility along stromal cell surfaces (Acton et al., 2012). On 
the other hand, interaction between gp38 and CLEC-2 allows relaxation of 
FRC cytoskeleton and cell stretching, allowing rapid lymph node expansion 
(Acton et al., 2014).  
Previous data from our group has shown that a population of gp38+ stromal 
cells expands in the target organ of inflammation (salivary glands). This 
population is characterised by expression of ER-TR7, ICAM-1 and VCAM-1 
(Saba Nayar, unpublished data).  
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During lymph node formation, mature LTo stromal cells express ICAM-1 and 
VCAM-1 and produce homeostatic chemokines. The maturation of resident 
mesenchyme from ICAMintVCAMint to ICAMhiVCAMhiMadCAM+ cells is 
dependent on LTβR signalling and crosstalk with LTi cells (Cupedo et al., 
2004, White et al., 2007, Benezech et al., 2010). 
Accordingly, the population of gp38+ stromal cells found in inflamed salivary 
glands acquire the capability to secrete lymphoid chemokines CXCL13 
(Barone et al., 2015b), CCL19 and CCL21, survival factors BAFF and IL-7 and 
also LTβR and TNFR1 (Saba Nayar, unpublished data). On the basis of these 
features we named these cells lymphoid-like stromal cells (LLSc). In our 
published model of viral-induced TLO formation, this gp38+CD31- LLSc 
population expands from as early as 3 hours post cannulation (p.c.) and 
peaks at day 5, representing over 40% of the CD45-EpCAM- component. 
FACS analysis for Ki67 and BrdU suggested that the expansion of this 
population within the first few hours of virus delivery was most likely not due to 
proliferation but to upregulation of gp38 on CD45-EpCAM-CD31- cells, since 
active proliferation was observed between day 2 and day 5 (Saba Nayar, 
unpublished data). Resolution of the lymphoid aggregates occurs from day 23 
p.c. and by day 26 the percentage of LLSc is comparable with what can be 
observed in resting salivary glands (about 7%) (Saba Nayar, unpublished 
data).  
Histologically, gp38 expression is largely present in inflamed salivary glands 
on epithelial, lymphatic endothelial and stromal cells; while LLSc are detected 
in close proximity with lymphoid aggregates (Figure 4.1). 
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In order to investigate the role of g38 expression by resident stromal cells 
during inflammation we utilised a conditional Pdpn knockout mice to 
specifically dissect the role of gp38 in the formation of ectopic lymphoid 
structures. Since the genetic deletion of Pdpn is lethal (Schacht et al., 2003), 
we have induced TLO formation in a conditional Pdpn knockout strain 
(PDPNfl/flR26ERT2Cre/Cre), where deletion of gp38+ cells will be obtained upon 
administration of tamoxifen.  
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A 
Figure 4.1. Gp38 expression in inflamed salivary glands. Wt mice were cannulated, 
virus administered and mice sacrificed at day 8 p.c. (post cannulation). (A) 
Representative microphotograph of salivary glands examined by immunofluorescence 
for gp38 (blue) and DAPI nuclear staining (grey). Original magnification 25X. (B) 
Confocal image of cannulated wt salivary gland stained for gp38 (blue) and CD45 (red). 
Original magnification 10X. 
Figure 4.1 
DAPI / gp38  
B 
gp38 CD45   
106 
 
4.2. Results 
4.2.1. Tamoxifen treatment efficiently downregulates gp38 
expression in stromal cells from PDPNfl/flR26ERT2Cre/Cre 
salivary glands 
In order to study the role of gp38 expression we have used a conditional Pdpn 
knockout. Tamoxifen was administered for five consecutive days to 28 day old 
PDPNfl/flR26ERT2Cre/Cre mice; as described in section 2.1.1. Mice remained 
un-manipulated for a further period of 35 days to account for Tamoxifen wash 
out. 
FACS analysis was performed to address level of gp38 deletion. Dissected 
salivary glands from wt untreated, non-cannulated mice (8 weeks old) 
revealed the presence of two stromal cells populations within the CD45-
EpCAM-CD31- cell fraction. These two populations were defined by the 
presence or absence of gp38 expression; respectively named lymphoid-like 
stromal cells (LLSc) (gp38+CD31-) and double negative (DN) (gp38-CD31-) 
(Figure 4.2A and Bi). Similar stromal populations with distinct levels of gp38 
expression were also observed in Tamoxifen treated control 
PDPN+/+R26ERT2Cre/Cre mice (Figure 4.2A and Bii).  
On the contrary salivary glands isolated from PDPNfl/flR26ERT2Cre/Cre, at day 
36 post Tamoxifen, showed a significant loss of gp38 expression within the 
CD45-EpCAM-CD31- compartment (Figure 4.2A). Enzymatically digested 
salivary glands from PDPNfl/flR26ERT2Cre/Cre mice not only presented a 
smaller percentage of LLSc (3.97%) but also this population expressed lower 
levels of gp38 (Figure 4.2Biii), showing that even though the strain did not 
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behave as a complete knockout, Tamoxifen treatment did result in a 
significant downregulation of gp38 expression by the CD45-EpCAM-CD31- 
compartment in the salivary glands. 
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Figure 4.2. Tamoxifen treatment efficiently downregulates gp38 expression in 
stromal cells from Tamoxifen treated PDPN
Fl/Fl
R26ERT2
Cre/Cre
 salivary glands. (A) 
Histogram showing flow cytometry staining for gp38 expression in wt (grey), 
PDPN
+/+
R26ERT2
Cre/Cre
 (blue) and PDPN
Fl/Fl
R26ERT2
Cre/Cre 
(red) mice at day 36 post 
Tamoxifen administration. (B) Representative dot plot showing flow cytometry staining 
for gp38 expression in CD45-EpCAM- cells from wt (i), PDPN
+/+
R26ERT2
Cre/Cre
 (ii) and 
PDPN
fl/fl
R26ERT2
Cre/Cre 
(iii) salivary glands at day 36 post Tamoxifen.  
CD45-EpCAM-CD31- 
109 
 
4.2.2. Lower levels of gp38 expression by stromal cells is not 
maintained during inflammation in PDPNfl/flR26ERT2Cre/Cre 
mice 
After verifying that tamoxifen treatment downregulates gp38 expression in 
CD45-EpCAM-CD31- cells from PDPNfl/flR26ERT2Cre/Cre salivary glands, we 
aimed to study the development and maintenance of TLOs in these mice post 
adenoviral delivery. 
Post salivary gland cannulation and adenovirus infection, FACS analysis of 
gp38 expression in PDPN+/+R26ERT2Cre/Cre cannulated glands revealed a 
similar dynamic to that observed in the wt mice (Saba Nayar unpublished). 
The LLSc population in the control mice expanded to about 40% (of CD45-
EpCAM- cells) at days 5 and 8 p.c. (Figure 4.3Ai and Bi). On the contrary, in 
the salivary glands from PDPNfl/flR26ERT2Cre/Cre mice the percentage of LLSc 
was around 10%, thus showing a significant decrease as compared to 
controls (Figure 4.3Aii and Bii). At day 15 p.c., the percentage of gp38+ 
stromal cells in the PDPNfl/flR26ERT2Cre/Cre was closer to control mice, 
although still showing a difference in the expression of gp38 (Figure 4.3Ci, ii). 
A similar phenotype was observed at day 23 p.c. (Figure 4.3Di, ii). 
The mean fluorescence intensity for gp38 expression from the flow cytometry 
data was significantly reduced at days 5 and 15 p.c. in PDPNfl/flR26ERT2Cre/Cre 
salivary glands (Figure 4.3E).   
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Absolute numbers of this population of activated stromal cells was also 
reduced between PDPNfl/flR26ERT2Cre/Cre and control mice, however no 
significant differences were found between the tamoxifen treated mice and the 
controls (Figure 4.4B).  
Ki67 analysis showed a trend in increased proliferation in the tamoxifen 
treated mice that was found statistically significant at day 8 and 23 post 
cannulation and interpreted as mechanism of compensation of the stromal cell 
compartment for the loss of gp38 (Figure 4.4C). 
Figure 4.3 (cont.) 
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Figure 4.3. Stromal cells from cannulated PDPN
fl/fl
R26ERT2
Cre/Cre
 salivary glands 
post Tamoxifen treatment express reduced levels of gp38. PDPN
+/+
R26ERT2
Cre/Cre
 
and PDPN
fl/fl
R26ERT2
Cre/Cre
 mice were treated with Tamoxifen and cannulated at day 
35. Mice were sacrificed at days 5 (A), 8 (B), 15 (C) and 23 (D) p.c.. Representative dot 
plots showing flow cytometry staining for gp38 expression in CD45-EpCAM- cells from 
PDPN
+/+
R26ERT2
Cre/Cre
 (i) and PDPN
Fl/Fl
R26ERT2
Cre/Cre 
(ii) salivary glands. (E) Mean 
fluorescence intensity of gp38 in LLSc at days 5, 8 and 15 p.c. from 
PDPN
+/+
R26ERT2
Cre/Cre
 (i) and PDPN
Fl/Fl
R26ERT2
Cre/Cre 
(ii) salivary glands. Data 
presented as mean (SD) with three to four glands analysed per group. ** p < 0.01; *** p 
< 0.001, unpaired t test.  
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Figure 4.4. Tamoxifen treated PDPN
Fl/Fl
R26ERT2
Cre/Cre
 salivary glands fail to expand 
LLSc population early post salivary gland cannulation. PDPN
+/+
R26ERT2
Cre/Cre
 and 
PDPN
fl/fl
R26ERT2
Cre/Cre
 mice were treated with Tamoxifen and cannulated at day 35. 
Mice were sacrificed at days 5 (A), 8 (B), 15 (C) and 23 (D) p.c.. Percentage (A) and 
absolute numbers (B) of LLSc as well as percentage of Ki67+LLSc (C) was assessed by 
flow cytometry staining for gp38+CD31- cells in a CD45-EpCAM- population from day 0 
to day 23 p.c. in PDPN
+/+
R26ERT2
Cre/Cre
 treated with Tamoxifen (black) and 
PDPN
fl/fl
R26ERT2
Cre/Cre 
mice
 
treated with Tamoxifen
 
(grey). Data presented as mean (SD) 
with two to fifteen glands analysed per group. * p < 0.05; *** p < 0.001, unpaired t test.  
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4.2.3. Lymphoid chemokine expression is not affected by gp38 
downregulation in PDPNfl/flR26ERT2Cre/Cre mice 
Analysis of mRNA transcripts from whole frozen tissue sections has further 
confirmed gp38 downregulation in tamoxifen treated PDPNfl/flR26ERT2Cre/Cre 
salivary glands (Figure 4.5A). Nonetheless, consistent with what we had 
observed in single cell suspensions, low expression of gp38 expression was 
maintained in the early inflammatory phases, although significantly reduced as 
compared to control glands. mRNA transcripts for gp38 were significantly 
increased at day 15 and 23 p.c. in the salivary glands from 
PDPNfl/flR26ERT2Cre/Cre, while maintaining significantly lower levels as 
compared to the wt and PDPN+/+R26ERT2Cre/Cre controls (Figure 4.5A). 
Within the lymph node environment, gp38+ lymphoid stromal cells have been 
shown to produce lymphoid chemokines responsible for lymphocyte 
recruitment and lymphoid aggregate organization (Peduto et al., 2009). Our 
group and others have described similar functions of the gp38+ LLSc in 
ectopic TLO structures and murine salivary glands upon cannulation (Peduto 
et al., 2009, Barone et al., 2015b).  
In Pdpn-deficient salivary glands, levels of mRNA transcripts coding lymphoid 
chemokines CCL19 and CXCL13 were not affected, showing an analogous 
dynamic to experimental controls (Figure 4.5B and C). 
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Figure 4.5. Tamoxifen treatment downregulates gp38 expression but does not 
affect expression levels of lymphoid chemokines. qRT-PCR analysis of Pdpn (A), 
ccl19 (B) and cxcl13 (C) mRNA transcripts from PDPN
+/+
R26ERT2
Cre/Cre
 treated with 
Tamoxifen (black) and PDPN
fl/fl
R26ERT2
Cre/Cre 
mice
 
treated with Tamoxifen
 
(grey). qRT-
PCR results for Pdpn were normalised to housekeeping gene β-actin and ccl19 and 
cxcl13 results normalised to Pdgfrb. ** p < 0.01; *** p < 0.001, unpaired t test, data 
represented as mean (SD) with two to nine glands analysed per group.  
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4.2.4. TLO formation is not impaired in cannulated salivary glands 
of Tamoxifen treated PDPNfl/flR26ERT2Cre/Cre mice 
Cannulated salivary glands from both tamoxifen treated 
PDPN+/+R26ERT2Cre/Cre and PDPNfl/flR26ERT2Cre/Cre mice were sectioned and 
stained for identification and characterisation of lymphoid aggregates using 
immunofluorescence.  
At day 8 p.c. aggregates comprising both CD3ε+ and CD19+ cells could be 
equally observed in both experimental groups (Figure 4.6Ai, ii). Also, as 
expected for this specific time point, scattered CD3+ cells were found and no 
striking differences were noted between salivary glands lacking gp38 and 
control glands (Figure 4.6Ai, ii). 
Later, when full TLO formation was expected and indeed observed in control 
salivary glands at day 15 p.c., tamoxifen treated PDPNfl/flR26ERT2Cre/Cre 
glands presented fully developed, organised and segregated lymphoid 
aggregates (Figure 4.6Aiii, iv). 
Image analysis of immunofluorescence staining on both groups unveiled a 
higher area of salivary gland tissue occupied by lymphoid aggregates in 
PDPNfl/flR26ERT2Cre/Cre mice (Figure 4.6B). The average follicle area was 
also increased in this group, however also for this parameter the difference 
observed was not statistically significant (Figure 4.6B). 
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Figure 4.6 (cont.) 
Figure 4.6. Diminished expression of gp38 do not impair TLO formation in inflamed 
salivary glands. PDPN
+/+
R26ERT2
Cre/Cre
 and PDPN
fl/fl
R26ERT2
Cre/Cre
 mice were treated 
with tamoxifen and cannulated at day 35. Mice were sacrificed at days 8 and 15 p.c.. (A) 
Representative microphotographs of salivary glands examined by immunofluorescence 
for CCL21 (green), CD3ε (red) and CD19 (blue) showing lymphocytic infiltration. Original 
magnification 25X. (B) Image analysis of immunofluorescence images for volume fraction 
of lymphoid follicles and average follicle area. Data presented as mean (SD) with three 
glands analysed per group, unpaired t test.  
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4.2.5. Decreased gp38 expression associates with failed 
upregulation of adhesion chemokines at day 8 p.c.  
In the context of secondary lymphoid organ formation, upregulation of 
adhesion chemokines by gp38+ stromal cells has been described as one of 
the features of their maturation into lymphoid tissue organizer cells (Benezech 
et al., 2010) 
Here we have investigated by flow cytometry analysis both percentage and 
absolute numbers of VCAMintICAMint and VCAMhiICAMhi cells within the 
CD45-EpCAM-CD31- compartment of PDPNfl/flR26ERT2Cre/Cre and control 
mice. In the VCAMintICAMint population no significant changes were observed 
between the two groups, with the exception of an increase in percentage (but 
not absolute cell number) in the PDPNfl/flR26ERT2Cre/Cre salivary glands at day 
15 p.c. (Figure 4.7Ai, ii). However, a reduction of about 50% in both absolute 
number and percentage of VCAMhiICAMhi cells was observed in cannulated 
salivary glands of PDPNfl/flR26ERT2Cre/Cre mice at day 8 p.c. (Figure 4.7Bi, ii). 
No other time point showed any statistically significant changes in the 
proportion of VCAMhiICAMhi stromal cells.  
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Figure 4.7 
A 
Figure 4.7. Gp38 expression do not affect upregulation of adhesion molecules 
by activated stromal cells. PDPN
+/+
R26ERT2
Cre/Cre
 (blue) and 
PDPN
fl/fl
R26ERT2
Cre/Cre
 (red) mice were treated with Tamoxifen and cannulated at 
day 35. Mice were sacrificed at days 5, 8, 15 and 23 p.c.. Percentage and absolute 
numbers of VCAM
int
ICAM
int
 (A) VCAM
hi
ICAM
hi
 (B) was assessed by flow cytometry 
staining of CD45-CD31-EpCAM- cells Data presented as mean (SD) with two to 
fifteen glands analysed per group. ** p < 0.01; *** p < 0.001, unpaired t test.  
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4.2.6. Resting and immunized PDPNfl/flR26ERT2Cre/Cre lymph nodes 
exhibit no defects in architecture or organization 
We then sought to explore the consequences of gp38 downregulation in 
SLOs, particularly in the capability to mount an immune response against a T 
cell dependent antigen by immunizing brachial lymph nodes of Pdpn-deficient 
mice. 
Firstly we examined resting un-immunized brachial lymph nodes from 
Tamoxifen treated PDPN+/+R26ERT2Cre/Cre mice and found normal lymph 
node architecture with well-defined CD3+ and CD19+ areas (Figure 4.8A). 
Gp38 positive staining was identified in both CD3+ and CD19+ areas as well 
as co-localization with Lyve-1+ lymphatic vessels (Figure 4.8A). Lymph 
nodes from PDPNfl/flR26ERT2Cre/Cre mice were, on the contrary almost 
completely negative for gp38 staining and only a few scattered gp38+ cells 
could be found in T cell areas and in close proximity with lymphatic vessels 
(Figure 4.8B). Nonetheless, in the absence of gp38, lymph node structure 
and organization was intact. 
Post immunization, both the wt and PDPN+/+R26ERT2Cre/Cre control mice 
exhibited highly expanded lymph nodes with dense networks of gp38+ cells 
and an enlarged lymphatic structure (Figure 4.9A and B). Immunized lymph 
nodes from gp38-deficient mice lacked the gp38+ networks observed in the 
control mice (Figure 4.9C).  
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   Figure 4.8 
Figure 4.8. Lymph nodes from un-manipulated PDPN
fl/fl
R26ERT2
Cre/Cre
 mice show 
normal architecture and organization. Brachial lymph nodes from 
PDPN
+/+
R26ERT2
Cre/Cre
 (A) and PDPN
fl/fl
R26ERT2
Cre/Cre 
(B) mice post tamoxifen 
administration were dissected. Representative immunofluorescence staining of lymph 
nodes for CD3ε (green), gp38 (red) and CD19 (blue), and Lyve-1 (green), gp38 (red) 
and CD4 (blue). Original magnification 25X.  
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Figure 4.9. In the absence of gp38, immunized lymph nodes from 
PDPN
fl/fl
R26ERT2
Cre/Cre
 mice show no apparent defect. Brachial lymph nodes from 
Tamoxifen-treated PDPN
+/+
R26ERT2
Cre/Cre 
(A) and PDPN
fl/fl
R26ERT2
Cre/Cre 
(B) mice were 
dissected at day 8 post immunization. Representative immunofluorescence staining of 
lymph nodes for CD3ε (green), gp38 (red) and CD19 (blue), and Lyve-1 (green), gp38 
(red) and CD4 (blue). Original magnification 25X.  
Figure 4.9 (cont.) 
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4.3. Discussion  
It has been shown previously that during inflammation and cancer, activated 
tissue-resident stromal cells acquire features similar to those of lymphoid 
stromal cells and are able to sustain TLO formation (Peduto et al., 2009). 
Lymphoid stromal cells induced upon inflammation were characterized by 
upregulation of adhesion molecules and gp38 expression (Peduto et al., 
2009).  
Accordingly, our group has demonstrated the ability of gp38+ stromal cells to 
secrete lymphoid chemokines (CCL19, CCL21 and CXCL13) under 
inflammatory conditions at sites of TLO formation, in a model of viral induced 
salivary gland inflammation. While in resting salivary glands of wt mice gp38 
expression is detected on epithelial cells and in a small percentage of stromal 
cells, this expression is significantly increased during inflammation.  
In patients with RA, gp38 expression was found to be abundant in inflamed 
joints, but not detectable in normal synovial tissues (Del Rey et al., 2014). 
Interestingly, gp38 overexpression appeared to correlate with the presence of 
ectopic TLO in the synovium (Del Rey et al., 2014). Expansion of the gp38+ 
compartment has also been described in SS and primary biliary cirrhosis 
patients as well as in animal models of salivary gland, pancreas, kidney and 
liver injuries (Link et al., 2011, Buckley et al., 2015, Barone et al., 2015b, 
Eckert et al., 2016).  
Genetic deletion of Pdpn is lethal and mice die shortly after birth due to 
respiratory complications and exhibit severe defects in lymphatic vessel 
formation (Schacht et al., 2003). In this chapter we aimed to investigate the 
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consequences of gp38 deletion in the context of TLO formation, using a 
Tamoxifen mediated conditional Pdpn knockout. 
Here we demonstrate that we can achieve efficient downregulation of gp38 
with tamoxifen administration, both in resting conditions and at the early time 
points after salivary gland cannulation. However, an apparent inflammation-
induced upregulation of gp38 was observed, both at protein and at mRNA 
levels that was sufficient to re-establish the levels of gp38 observed in the wt 
mice and in the PDPNfl/flR26ERT2Cre/Cre mice. These results led us to 
conclude that the conditional knockout PDPNfl/flR26ERT2Cre/Cre strain might 
not represent the ideal model to dissect the role of gp38 in inflammation. We 
are aware of the limitation of our ablation technique, however we are confident 
that our results sustain the conclusion that gp38 is not an essential 
requirement in the initiation of the processes involved in TLO formation, 
however the cells that express this molecule may have a role. 
As previously described, both by Yang et al. and our group (Saba Nayar, 
unpublished data), gp38 upregulation takes place as quickly as 3 hours post 
inflammatory insult, acting as an activation/danger signal for the neighbouring 
cells (Yang et al., 2014). Furthermore, unpublished data from our group 
shows that gp38+ stromal cells are significantly more proliferative than their 
gp38- counterparts. In line with these findings, and considering that tamoxifen 
administration does not induce a complete Pdpn knockout phenotype, 
increased gp38 expression upon inflammation in these mice can be explained 
by the expansion of resident cells that acquire the ability to  express gp38, 
and are not deleted by our original treatment. Indeed, even though 
PDPNfl/flR26ERT2Cre/Cre salivary glands have reduced numbers of gp38+ 
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stromal cells to start with, these cells exhibited a significantly higher 
proliferative ability, which we believe is acting as a compensatory mechanism 
in an attempt to repopulate the gp38+ compartment and sustain TLO 
formation in these mice. 
On the other hand, even though an upregulation of gp38 was observed, the 
levels of gp38 mRNA were still significantly lower in PDPNfl/flR26ERT2Cre/Cre 
salivary glands as compared to control mice, and at all time points post 
salivary gland cannulation. Still, this defect did not affect lymphocyte 
aggregation within the TLO or the expression of lymphoid chemokines by 
stromal cells. This suggests that either gp38 might not be required for ectopic 
lymphoid tissue neogenesis or that the lower levels of gp38 maintained in our 
knockout were sufficient to provide and contribute to the initiation of the 
cascade of activation signals required in this model. 
A significant decrease in both absolute numbers and percentage of 
VCAMhiICAMhi cells was found in the CD45-EpCAM-CD31- compartment of 
PDPNfl/flR26ERT2Cre/Cre at day 8 p.c.. As already discussed above, this 
reduction was not maintained but the levels of gp38 mRNA significantly 
increased after day 8 p.c.. Benezech et al. demonstrated that VCAMintICAMint 
cells give rise to VCAMhiICAMhi MAdCAM-1+ stromal organizer cells 
(Benezech et al., 2010) and our results lead us to hypothesize that, if the 
strain maintained the knockout phenotype throughout inflammation, gp38 
expression could potentially be required for the full maturation of stromal cells 
and acquisition of some of the LTo features such as expression of high levels 
of adhesion molecules. 
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In a murine model of sepsis, FRCs have been described as 
immunosuppressive since their administration significantly reduced mortality 
and secretion of pro-inflammatory cytokines (Fletcher et al., 2014). 
Furthermore, FRCs can suppress T cell proliferation via nitric oxide synthase 
2 (NOS2); particularly, nitric oxide expression was associated with a reduction 
in the proportion of activated T cells in lymph nodes and the DC ability to 
prime T cells (Lukacs-Kornek et al., 2011, Siegert et al., 2011, Khan et al., 
2011). 
Chai et al. have reported that in the absence of gp38+ FRCs, following 
conditional ablation of LTβR, lymph nodes were not able to generate an 
appropriate immune response against a virus insult (Chai et al., 2013). Our 
preliminary work on lymph nodes from PDPNfl/flR26ERT2Cre/Cre following 
immunization with NP-CGG showed a general apparent normal structure and 
expansion of brachial lymph nodes. However, no functional analysis was 
performed during this preliminary experiment. Interestingly, at day 8 post 
immunization the gp38+ stromal cell network, usually easily identified in wt 
mice, was not present in PDPNfl/flR26ERT2Cre/Cre mice. The functional 
consequences of gp38 loss in lymph nodes and within the TLO have to be 
addressed.  
Collectively, the results described in this chapter show that temporary deletion 
of gp38 does not affect the formation of ectopic lymphoid structure but 
significantly affects the number of VCAMhiICAMhi cells. The mechanism by 
which this reflects a stronger ANA reactivity in the mice is not clear. Possibly 
our deletion protocol has not been appropriate and an improved one could be 
implemented, possibly by extending the original depletion with a tamoxifen 
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based diet. A persistent downregulation of gp38 would allow us to better 
dissect the role of this molecule not only in TLO establishment but also in 
maintenance of such structures. Similarly the role of gp38 in lymph node 
remodelling after insult could be addressed by maintaining gp38 suppression. 
These experiments are currently been undertaken in our laboratory. 
In order to further dissect the role of LLSc we have taken advantage of co-
expression of FAP by gp38+ stromal cells and utilised a murine model of 
conditional depletion of FAP-expressing cells (Kraman et al., 2010). Results 
illustrating the consequences of depleting LLSc, rather than downregulating 
gp38 expression, in our model of salivary gland inflammation are described in 
Chapter 5. 
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Chapter 5 
DEPLETION OF FAP+GP38+ STROMAL CELLS 
IMPAIRS TLO FORMATION  
 
5.1. Introduction 
Postnatal TLO formation is seen in association with chronic inflammation, 
cancer and chronic antigen stimulation. The development of these structures 
is associated with the activation of tissue resident stromal fibroblasts, their up-
regulation of the expression of gp38 and the acquisition by these stromal 
cells, of an FRC-like phenotype. Critically, the development of this lymphoid 
tissue like stroma derived from inflammatory stromal cells is a key determinant 
of TLO formation within chronically inflamed tissue (Buckley et al., 2015).  
Despite their importance, studies into the functional role of lymphoid-like 
stromal cells in the development of TLOs has been compounded by an 
inability to examine the functional consequence of experimental deletion of 
these cells. 
The conditional deletion of Pdpn could not be used to address this question, 
since in the salivary gland we observed a significant up-regulation of gp38 
post inflammatory insult. However, the co-expression of FAP by FRCs allowed 
us to use an alternative approach utilising a Tg mouse in which FAP 
expressing cells can be experimentally ablated (Denton et al., 2014, Kraman 
et al., 2010).   
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FAP was first described as a cell-surface antigen identified on human 
astrocytoma and sarcoma cell lines in vitro (Garin-Chesa et al., 1990a). Fap 
gene expression is significantly upregulated in activated fibroblasts under 
pathological conditions, including cancer, wound healing and chronic 
inflammation (Dolznig et al., 2005, Bauer et al., 2006, Garin-Chesa et al., 
1990b, Levy et al., 1999). FAP is highly expressed in fibroblast-like synovial 
cells, resident in the synovial lining layer of inflamed joints of patients with RA 
(Bauer et al., 2006). Furthermore, it has been suggested that in the context of 
chronic synovial inflammation, FAP might be involved in both cartilage and 
bone damage (McIndoe et al., 1999, Waldele et al., 2015). 
Fearon et al., have addressed the role of FAP+ fibroblasts in cancer biology 
using a FAP-DTR mouse strain that carries the DTR under the FAP promoter 
that allows for the selective deletion of FAP-expressing cells on administration 
of DTx. The researchers demonstrated that selective experimental deletion of 
FAP+ cells caused growth arrest of immunogenic tumours through hypoxic 
necrosis of both cancer and stromal cells (Kraman et al., 2010). These results 
implied an immunosuppressive role for FAP+ cells in neoplastic disease 
raising the intriguing possibility that these cells might play a relevant biological 
role in the context of autoimmunity, inflammation and TLO formation. 
Denton et al. has recently reported that about 90% of CD45-FAP+ cells in the 
lymph node are CD31-gp38+, meaning that almost the totality of the CD45-
FAP+ component in the lymph node is composed of FRCs (Denton et al., 
2014). The group used the same FAP-DTR mouse model described above to 
deplete FRCs in the lymph node, leading to disrupted homeostatic numbers of 
DCs, T and B cells (Denton et al., 2014). Influenza A infection post depletion 
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of FAP+ cells resulted in diminished numbers of TFH and plasma B cells 
(Denton et al., 2014).  
Given the significant degree of overlap between gp38 and FAP expression in 
the lymph node we hypothesized that FRC-like cells forming in the salivary 
glands post cannulation with adenovirus would also upregulate FAP. If this 
were the case, the FAP-DTR mouse strain would allow us to experimentally 
deplete FRC-like gp38+ stromal cells during TLO formation, based on their 
co-expression of FAP, and dissect the role of this cell component in 
lymphoneogenesis and autoimmunity in our model of salivary gland 
inflammation.  
In the studies described in this chapter we aimed to characterise the 
expression of FAP in wt salivary glands during inflammation and examine the 
functional consequences of experimental deletion of these cells in a murine 
model of inflammatory TLO formation.  
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5.2. Results  
5.2.1. FAP is expressed in murine salivary glands during 
inflammation  
In order to investigate the expression of FAP in murine salivary glands, 
immunofluorescence, flow cytometry and qRT-PCR were used in both resting 
and inflamed salivary glands (following cannulation and administration of 
virus).  
Immunofluorescent staining showed that resting salivary glands do not 
express FAP (Figure 5.1A) but, upon inflammatory insult, at day 15 p.c., 
positive staining for FAP could be detected in cells surrounding the lymphoid 
infiltrates, areas known to be rich in gp38+ stromal cells (Figure 5.1A). Flow 
cytometry staining confirmed FAP expression by more than 50% of gp38+ 
stromal cells (CD45-EpCAM-CD31-) at day 8 p.c. (Figure 5.1B). Accordingly, 
upregulation of FAP expression in murine salivary glands post virus delivery 
was demonstrated by qRT-PCR in whole-tissue frozen sections (Figure 5.1C) 
and gene expression analysis in FACS sorted cells revealed increased FAP 
expression in gp38+LLSc upon salivary gland cannulation at days 5 and 8 
p.c., which progressively decreases with resolution of inflammation (Figure 
5.1D).  
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Figure 5.1 (cont.) 
Figure 5.1. Expression of FAP in murine salivary glands post viral delivery. (A) 
Representative microphotographs of resting and inflamed salivary glands at 8 days p.c: 
examined by immunofluorescence for DAPI nuclear staining (grey), FAP (red or green), 
gp38 (blue) and CD45 (red). Original magnification 10X. (B) Representative FACS plot 
for FAP+ staining in CD45-EpCAM-CD31-gp38+ cells and respective isotype control. 
(C) qRT-PCR results for Fap mRNA in whole tissue sections from cannulated wt 
salivary glands from 3h to day 15 p.c.. Transcript levels were normalized to 
housekeeping gene β-actin. Data represented as mean (SD) with four to nine glands 
analysed per group. * p < 0.05; ** p < 0.01, unpaired t test. (D) Fap expression in FACS 
sorted CD45-EpCAM-CD31-gp38+ (LLSc) (black bars), CD45-EpCAM-CD31-gp38- 
(DN) (grey bars), gp38+EpCAM+ (red bars) and gp38-EpCAM+ (blue bars). mRNA 
transcripts were assessed by qRT-PCR and normalised to housekeeping gene β-actin. 
RQ values calculated with calibrator day 0 DN cells. Data showed as mean (SD) of two 
independent experiments with at least two salivary glands per group.    
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5.2.2. Deletion of FAP expressing cells using the FAP-DTR Tg 
mouse strain is an efficient model of gp38+ stromal cell 
depletion 
The co-expression of FAP by gp38+ LLSc allowed us to consider a targeted 
and selective approach to depletion of gp38+ stromal cells using the FAP-
DTR Tg mouse. To induce ablation of FAP-expressing cells, as described 
previously (Chapter 2.1.2.), FAP-DTR mice were treated with 4 doses of DTx 
or vehicle control, twice/day, at day 0 and day 2 (Figure 5.2A). Mice were 
cannulated and virus administrated 8 days after the first DTx/vehicle 
administration and sacrificed at days 8, 15 and 23 p.c. Findings from those 
time points will be described throughout the next section of this chapter. 
Body weight of every animal was recorded for all experimental groups and 
FAP-DTR+ mice treated with DTx consistently exhibited a weight loss of 
approximately 10% as compared to wt mice injected with DTX and control 
mice injected with sterile water in the first week following DTx administration 
(Figure 5.2B). Weight loss occurred as a result of the loss of muscle mass 
and developed cachexia (Roberts et al., 2013).  
In order to assess the efficiency of FAP+ cell deletion in the salivary glands of 
FAP-DTR+ mice administrated DTx, we investigated by flow cytometry the 
proportion of gp38+ stromal cells (as a surrogate marker of cell deletion) 
(Figure 5.3A). Un-manipulated mice (no salivary gland cannulation) and FAP-
DTR+ mice treated with vehicle, or FAP-DTR- mice treated with DTx were 
used as experimental controls. All mice, apart from those in the un-
manipulated group, were cannulated and sacrificed at day 8 p.c. (peak of FAP 
mRNA expression) (Figure 5.1C, D). Indeed, upon treatment with DTx, FAP-
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DTR+ mice but not controls, exhibited a significant reduced percentage and 
absolute numbers of gp38+ stromal cells (Figure 5.3A, B). In the remaining 
gp38+ stromal cells that were still present post DTx, the percentage of 
FAP+LLSc was also reduced (Figure 5.3Aiii).  
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weight of resting DTR+ and DTR-, DTR+ treated with DTx and vehicle, and DTR- 
treated with DTx and vehicle control. Red arrows indicate DTx/vehicle i.p. injections 
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Figure 5.3. LLSc depletion in FAP-DTR salivary glands is achieved post DTx 
administration. (A) Representative dot plots showing flow cytometry staining for FAP 
expression in CD45-EpCAM-CD31-gp38+ cells (LLSc) in FAP-DTR un-manipulated 
(i), vehicle (ii) and DTx treated (iii) salivary glands at day 8 p.c.. (B) Percentage (i) and 
absolute numbers (ii) of LLsc in day 8 p.c. salivary glands of FAP-DTR+ un-
manipulated (black), FAP-DTR- treated with DTx (dark grey), vehicle (light grey) and 
DTx treated (white). Results were determined by flow cytometry and presented as 
mean (SD) of two independent experiments with at least four salivary glands per 
group. * p < 0.05; ** p < 0.01; *** p < 0.001, unpaired t test.  
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5.2.3. Depletion of LLSc impairs full TLO development 
After confirming that the FAP-DTR mouse strain can be used to efficiently 
delete gp38+ LLSc we aimed to investigate the impact of such depletion on 
TLO formation in inflamed salivary glands. A week after administration of the 
first DTx dose, mice were cannulated and sacrificed at days 8, 15 and 23 p.c. 
and their salivary glands were analysed by IF, flow cytometry and real time 
PCR. Due to unexpected results in FAP-DTR+ mice treated with vehicle 
(discussed in section 5.3.) each section of the following described results  
compares findings between FAP-DTR+ treated with either vehicle or DTx. 
 
5.2.3.1. Analysis of day 8 samples  
At day 8 p.c., flow cytometric analysis revealed a significant loss of the gp38+ 
stromal cells in FAP-DTR+ mice treated with DTx, both in percentage and 
absolute numbers of cells. The LLSc compartment was reduced by ~2/3 
compared to untreated and DTR- mice (Figure 5.4Ai, ii). Following DTx 
treatment, the numbers of LLSc FAP expressing cells were also significantly 
reduced, whilst in percentage no significant changes were detected (Figure 
5.4Bii). The proliferative status of the remaining gp38+ stromal cells following 
deletion was assessed by Ki67 intracellular staining and showed increased 
percentage of Ki67+ LLSc but, unsurprisingly, reduced absolute numbers of 
Ki67+LLSc, confirming the proliferative status of LLSc prior to deletion of 
FAP+ cells (Figure 5.4Ci, ii).  
Infiltrating leukocytes were also analysed by flow cytometry staining that show 
a reduction in the percentage of CD45+, CD3ε+, CD19+ and CD4+CD3ε+ 
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cells (Figure 5.5Ai, Bi, Ci, Cii, Di). Absolute numbers of the populations 
above were also reduced but no significant differences were found (Figure 
5.5Aii, Bii, Dii). Regarding infiltrating CD8+ T cells, the absolute numbers in 
DTx-treated FAP-DTR+ mice were significantly reduced and the percentage 
was also decreased, but this difference was found not statistically significant 
(Figure 5.5Ei, ii). 
mRNA levels of Fap, Pdpn, Ccl19 and Cxcl13 were analysed in whole-tissue 
cryosections but only CCL19 expression was found to be significantly reduced 
in mice lacking FAP+ cells (Figure 5.6A-D).  
Histologically, DTx treated FAP-DTR+ mice developed less and smaller 
lymphoid aggregates (Figure 5.7A-C) and a significantly smaller area of 
salivary gland tissue was occupied by infiltrating lymphocytes when compared 
to DTR- controls (Figure 5.7B). At this particular time point, salivary glands 
from FAP+ cell depleted mice were characterised by an obvious absence of 
infiltrating B cells (Figure 5.7A). 
When the results from DTx treated FAP-DTR+ mice are compared only to 
DTR+ mice treated with vehicle, at day 8 p.c. only the percentage (Figure 
5.4Ai) and numbers of LLSc (Figure 5.4Aii), number of FAP+LLSc (Figure 
5.7Bii) and percentage of Ki67+ LLSc (Figure 5.4C) are significantly 
decreased in DTx treated mice.  
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Figure 5.4 
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Figure 5.4. Flow cytometry analysis of the stroma compartment in FAP-DTR mice at 
day 8 p.c.. FAP-DTR- mice treated with vehicle (black) and DTx (dark grey) and FAP-
DTR+ mice treated with vehicle (light grey) and DTx (white) were cannulated post DTx or 
vehicle administration and sacrificed at day 8 p.c.. Percentage (i) and absolute numbers 
(ii) of LLSc (A), FAP+LLSc (B) and Ki67+LLSc (C) were determined by flow cytometry 
staining and presented as mean (SD) of two independent experiments with at least four 
salivary glands per group. * p < 0.05; ** p < 0.01; *** p < 0.001, unpaired t test.  
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Figure 5.5  
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Figure 5.5 (cont.)  
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Figure 5.5. Flow cytometry analysis of the leukocyte compartment of inflamed 
salivary glands in FAP-DTR mice at day 8 p.c.. FAP-DTR- mice treated with vehicle 
(black) and DTx (dark grey) and FAP-DTR+ mice treated with vehicle (light grey) and DTx 
(white) were cannulated post DTx or vehicle administration and sacrificed at day 8 p.c.. 
Percentage (i) and absolute numbers (ii) of CD45+ cells (A), CD3ε+ T cells (B), CD19+ B 
cells (C), CD4+CD3ε+ T cells (D) and CD8+CD3ε+ T cells (E) were determined by flow 
cytometry staining and presented as mean (SD) of two independent experiments with at 
least four salivary glands per group. * p < 0.05; ** p < 0.01, unpaired t test.  
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Figure 5.6 
F a p  m R N A
V e h ic le D T x V e h ic le D T x
0 .0 0 0
0 .0 0 1
0 .0 0 2
0 .0 0 3
0 .0 0 4
F A P -D T R - F A P -D T R +
2
^
(-

C
t)
n
o
rm
a
li
s
e
d
 t
o
 B
-A
c
ti
n
P d p n  m R N A
V e h ic le D T x V e h ic le D T x
0 .0 0 0
0 .0 0 5
0 .0 1 0
0 .0 1 5
F A P -D T R - F A P -D T R +
2
^
(-

C
t)
n
o
rm
a
li
s
e
d
 t
o
 B
-A
c
ti
n
C c l1 9  m R N A
V e h ic le D T x V e h ic le D T x
0 .0
0 .2
0 .4
0 .6
0 .8
F A P -D T R - F A P -D T R +
**
*
2
^
(-

C
t)
n
o
rm
a
li
s
e
d
 t
o
 P
d
g
fr
b
C x c l1 3  m R N A
V e h ic le D T x V e h ic le D T x
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5
F A P -D T R - F A P -D T R +
2
^
(-

C
t)
n
o
rm
a
li
s
e
d
 t
o
 P
d
g
fr
b
Day 8 p.c. 
A 
C 
B 
D 
Figure 5.6. DTx treatment affects expression levels of lymphoid chemokines. 
qRT-PCR analysis of Fap (A), Pdpn (B), ccl19 (C) and cxcl13 (D) mRNA transcripts 
from FAP-DTR- mice treated with vehicle (black) and DTx (dark grey) and FAP-DTR+ 
mice treated with vehicle (light grey) and DTx (white) at day 8 p.c.. qRT-PCR results 
for Fap and Pdpn were normalised to housekeeping gene β-actin and ccl19 and 
cxcl13 results normalised to Pdgfrb. * p < 0.05; ** p < 0.01, unpaired t test, data 
represented as mean  s.e.m. with two to nine glands analysed per group.  
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Figure 5.7 
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Figure 5.7. TLO formation is impaired in DTx treated FAP-DTR+ mice at day 8 
p.c.. FAP-DTR- mice treated with vehicle (black) and DTx (dark grey) and FAP-
DTR+ mice treated with vehicle (light grey) and DTx (white) were cannulated post 
DTx or vehicle administration and sacrificed at day 8 p.c.. (A) Representative 
microphotographs of salivary glands examined by immunofluorescence for CD3ε 
(green) and CD19 (blue) showing lymphocytic infiltration. Original magnification 
25X. Volume fraction of lymphoid follicles (B) and average follicle area (C) were 
determined in all experimental groups and data represented as mean (SD) of two 
independent experiments with at least four salivary glands per group. * p < 0.05, 
unpaired t test.  
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5.2.3.2. Analysis of day 15 samples  
At day 15 p.c., DTx treated FAP-DTR+ mice showed a significant reduction in 
percentage and absolute numbers of LLSc (Figure 5.8Ai, ii) and also in 
absolute number of FAP+gp38+ stromal cells (Figure 5.8Bii). Similarly to 
what was observed at day 8 p.c., no differences were registered in the 
percentage of FAP+LLSc between any of the groups (Figure 5.8Bi). 
At this time point, when the lymphocyte infiltrates are fully organized into 
TLOs in wt mice, in FAP-DTR+ mice lacking FAP+ stromal cells a significant 
decrease in the percentage of infiltrating CD45+ cells, percentage and 
absolute numbers of CD19+ cells was observed (Figure 5.9Ai, Ci, Cii). Total 
number of CD45+, CD3ε+, CD4+CD3ε+ and CD8+CD3ε+ cells was also 
affected in the absence of FAP+ cells, but did not reach significance (Figure 
5.9Aii, Bii, Dii, Eii). 
Once again, levels of Fap and Pdpn were not diminished in DTx treated FAP-
DTR+ mice (Figure 5.10A, B). However, mRNA transcripts for lymphoid 
chemokines Ccl19 and Cxcl13 were found to be greatly reduced in our group 
of interest when compared to vehicle treated FAP-DTR- mice (Figure 5.10C, 
D). Accordingly, also Ccr7 and Cxcr5 levels were affected in FAP-DTR+ mice 
treated with DTx (Figure 5.10E, F). 
Immunofluorescence staining revealed presence of smaller lymphocytic 
aggregates with a particular defect in the B cell component (Figure 5.11A). 
This was reflected in the decreased salivary gland area occupied by lymphoid 
aggregates in the DRT+ DTX treated mice as compared to their littermate 
controls FAP-DTR- (DTx and vehicle treated) (Figure 5.11 B and C).  
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When the results from DTx treated FAP-DTR+ mice are compared only to 
DTR+ mice treated with vehicle, at day 15 p.c. only the expression levels of 
cxcl13 (Figure 5.10D) and cxcr5 (Figure 5.10F) mRNA are significantly 
decreased in DTx treated mice.  
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Figure 5.8. Flow cytometry analysis of the stroma compartment in FAP-DTR mice at day 
15 p.c.. FAP-DTR- mice treated with vehicle (black) and DTx (dark grey) and FAP-DTR+ mice 
treated with vehicle (light grey) and DTx (white) were cannulated post DTx or vehicle 
administration and sacrificed at day 15 p.c.. Percentage (i) and absolute numbers (ii) of LLsc 
(A) and FAP+LLSc (B) were determined by flow cytometry staining and presented as mean 
(SD) of two independent experiments with at least four salivary glands per group. * p < 0.05; ** 
p < 0.01, unpaired t test.  
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Figure 5.9 
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Figure 5.9 (cont.) 
Day 15 p.c. 
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Figure 5.9. Flow cytometry analysis of the leukocyte compartment in FAP-DTR mice at 
day 15 p.c.. FAP-DTR- mice treated with vehicle (black) and DTx (dark grey) and FAP-DTR+ 
mice treated with vehicle (light grey) and DTx (white) were cannulated post DTx or vehicle 
administration and sacrificed at day 15 p.c.. Percentage (i) and absolute numbers (ii) of CD45+ 
cells (A), CD3ε+ T cells (B), CD19+ B cells (C), CD4+CD3ε+ T cells (D) and CD8+CD3ε+ T 
cells (E) were determined by flow cytometry staining and presented as mean (SD) of two 
independent experiments with at least four salivary glands per group. ** p < 0.01, unpaired t 
test.  
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Figure 5.10 
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Figure 5.10. DTx treatment in FAP-DTR mice affects expression levels of lymphoid 
chemokines and recruitment of lymphocytes. qRT-PCR analysis of Fap (A), Pdpn (B), ccl19 
(C), cxcl13 (D), ccr7 (E) and cxcr5 (F) mRNA transcripts from FAP-DTR- mice treated with 
vehicle (black) and DTx (dark grey) and FAP-DTR+ mice treated with vehicle (light grey) and 
DTx (white) at day 15 p.c.. qRT-PCR results for Fap, Pdpn, ccr7 and cxcr5 were normalised to 
housekeeping gene β-actin and ccl19 and cxcl13 results normalised to Pdgfrb. * p < 0.05; ** p 
< 0.01, unpaired t test, data represented as mean (SD) with two to nine glands analysed per 
group.  
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Figure 5.11 
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Figure 5.11. TLO formation is impaired in DTx treated FAP-DTR+ mice at day 
15 p.c.. FAP-DTR- mice treated with vehicle (black) and DTx (dark grey) and FAP-
DTR+ mice treated with vehicle (light grey) and DTx (white) were cannulated post 
DTx or vehicle administration and sacrificed at day 15 p.c.. (A) Representative 
microphotographs of salivary glands examined by immunofluorescence for CD3ε 
(green) and CD19 (blue) showing lymphocytic infiltration. Original magnification 
25X. Volume fraction of lymphoid follicles (B) and average follicle area (C) were 
determined in all experimental groups and data represented as mean (SD) of two 
independent experiments with at least four salivary glands per group. * p < 0.05, 
unpaired t test.  
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5.2.3.3. Analysis of day 23 samples  
At day 23 p.c., the salivary glands of cannulated FAP-DTR+ and FAP-DTR- 
mice treated with both DTx and vehicle control were analysed by flow 
cytometry and qRT-PCR. No significant differences were found in the 
percentage or absolute numbers of LLSc or FAP+LLSc between experimental 
groups (Figure 5.12Ai, Aii, Bi, Bii). On the other hand, a significant 
decreased in the numbers of CD45+, CD3ε+ and CD19+ cells was still 
registered in mice that display (non-significant) reduction of the FAP+ cells 
(Figure 5.13 Aii, Bii, Cii). We also observed a selective reduction in 
percentage of CD19+ cells but not in the total CD45 component or in the 
CD3+ cells (Figure 5.13Ai, Bi, Ci). Proportions of CD4+ and CD8+ T cells 
were unchanged in the different experimental groups (Figure 5.13Di, Ei); 
however, less CD3+ and CD8+ T cells we found in the DTR+ DTX treated 
mice (Figure 5.13Aii). 
Analysis of mRNA transcripts in whole-tissue sections revealed a 3-fold 
increase in the levels of Fap mRNA in FAP-DTR+ treated with vehicle, when 
compared to the other 3 experimental groups (Figure 5.14A). Pdpn and Ccr7 
transcripts did not show any significant changes between groups but FAP-
DTR+ mice treated with DTx presented slightly increased levels (Figure 
5.14B, E). Cxcl13, Ccl19 and Cxcr5 transcripts showed a, non-significant, 
trend towards decreased levels in FAP-DTR+ treated with DTx (Figure 5.14C, 
D, F). 
When the results from DTx treated FAP-DTR+ mice are compared only to 
DTR+ mice treated with vehicle, at day 23 p.c. only the percentage of 
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infiltrating CD19+ cells (Figure 5.13Ci) are significantly decreased in DTx 
treated mice.  
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Figure 5.12. Flow cytometry analysis of the stroma compartment in FAP-DTR mice at 
day 23 p.c.. FAP-DTR- mice treated with vehicle (black) and DTx (dark grey) and FAP-DTR+ 
mice treated with vehicle (light grey) and DTx (white) were cannulated post DTx or vehicle 
administration and sacrificed at day 23 p.c.. Percentage (i) and absolute numbers (ii) of LLsc 
(A) and FAP+LLSc (B) were determined by flow cytometry staining and presented as mean 
(SD) of two independent experiments with at least four salivary glands per group.   
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Figure 5.13 
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Figure 5.13 (cont.) 
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Figure 5.13. Flow cytometry analysis of the leukocyte compartment in FAP-DTR mice at 
day 23 p.c.. FAP-DTR- mice treated with vehicle (black) and DTx (dark grey) and FAP-DTR+ 
mice treated with vehicle (light grey) and DTx (white) were cannulated post DTx or vehicle 
administration and sacrificed at day 23 p.c.. Percentage (i) and absolute numbers (ii) of CD45+ 
cells (A), CD3ε+ T cells (B), CD19+ B cells (C), CD4+CD3ε+ T cells (D) and CD8+CD3ε+ T 
cells (E) were determined by flow cytometry staining and presented as mean (SD) of two 
independent experiments with at least four salivary glands per group. * p < 0.05, unpaired t 
test.  
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Figure 5.14 
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Figure 5.14. DTx treatment in FAP-DTR mice affects expression levels of lymphoid 
chemokines and recruitment of lymphocytes. qRT-PCR analysis of Fap (A), Pdpn (B), ccl19 
(C), cxcl13 (D), ccr7 (E) and cxcr5 (F) mRNA transcripts from FAP-DTR- mice treated with 
vehicle (black) and DTx (dark grey) and FAP-DTR+ mice treated with vehicle (light grey) and 
DTx (white) at day 23 p.c.. qRT-PCR results for Fap, Pdpn, ccr7 and cxcr5 were normalised to 
housekeeping gene β-actin and ccl19 and cxcl13 results normalised to Pdgfrb. *** p < 0.001, 
unpaired t test, data represented as mean (SD). with two to nine glands analysed per group.  
158 
 
5.3. Discussion 
In the present study we demonstrate that LLSc characterised by their 
expression of gp38 and FAP have a functional role in TLO formation during 
salivary gland inflammation. Using a Tg mouse strain in which FAP 
expressing cells could be experimentally deleted we demonstrated impaired 
TLO formation in inflamed salivary glands when FAP expressing cells were 
deleted prior to the induction of salivary gland inflammation. 
Administration of DTx to the FAP-DTR strain enabled the conditional and 
selective depletion of FAP+gp38+ stromal cells that display features of LLSc. 
This technique allowed us to evaluate the consequences of LLSc cell deletion 
in a murine model of TLO formation that mimics SS.  
In resting tissues, Dolzing et al., 2005 demonstrated that FAP is expressed 
only at low level, with the exception of the uterus and cervix (Dolznig et al., 
2005). In pathology, FAP is selectively expressed by activated stromal cells in 
areas undergoing tissue remodelling, reactive stroma of epithelial cancers and 
in chronic inflammatory lesions (Niedermeyer et al., 2000). In agreement with 
these observations we found that in resting murine salivary glands FAP 
expression was not detectable by immunofluorescence and detected only at 
very low levels in sorted gp38+ stromal cells. 
The presence of FAP+ stromal cells is common in various types of epithelial 
cancers, including breast, lung, colorectal and pancreatic (Garin-Chesa et al., 
1990b) and these cells have been described to be in close association with 
tumour capillaries, which allow the recruitment of lymphocytes and facilitate 
the release of peptide mediators and proteases (Rettig et al., 1993, Scanlan et 
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al., 1994). Accordingly, a large body of evidence in literature suggests a key 
role in cancer invasion, angiogenesis, growth and metastases.  
In patients with RA, FAP is highly expressed by fibroblast-like synoviocytes, 
mainly situated in the synovium lining layer and associated with key molecules 
involved in extracellular matrix degradation in RA joints (Bauer et al., 2006). 
FAP is also overexpressed in the membrane of stimulated chondrocytes and 
in the cartilage of osteoarthritis patients (Milner et al., 2006). Experimental 
arthritis in FAP-deficient mice results in less cartilage degradation whilst 
inflammation and bone erosion are unaffected (Waldele et al., 2015).  
During this project, we detected by flow cytometry, qRT-PCR and 
immunofluorescence a clear upregulation of FAP in murine salivary glands 
post cannulation with adenovirus. Moreover, not only was FAP expression  
increased in whole-tissue sections but also in isolated LLSc, particularly at 
days 5 and 8 p.c., during active inflammation but also decreased at day 15 
p.c. when inflammation within the gland begins to resolve. We demonstrate 
therefore that FAP is dynamically expressed by activated stromal cells during 
salivary gland inflammation and is an important biomarker of inflammation. To 
our knowledge, no literature has been published regarding FAP expression in 
biopsies of patients with SS, however we believe it would be relevant to 
screen SS biopsies for FAP expression and possibly correlate it with GC 
development and incidence of MALT lymphoma. 
FAP+ stromal cells have been shown to mediate immune suppression in the 
tumour microenvironment (Kraman et al., 2010, Feig et al., 2013). FAP+ cell 
deletion in a model of Lewis lung carcinoma resulted in hypoxic necrosis of 
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both stroma and cancer cells in tumours that elicit an immune response and in 
the same study absence of FAP+ stromal cells led to a decrease in tumour 
growth in a model of pancreatic ductal adenocarcinoma (Kraman et al., 2010).  
Denton et al. recently showed that depleting FAP+ FRCs from lymph nodes 
resulted in naïve T, B and dendritic cells loss, which impaired the immune 
response mounted against an influenza infection (Denton et al., 2014). Using 
the same model of conditional ablation of FAP+ cells we have, for the first 
time, achieved a consistent depletion of gp38+ stromal in murine salivary 
glands. Therefore, we used this model to test our hypothesis that stromal cells 
play a role in TLO formation and maintenance. 
Prior to salivary gland cannulation with a replication-deficient adenovirus, 
FAP+ cells were depleted in a prophylactic approach in FAP-DTR+ mice. In 
our study, the weight loss associated with DTx administration to FAP-DTR+ 
mice did not cause any obvious distress or reduction in activity and, even 
though this particular aspect was not investigated in depth and therefore we 
are unable to rule it out, we do not believe muscle mass loss should affect the 
immune response in our model of local inflammation. The effects of muscle 
mass loss would be a rather important question to address in other mouse 
models of inflammation such as models of rheumatoid arthritis where the 
inflammatory process in more spread.  
Depleting FAP+ LLSc resulted in a clear reduction in infiltrating lymphocytes 
particularly at day 8 and 15 p.c., associated with unsurprisingly reduced levels 
of lymphoid chemokines since these are known to be produced by activated 
stromal cells. Consequently, a defect in TLO formation was observed in mice 
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lacking FAP+ cells; these mice exhibited less and smaller aggregates of 
lymphocytes, usually completely absent of B cells. Altogether, these results 
seem to point towards an important role for FAP+ LLSc in TLO formation 
within inflamed salivary glands.  
In some of the parameters analysed in our study, FAP-DTR+ mice treated 
with vehicle seemed to show decreased number of infiltrating cells, 
expression of chemokines and size of lymphoid follicles formed in salivary 
glands when compared to FAP-DTR- mice. Some preliminary results from 
recent experiments in our group aimed at investigating these same 
parameters mentioned above in FAP-DTR- and FAP-DTR+ mice without DTx 
or vehicle administration. Indeed, cannulated DTR+ mice (without any 
treatment) have less infiltrating T and B cells, even when the depletion of 
FAP+ cells does not take place, and therefore further investigation is required 
to understand the impact of the DTR+ BAC insertion.  However this effect in 
one of the control groups is not as pronounced as the results observed in 
FAP-DTR+ mice treated with DTx and for this reason and at this moment we 
believe all controls should be taken in consideration and FAP+ stromal cells 
play a role in the formation of TLOs in inflamed salivary glands. 
Conversely, FRCs have been described as cells with immunosuppressive 
properties in murine lymph nodes and were recently used as an anti-
inflammatory therapy in animal models of sepsis (Fletcher et al., 2014, 
Fletcher et al., 2015, Siegert et al., 2011, Lukacs-Kornek et al., 2011). Indeed, 
administration of a single dose of FRCs significantly reduced mortality and 
local production of inflammatory cytokines (Fletcher et al., 2014).  
162 
 
There are some limitations of our work. Lymph nodes from cannulated FAP-
DTR+ mice were not analysed, however we believe this will be a key aspect 
to further explore in order to understand the role of stromal cells in 
inflammation. Lymph node immunization experiments are currently taking 
place in our laboratory to address this question. At the moment, we are not 
able to comment on the possible immunosuppressive role of these cells, 
however we believe it would be interesting to isolate FAP+FRCs and 
FAP+LLSc and deliver them post inflammatory insult.  
Similarly, only a prophylactic experimental approach was adopted regarding 
FAP+ cell ablation and described in this thesis. In the future, it would be highly 
interesting to deplete FAP+ stromal cells when we know FAP expression 
peaks after cannulation (day 8 p.c.) or at the peak of TLO organization (day 
15 p.c.), since in this model of conditional depletion only cells expressing FAP 
at the time of depletion are affected.  
Altogether, this model has provided us with an extremely powerful tool to 
study the role of activated stromal cells in the recruitment of lymphocytes into 
inflamed salivary glands and in the formation of TLOs. Both FAP+ cancer 
associated fibroblasts and lymph node FRCs have been described as 
immunosuppressive since they were shown to dampen immune responses 
(Kraman et al., 2010, Fletcher et al., 2014). In our model of salivary gland 
inflammation, depletion of FAP+ LLSc resulted in compromised formation of 
TLO and reduced leucocyte infiltration.  
Our work establishes yet another link between salivary gland LLSc and lymph 
nodes FRCs by showing co-expression of both gp38 and FAP in both 
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populations of activated stromal cells. Furthermore, these studies suggest that 
gp38+FAP+ stromal cells are critically required for the organised development 
of TLOs within inflamed tissues and have a potentially pathogenic function 
and thus an important therapeutic target.  
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Chapter 6 
GENERAL DISCUSSION AND FUTURE WORK 
TLOs are ectopic structures that form at sites of chronic inflammation and are 
characterized by an organized and compartmentalized infiltration of immune 
cells within a functional scaffold of stromal cells (Buckley et al., 2015). Despite 
the importance of TLOs in autoimmune and chronic inflammatory diseases, 
little is known about the functional role of the stromal compartment in the 
development and maintenance of these structures. Recently, increased 
understanding of the role of stromal cells in SLO formation and homeostasis 
has highlighted the need of better understanding the role of stroma in TLOs.  
Several groups, including ours, have attempted to characterise the events and 
molecular pathways involved in the activation of resident mesenchyme to 
activated stroma. While the homeostatic role of the stroma in sustaining 
lymphocyte survival and organization has been largely established (Lindhout 
et al., 1999, Parsonage et al., 2005, Barone et al., 2015b, Buckley et al., 
2015), the ability of stromal cells to influence the dynamic of the autoimmune 
response is still not fully understood.  
Within TLOs, activated stromal cells, that we named LLSc are characterised 
by the up-regulation of gp38 (Barone et al., 2015b) and FAP, two features 
shared with the lymphoid stroma within SLOs (Peduto et al., 2009, Denton et 
al., 2014). Taking advantage of these shared features, we aimed to 
investigate the functional role of activated stromal cells in the formation of 
TLOs utilising a mouse model of salivary gland inflammation. In this model of 
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TLO formation, inflammation was induced by retrograde cannulation of the 
salivary gland excretory duct with a replication deficient adenovirus, that 
shared TLO features, such as T/B cell compartmentalization and formation of 
FDC networks (Bombardieri et al., 2012).  
Whilst investigating the function of gp38+ LLSc in inflamed murine salivary 
glands, we discovered a novel immunological function of the stroma 
associated with TLOs. We showed that, upon cannulation, LLSc upregulate 
ICOSL and actively provide costimulatory signals to locally recruited T cells. 
ICOSL expression by fibroblasts has been previously described in vitro 
(Swallow et al., 1999); however, to our knowledge, our results are the first to 
describe in vivo expression of ICOSL in non-hematopoietic cells. This 
expression of ICOSL in combination with the expression of ICOSL provided by 
DCs is required for the release of LTα by T cells that, in turn, influences the 
early production of lymphoid chemokines necessary for TLO assembly.  
 
This novel function associated with the ability of activated stromal cells in 
TLOs to secrete lymphoid chemokines and cytokines (Peduto et al., 2009), 
prompted us to investigate the effects that interfering with the function or the 
formation of the LLSc network would have on TLO formation and 
maintenance.  LLSc typically upregulate gp38, a mucin-type transmembrane 
glycoprotein whose expression is shared with SLOs stromal cells but also with 
cancer associated fibroblasts and inflamed epithelium (Astarita et al., 2012). 
Recently published work demonstrated that FRCs-derived gp38 engagement 
with CLEC-2, a type 2 lectin expressed by DCs, is required to support DCs 
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motility across the FRC network (Acton et al., 2012). Furthermore, FRC 
contractility is regulated by gp38 expression (Acton et al., 2014). Using a 
model in which we could selectively and conditionally knockdown Pdpn, we 
aimed to explore the functional role of gp38 expression in the context of 
inflammation-induced TLO formation. Our experimental setting, in which gp38 
deletion was achieved by administration of tamoxifen, did not allow full 
deletion of gp38 transcription throughout the full duration of the inflammatory 
response. Indeed, in our setting, downregulation of Pdpn did not affect TLO 
formation as shown by immunofluorescence and qRT-PCR. However, we 
could observe a defect in maturation of the inflammatory mesenchyme into 
VCAMhiICAMhi cells. Upregulation of ICAM and VCAM is critically required in 
the early phases of lymph node formation to enable cell-cell contact between 
LTi and LTo. LTi are not required for TLO formation, however upregulation of 
ICAM and VCAM occurs and might be involved in the clustering of T and B 
cells required for the production of lymphoid chemokines. Accordingly, in our 
in vitro setting (Chapter 3) we demonstrated that cell-cell contact is required 
for the production of LTα that, in turn, regulates chemokine production upon 
binding to TNFR.  
Gp38 expression seems therefore able to regulate the upregulation of 
adhesion molecules required for cell clustering. Whilst limited by the 
experimental setting, our observation is important and we are currently 
optimising a methodology of tamoxifen injections combined with tamoxifen-
based diet for the duration of the experiment to extend the length of gp38 
deletion and better dissect the role of gp38 in the later stages of TLO 
establishment. 
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We then sought to delete the gp38+ stromal cell component taking advantage 
of the FAP-DTR mouse in which deletion of the FAP+ cells in the stroma 
results in a significant loss of gp38+ cells.  
In our hands depletion of FAP+ cells resulted in impaired TLO formation, with 
diminished expression of lymphoid chemokines and survival factors and 
decreased lymphocyte aggregation. 
Indeed SLO stromal cells exhibit an immune-modulatory activity by influencing 
the availability of survival factors, inducing clonal deletion and preventing the 
expansion of auto-reactive T cell clones (Fletcher et al., 2010). This central 
role in balancing immune stimulation versus peripheral tolerance is achieved 
by the ability of stromal cells to present a range of peripheral tissue restricted 
antigens within lymph nodes (e.g. the melanocyte-associated enzyme 
tyrosinase) and to induce deletion of self-reactive naïve T cell clones (Fletcher 
et al., 2010, Siegert et al., 2011, Lukacs-Kornek et al., 2011). FRC also limit T 
cell expansion and priming through a series of mechanisms, for example the 
release of nitric oxide (Siegert et al., 2011, Lukacs-Kornek et al., 2011). 
Accordingly, Fletcher et al. recently described FRCs as immunosuppressive 
cells in the context of murine sepsis (Fletcher et al., 2014).  
TLO formation in autoimmune diseases correlates with autoantibody serum 
levels, local damage and disease severity both in human disease and in 
animal models (Rangel-Moreno et al., 2011, Salomonsson et al., 2002, Astorri 
et al., 2010, Bugatti et al., 2012, Bugatti et al., 2005). TLO-associated B cell 
activation is a recognized mechanism of lymphoma development in the 
salivary glands of patients with SS and in the gastric mucosa of patients with 
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Helicobacter Pylori gastritis (Barone et al., 2008, Hallas et al., 1998, Qin et al., 
1997, Barone et al., 2012). In SS the identification of ectopic TLOs within the 
minor salivary glands is currently used as a histological biomarker and 
prognostic tool for lymphoma development (Theander et al., 2011). However, 
the role of TLOs in disease pathogenesis and progression remains 
controversial. Compelling new evidence suggests that, in some cases, TLO 
formation is protective. TLO formation in the vascular adventitia during 
atherosclerosis provides an appropriate microenvironment for the generation 
of T-regulatory cells (Hu et al., 2015). Yet other findings in solid tumours 
suggest that TLOs are pathogenic through their immunosuppressive role. 
These contradictory findings suggest a potential dualistic functional role for 
TLOs that appear to be context, phase and potentially disease-specific. Within 
TLOs production of IL-7 and BAFF induces maturation into TH17 cells and 
survival of B cells, respectively. Is it possible that LLSc within TLOs, alongside 
providing survival factors and chemokines could provide suppressive signals 
to counterbalance uncontrolled activation of lymphocytes? Are those functions 
stable or plastic? Could they change during the different phases of the 
inflammatory process? Those are questions that yet remain to be addressed.  
Recently, our group has discovered that LLSc in the salivary glands post 
cannulation are characterised by upregulation of another co-stimulatory 
molecule PD-L1, a protein known to suppress the immune system by 
inhibiting T cell activation and proliferation and cytokine production (Freeman 
et al., 2000, Latchman et al., 2001, Carter et al., 2002). Indeed, administration 
of PD-L1 blocking antibody to NOD mice precipitates the development of 
diabetes and PD-L1-deficient mice are more susceptible to the development 
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of more severe EAE compared to wt controls (Ansari et al., 2003, Carter et al., 
2007). In contrast, IL-17+ T cells both in psoriatic patients and mice 
overexpress PD-1 and administration of PD-L1-Fc fusion protein ameliorates 
inflammation in a mouse model of psoriasis and central nervous system 
inflammation (Bodhankar et al., 2015, Kim et al., 2016).  
This finding is compelling given our previous observation on ICOSL 
expression by LLSc. Further investigations on PD-L1 expression in the 
context of TLO formation in inflamed salivary glands and the relative ability of 
LLSc to provide inhibitory vs. co-stimulatory stimuli are currently taking place 
in our laboratory.  
Despite technical difficulties, in the course of this project I have demonstrated 
that LLSc display critical immunological functions, among which co-stimulation 
and potentially immunosuppression, clearly establishing the role of those cells 
as instrumental players in the establishment and organization of TLOs. These 
important findings open a series of exciting questions on the broader role of 
stromal cells in the context of chronic inflammation.  
The use of different experimental approaches during the course of this project 
enabled us to conclude that more than the markers expressed by stromal cells 
it’s the cell population that express FAP, gp38 and co-stimulatory molecules 
that play a role in the process of TLO formation. In summary, the 
immunological features of stromal cells reported here support the need to 
consider these cells as very strong potential therapeutic targets in TLO-
associated chronic inflammatory conditions with cell depleting therapies. 
  
170 
 
References 
ABDULKADIR, S. A. 2005. Mechanisms of prostate tumorigenesis: roles for 
transcription factors Nkx3.1 and Egr1. Ann N Y Acad Sci, 1059, 33-40. 
ACHARYA, P. S., ZUKAS, A., CHANDAN, V., KATZENSTEIN, A. L. & PURE, E. 
2006. Fibroblast activation protein: a serine protease expressed at the 
remodeling interface in idiopathic pulmonary fibrosis. Hum Pathol, 37, 352-60. 
ACTON, S. E., ASTARITA, J. L., MALHOTRA, D., LUKACS-KORNEK, V., FRANZ, 
B., HESS, P. R., JAKUS, Z., KULIGOWSKI, M., FLETCHER, A. L., ELPEK, K. 
G., BELLEMARE-PELLETIER, A., SCEATS, L., REYNOSO, E. D., 
GONZALEZ, S. F., GRAHAM, D. B., CHANG, J., PETERS, A., WOODRUFF, 
M., KIM, Y. A., SWAT, W., MORITA, T., KUCHROO, V., CARROLL, M. C., 
KAHN, M. L., WUCHERPFENNIG, K. W. & TURLEY, S. J. 2012. Podoplanin-
rich stromal networks induce dendritic cell motility via activation of the C-type 
lectin receptor CLEC-2. Immunity, 37, 276-89. 
ACTON, S. E., FARRUGIA, A. J., ASTARITA, J. L., MOURAO-SA, D., JENKINS, R. 
P., NYE, E., HOOPER, S., VAN BLIJSWIJK, J., ROGERS, N. C., 
SNELGROVE, K. J., ROSEWELL, I., MOITA, L. F., STAMP, G., TURLEY, S. 
J., SAHAI, E. & REIS E SOUSA, C. 2014. Dendritic cells control fibroblastic 
reticular network tension and lymph node expansion. Nature, 514, 498-502. 
AGUZZI, A., KRANICH, J. & KRAUTLER, N. J. 2014. Follicular dendritic cells: origin, 
phenotype, and function in health and disease. Trends in immunology, 35, 
105-13. 
AKIBA, H., TAKEDA, K., KOJIMA, Y., USUI, Y., HARADA, N., YAMAZAKI, T., MA, 
J., TEZUKA, K., YAGITA, H. & OKUMURA, K. 2005. The role of ICOS in the 
CXCR5+ follicular B helper T cell maintenance in vivo. J Immunol, 175, 2340-
8. 
ALLEN, C. D., ANSEL, K. M., LOW, C., LESLEY, R., TAMAMURA, H., FUJII, N. & 
CYSTER, J. G. 2004. Germinal center dark and light zone organization is 
mediated by CXCR4 and CXCR5. Nat Immunol, 5, 943-52. 
ALLEN, C. D. & CYSTER, J. G. 2008. Follicular dendritic cell networks of primary 
follicles and germinal centers: phenotype and function. Semin Immunol, 20, 
14-25. 
ALOISI, F. & PUJOL-BORRELL, R. 2006. Lymphoid neogenesis in chronic 
inflammatory diseases. Nat Rev Immunol, 6, 205-17. 
AMFT, N., CURNOW, S. J., SCHEEL-TOELLNER, D., DEVADAS, A., OATES, J., 
CROCKER, J., HAMBURGER, J., AINSWORTH, J., MATHEWS, J., 
SALMON, M., BOWMAN, S. J. & BUCKLEY, C. D. 2001. Ectopic expression 
of the B cell-attracting chemokine BCA-1 (CXCL13) on endothelial cells and 
within lymphoid follicles contributes to the establishment of germinal center-
like structures in Sjogren's syndrome. Arthritis Rheum, 44, 2633-41. 
ANAYA, J. M., DELGADO-VEGA, A. M. & CASTIBLANCO, J. 2006. Genetic basis of 
Sjogren's syndrome. How strong is the evidence? Clinical & developmental 
immunology, 13, 209-22. 
ANDROLEWICZ, M. J., BROWNING, J. L. & WARE, C. F. 1992. Lymphotoxin is 
expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on 
the surface of an activated human T cell hybridoma. J Biol Chem, 267, 2542-
7. 
171 
 
ANSARI, M. J., FIORINA, P., DADA, S., GULERIA, I., UENO, T., YUAN, X., 
TRIKUDANATHAN, S., SMITH, R. N., FREEMAN, G. & SAYEGH, M. H. 
2008. Role of ICOS pathway in autoimmune and alloimmune responses in 
NOD mice. Clin Immunol, 126, 140-7. 
ANSARI, M. J., SALAMA, A. D., CHITNIS, T., SMITH, R. N., YAGITA, H., AKIBA, H., 
YAMAZAKI, T., AZUMA, M., IWAI, H., KHOURY, S. J., AUCHINCLOSS, H., 
JR. & SAYEGH, M. H. 2003. The programmed death-1 (PD-1) pathway 
regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp 
Med, 198, 63-9. 
ANSEL, K. M., NGO, V. N., HYMAN, P. L., LUTHER, S. A., FORSTER, R., 
SEDGWICK, J. D., BROWNING, J. L., LIPP, M. & CYSTER, J. G. 2000. A 
chemokine-driven positive feedback loop organizes lymphoid follicles. Nature, 
406, 309-14. 
AOYAMA, A. & CHEN, W. T. 1990. A 170-kDa membrane-bound protease is 
associated with the expression of invasiveness by human malignant 
melanoma cells. Proc Natl Acad Sci U S A, 87, 8296-300. 
ARTIS, D. & SPITS, H. 2015. The biology of innate lymphoid cells. Nature, 517, 293-
301. 
ASTARITA, J. L., ACTON, S. E. & TURLEY, S. J. 2012. Podoplanin: emerging 
functions in development, the immune system, and cancer. Front Immunol, 3, 
283. 
ASTARITA, J. L., CREMASCO, V., FU, J., DARNELL, M. C., PECK, J. R., NIEVES-
BONILLA, J. M., SONG, K., KONDO, Y., WOODRUFF, M. C., GOGINENI, A., 
ONDER, L., LUDEWIG, B., WEIMER, R. M., CARROLL, M. C., MOONEY, D. 
J., XIA, L. & TURLEY, S. J. 2015. The CLEC-2-podoplanin axis controls the 
contractility of fibroblastic reticular cells and lymph node microarchitecture. 
Nat Immunol, 16, 75-84. 
ASTORRI, E., BOMBARDIERI, M., GABBA, S., PEAKMAN, M., POZZILLI, P. & 
PITZALIS, C. 2010. Evolution of ectopic lymphoid neogenesis and in situ 
autoantibody production in autoimmune nonobese diabetic mice: cellular and 
molecular characterization of tertiary lymphoid structures in pancreatic islets. 
J Immunol, 185, 3359-68. 
ATKINSON, M. A. & LEITER, E. H. 1999. The NOD mouse model of type 1 diabetes: 
as good as it gets? Nat Med, 5, 601-4. 
AYOAMA, A. & CHEN, W. T. 1990. A 170-kDa membrane-bound protease is 
associated with the expression of invasiveness by human malignant 
melanoma cells. Proc. Nati. Acad. Sci. USA, 87, 8296-8300. 
BACH, J. F. 1994. Insulin-dependent diabetes mellitus as an autoimmune disease. 
Endocr Rev, 15, 516-42. 
BARON, V., ADAMSON, E. D., CALOGERO, A., RAGONA, G. & MERCOLA, D. 
2006. The transcription factor Egr1 is a direct regulator of multiple tumor 
suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene 
Ther, 13, 115-24. 
BARONE, F., BOMBARDIERI, M., MANZO, A., BLADES, M. C., MORGAN, P. R., 
CHALLACOMBE, S. J., VALESINI, G. & PITZALIS, C. 2005. Association of 
CXCL13 and CCL21 expression with the progressive organization of 
lymphoid-like structures in Sjogren's syndrome. Arthritis and rheumatism, 52, 
1773-84. 
172 
 
BARONE, F., BOMBARDIERI, M., ROSADO, M. M., MORGAN, P. R., 
CHALLACOMBE, S. J., DE VITA, S., CARSETTI, R., SPENCER, J., 
VALESINI, G. & PITZALIS, C. 2008. CXCL13, CCL21, and CXCL12 
expression in salivary glands of patients with Sjogren's syndrome and MALT 
lymphoma: association with reactive and malignant areas of lymphoid 
organization. Journal of immunology, 180, 5130-40. 
BARONE, F., CAMPOS, J., BOWMAN, S. & FISHER, B. A. 2015a. The value of 
histopathological examination of salivary gland biopsies in diagnosis, 
prognosis and treatment of Sjogren's Syndrome. Swiss Med Wkly, 145, 
w14168. 
BARONE, F., NAYAR, S. & BUCKLEY, C. D. 2012. The role of non-hematopoietic 
stromal cells in the persistence of inflammation. Front Immunol, 3, 416. 
BARONE, F., NAYAR, S., CAMPOS, J., CLOAKE, T., WITHERS, D. R., TOELLNER, 
K. M., ZHANG, Y., FOUSER, L., FISHER, B., BOWMAN, S., RANGEL-
MORENO, J., GARCIA-HERNANDEZ MDE, L., RANDALL, T. D., LUCCHESI, 
D., BOMBARDIERI, M., PITZALIS, C., LUTHER, S. A. & BUCKLEY, C. D. 
2015b. IL-22 regulates lymphoid chemokine production and assembly of 
tertiary lymphoid organs. Proc Natl Acad Sci U S A, 112, 11024-9. 
BAUER, S., JENDRO, M. C., WADLE, A., KLEBER, S., STENNER, F., DINSER, R., 
REICH, A., FACCIN, E., GODDE, S., DINGES, H., MULLER-LADNER, U. & 
RENNER, C. 2006. Fibroblast activation protein is expressed by rheumatoid 
myofibroblast-like synoviocytes. Arthritis Res Ther, 8, R171. 
BAUQUET, A. T., JIN, H., PATERSON, A. M., MITSDOERFFER, M., HO, I. C., 
SHARPE, A. H. & KUCHROO, V. K. 2009. The costimulatory molecule ICOS 
regulates the expression of c-Maf and IL-21 in the development of follicular T 
helper cells and TH-17 cells. Nat Immunol, 10, 167-75. 
BEKIARIS, V., WITHERS, D., GLANVILLE, S. H., MCCONNELL, F. M., PARNELL, 
S. M., KIM, M. Y., GASPAL, F. M., JENKINSON, E., SWEET, C., 
ANDERSON, G. & LANE, P. J. 2007. Role of CD30 in B/T segregation in the 
spleen. J Immunol, 179, 7535-43. 
BENEZECH, C., WHITE, A., MADER, E., SERRE, K., PARNELL, S., PFEFFER, K., 
WARE, C. F., ANDERSON, G. & CAAMANO, J. H. 2010. Ontogeny of 
stromal organizer cells during lymph node development. J Immunol, 184, 
4521-30. 
BERG, A. R., WEISENBURGER, D. D., LINDER, J. & ARMITAGE, J. O. 1986. 
Lymphoplasmacytic lymphoma. Report of a case with three monoclonal 
proteins derived from a single neoplastic clone. Cancer, 57, 1794-7. 
BERTOSSI, A., AICHINGER, M., SANSONETTI, P., LECH, M., NEFF, F., PAL, M., 
WUNDERLICH, F. T., ANDERS, H. J., KLEIN, L. & SCHMIDT-SUPPRIAN, M. 
2011. Loss of Roquin induces early death and immune deregulation but not 
autoimmunity. J Exp Med, 208, 1749-56. 
BERTOZZI, C. C., SCHMAIER, A. A., MERICKO, P., HESS, P. R., ZOU, Z., CHEN, 
M., CHEN, C. Y., XU, B., LU, M. M., ZHOU, D., SEBZDA, E., SANTORE, M. 
T., MERIANOS, D. J., STADTFELD, M., FLAKE, A. W., GRAF, T., SKODA, 
R., MALTZMAN, J. S., KORETZKY, G. A. & KAHN, M. L. 2010. Platelets 
regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. 
Blood, 116, 661-70. 
BODHANKAR, S., CHEN, Y., LAPATO, A., DOTSON, A. L., WANG, J., 
VANDENBARK, A. A., SAUGSTAD, J. A. & OFFNER, H. 2015. PD-L1 
173 
 
Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous 
System Inflammation. Stroke, 46, 2926-34. 
BOIRIVANT, M., FUSS, I. J., CHU, A. & STROBER, W. 1998. Oxazolone colitis: A 
murine model of T helper cell type 2 colitis treatable with antibodies to 
interleukin 4. J Exp Med, 188, 1929-39. 
BOMBARDIERI, M., BARONE, F., HUMBY, F., KELLY, S., MCGURK, M., MORGAN, 
P., CHALLACOMBE, S., DE VITA, S., VALESINI, G., SPENCER, J. & 
PITZALIS, C. 2007. Activation-induced cytidine deaminase expression in 
follicular dendritic cell networks and interfollicular large B cells supports 
functionality of ectopic lymphoid neogenesis in autoimmune sialoadenitis and 
MALT lymphoma in Sjogren's syndrome. Journal of immunology, 179, 4929-
38. 
BOMBARDIERI, M., BARONE, F., LUCCHESI, D., NAYAR, S., VAN DEN BERG, W. 
B., PROCTOR, G., BUCKLEY, C. D. & PITZALIS, C. 2012. Inducible tertiary 
lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model 
of salivary gland inflammation in C57BL/6 mice. J Immunol, 189, 3767-76. 
BOSSALLER, L., BURGER, J., DRAEGER, R., GRIMBACHER, B., KNOTH, R., 
PLEBANI, A., DURANDY, A., BAUMANN, U., SCHLESIER, M., WELCHER, 
A. A., PETER, H. H. & WARNATZ, K. 2006. ICOS deficiency is associated 
with a severe reduction of CXCR5+CD4 germinal center Th cells. J Immunol, 
177, 4927-32. 
BOULIANNE, B., PORFILIO, E. A., PIKOR, N. & GOMMERMAN, J. L. 2012. 
Lymphotoxin-sensitive microenvironments in homeostasis and inflammation. 
Front Immunol, 3, 243. 
BOWMAN, S. J. & FOX, R. I. 2014. Classification criteria for Sjogren's syndrome: 
nothing ever stands still! Annals of the rheumatic diseases, 73, 1-2. 
BOWMAN, S. J., IBRAHIM, G. H., HOLMES, G., HAMBURGER, J. & AINSWORTH, 
J. R. 2004. Estimating the prevalence among Caucasian women of primary 
Sjogren's syndrome in two general practices in Birmingham, UK. 
Scandinavian journal of rheumatology, 33, 39-43. 
BREITENEDER-GELEFF, S., MATSUI, K., SOLEIMAN, A., MERANER, P., 
POCZEWSKI, H., KALT, R., SCHAFFNER, G. & KERJASCHKI, D. 1997. 
Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is 
down-regulated in puromycin nephrosis. Am J Pathol, 151, 1141-52. 
BRKIC, Z., MARIA, N. I., VAN HELDEN-MEEUWSEN, C. G., VAN DE MERWE, J. 
P., VAN DAELE, P. L., DALM, V. A., WILDENBERG, M. E., BEUMER, W., 
DREXHAGE, H. A. & VERSNEL, M. A. 2013. Prevalence of interferon type I 
signature in CD14 monocytes of patients with Sjogren's syndrome and 
association with disease activity and BAFF gene expression. Ann Rheum Dis, 
72, 728-35. 
BROKOPP, C. E., SCHOENAUER, R., RICHARDS, P., BAUER, S., LOHMANN, C., 
EMMERT, M. Y., WEBER, B., WINNIK, S., AIKAWA, E., GRAVES, K., 
GENONI, M., VOGT, P., LUSCHER, T. F., RENNER, C., HOERSTRUP, S. P. 
& MATTER, C. M. 2011. Fibroblast activation protein is induced by 
inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur 
Heart J, 32, 2713-22. 
BROWN, D. D., WANG, Z., FURLOW, J. D., KANAMORI, A., SCHWARTZMAN, R. 
A., REMO, B. F. & PINDER, A. 1996. The thyroid hormone-induced tail 
resorption program during Xenopus laevis metamorphosis. Proceedings of 
174 
 
the National Academy of Sciences of the United States of America, 93, 1924-
9. 
BRUNET, J. F., DENIZOT, F., LUCIANI, M. F., ROUX-DOSSETO, M., SUZAN, M., 
MATTEI, M. G. & GOLSTEIN, P. 1987. A new member of the immunoglobulin 
superfamily--CTLA-4. Nature, 328, 267-70. 
BUCALA, R., SPIEGEL, L. A., CHESNEY, J., HOGAN, M. & CERAMI, A. 1994. 
Circulating fibrocytes define a new leukocyte subpopulation that mediates 
tissue repair. Molecular medicine, 1, 71-81. 
BUCH, M. H., CONAGHAN, P. G., QUINN, M. A., BINGHAM, S. J., VEALE, D. & 
EMERY, P. 2004. True infliximab resistance in rheumatoid arthritis: a role for 
lymphotoxin alpha? Ann Rheum Dis, 63, 1344-6. 
BUCKLEY, C. D. 2011. Why does chronic inflammation persist: An unexpected role 
for fibroblasts. Immunol Lett, 138, 12-4. 
BUCKLEY, C. D., BARONE, F., NAYAR, S., BENEZECH, C. & CAAMANO, J. 2015. 
Stromal cells in chronic inflammation and tertiary lymphoid organ formation. 
Annu Rev Immunol, 33, 715-45. 
BUCKLEY, C. D., FILER, A., HAWORTH, O., PARSONAGE, G. & SALMON, M. 
2004. Defining a role for fibroblasts in the persistence of chronic inflammatory 
joint disease. Ann Rheum Dis, 63 Suppl 2, ii92-ii95. 
BUGATTI, S., CAPORALI, R., MANZO, A., VITOLO, B., PITZALIS, C. & 
MONTECUCCO, C. 2005. Involvement of subchondral bone marrow in 
rheumatoid arthritis: lymphoid neogenesis and in situ relationship to 
subchondral bone marrow osteoclast recruitment. Arthritis Rheum, 52, 3448-
59. 
BUGATTI, S., MANZO, A., BENAGLIO, F., KLERSY, C., VITOLO, B., TODOERTI, 
M., SAKELLARIOU, G., MONTECUCCO, C. & CAPORALI, R. 2012. Serum 
levels of CXCL13 are associated with ultrasonographic synovitis and predict 
power Doppler persistence in early rheumatoid arthritis treated with non-
biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther, 14, 
R34. 
BURMEISTER, Y., LISCHKE, T., DAHLER, A. C., MAGES, H. W., LAM, K. P., 
COYLE, A. J., KROCZEK, R. A. & HUTLOFF, A. 2008. ICOS controls the 
pool size of effector-memory and regulatory T cells. J Immunol, 180, 774-82. 
CALMON-HAMATY, F., COMBE, B., HAHNE, M. & MOREL, J. 2011. Lymphotoxin 
alpha revisited: general features and implications in rheumatoid arthritis. 
Arthritis Res Ther, 13, 232. 
CARBONE, A., GLOGHINI, A. & FERLITO, A. 2000. Pathological features of 
lymphoid proliferations of the salivary glands: lymphoepithelial sialadenitis 
versus low-grade B-cell lymphoma of the malt type. The Annals of otology, 
rhinology, and laryngology, 109, 1170-5. 
CARRAGHER, D. M., RANGEL-MORENO, J. & RANDALL, T. D. 2008. Ectopic 
lymphoid tissues and local immunity. Semin Immunol, 20, 26-42. 
CARTER, L., FOUSER, L. A., JUSSIF, J., FITZ, L., DENG, B., WOOD, C. R., 
COLLINS, M., HONJO, T., FREEMAN, G. J. & CARRENO, B. M. 2002. PD-
1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is 
overcome by IL-2. Eur J Immunol, 32, 634-43. 
CARTER, L. L., LEACH, M. W., AZOITEI, M. L., CUI, J., PELKER, J. W., JUSSIF, J., 
BENOIT, S., IRELAND, G., LUXENBERG, D., ASKEW, G. R., MILARSKI, K. 
175 
 
L., GROVES, C., BROWN, T., CARITO, B. A., PERCIVAL, K., CARRENO, B. 
M., COLLINS, M. & MARUSIC, S. 2007. PD-1/PD-L1, but not PD-1/PD-L2, 
interactions regulate the severity of experimental autoimmune 
encephalomyelitis. J Neuroimmunol, 182, 124-34. 
CASH, E., MINTY, A., FERRARA, P., CAPUT, D., FRADELIZI, D. & ROTT, O. 1994. 
Macrophage-inactivating IL-13 suppresses experimental autoimmune 
encephalomyelitis in rats. J Immunol, 153, 4258-67. 
CHAI, Q., ONDER, L., SCANDELLA, E., GIL-CRUZ, C., PEREZ-SHIBAYAMA, C., 
CUPOVIC, J., DANUSER, R., SPARWASSER, T., LUTHER, S. A., THIEL, V., 
RULICKE, T., STEIN, J. V., HEHLGANS, T. & LUDEWIG, B. 2013. 
Maturation of lymph node fibroblastic reticular cells from myofibroblastic 
precursors is critical for antiviral immunity. Immunity, 38, 1013-24. 
CHANG, H. Y., CHI, J. T., DUDOIT, S., BONDRE, C., VAN DE RIJN, M., BOTSTEIN, 
D. & BROWN, P. O. 2002. Diversity, topographic differentiation, and 
positional memory in human fibroblasts. Proc Natl Acad Sci U S A, 99, 12877-
82. 
CHEN, H., YANG, W. W., WEN, Q. T., XU, L. & CHEN, M. 2009. TGF-beta induces 
fibroblast activation protein expression; fibroblast activation protein 
expression increases the proliferation, adhesion, and migration of HO-
8910PM [corrected]. Experimental and molecular pathology, 87, 189-94. 
CHEN, S. C., VASSILEVA, G., KINSLEY, D., HOLZMANN, S., MANFRA, D., 
WIEKOWSKI, M. T., ROMANI, N. & LIRA, S. A. 2002. Ectopic expression of 
the murine chemokines CCL21a and CCL21b induces the formation of lymph 
node-like structures in pancreas, but not skin, of transgenic mice. J Immunol, 
168, 1001-8. 
CHENG, J. D., DUNBRACK, R. L., JR., VALIANOU, M., ROGATKO, A., ALPAUGH, 
R. K. & WEINER, L. M. 2002. Promotion of tumor growth by murine fibroblast 
activation protein, a serine protease, in an animal model. Cancer Res, 62, 
4767-72. 
CHESNEY, J. & BUCALA, R. 1997. Peripheral blood fibrocytes: novel fibroblast-like 
cells that present antigen and mediate tissue repair. Biochemical Society 
transactions, 25, 520-4. 
CHISHOLM, D. M. & MASON, D. K. 1968. Labial salivary gland biopsy in Sjogren's 
disease. Journal of clinical pathology, 21, 656-60. 
CHRISTODOULOU, M. I., KAPSOGEORGOU, E. K. & MOUTSOPOULOS, H. M. 
2010. Characteristics of the minor salivary gland infiltrates in Sjogren's 
syndrome. Journal of autoimmunity, 34, 400-7. 
CHRISTODOULOU, M. I., KAPSOGEORGOU, E. K., MOUTSOPOULOS, N. M. & 
MOUTSOPOULOS, H. M. 2008. Foxp3+ T-regulatory cells in Sjogren's 
syndrome: correlation with the grade of the autoimmune lesion and certain 
adverse prognostic factors. The American journal of pathology, 173, 1389-96. 
CLEMENT, M., GUEDJ, K., ANDREATA, F., MORVAN, M., BEY, L., KHALLOU-
LASCHET, J., GASTON, A. T., DELBOSC, S., ALSAC, J. M., BRUNEVAL, P., 
DESCHILDRE, C., LE BORGNE, M., CASTIER, Y., KIM, H. J., CANTOR, H., 
MICHEL, J. B., CALIGIURI, G. & NICOLETTI, A. 2015. Control of the T 
follicular helper-germinal center B-cell axis by CD8(+) regulatory T cells limits 
atherosclerosis and tertiary lymphoid organ development. Circulation, 131, 
560-70. 
176 
 
COLUMBA-CABEZAS, S., GRIGUOLI, M., ROSICARELLI, B., MAGLIOZZI, R., RIA, 
F., SERAFINI, B. & ALOISI, F. 2006. Suppression of established 
experimental autoimmune encephalomyelitis and formation of meningeal 
lymphoid follicles by lymphotoxin beta receptor-Ig fusion protein. J 
Neuroimmunol, 179, 76-86. 
CONSTANTINOVITS, M., SIPOS, F., MOLNAR, B., TULASSAY, Z. & MUZES, G. 
2012. Organizer and regulatory role of colonic isolated lymphoid follicles in 
inflammation. Acta Physiol Hung, 99, 344-52. 
CUPEDO, T., LUND, F. E., NGO, V. N., RANDALL, T. D., JANSEN, W., GREUTER, 
M. J., DE WAAL-MALEFYT, R., KRAAL, G., CYSTER, J. G. & MEBIUS, R. E. 
2004. Initiation of cellular organization in lymph nodes is regulated by non-B 
cell-derived signals and is not dependent on CXC chemokine ligand 13. J 
Immunol, 173, 4889-96. 
CUPEDO, T. & MEBIUS, R. E. 2005. Cellular interactions in lymph node 
development. J Immunol, 174, 21-5. 
DANIELS, T. E., COX, D., SHIBOSKI, C. H., SCHIODT, M., WU, A., LANFRANCHI, 
H., UMEHARA, H., ZHAO, Y., CHALLACOMBE, S., LAM, M. Y., DE SOUZA, 
Y., SCHIODT, J., HOLM, H., BISIO, P. A., GANDOLFO, M. S., SAWAKI, T., 
LI, M., ZHANG, W., VARGHESE-JACOB, B., IBSEN, P., KESZLER, A., 
KUROSE, N., NOJIMA, T., ODELL, E., CRISWELL, L. A., JORDAN, R. & 
GREENSPAN, J. S. 2011. Associations between salivary gland 
histopathologic diagnoses and phenotypic features of Sjogren's syndrome 
among 1,726 registry participants. Arthritis and rheumatism, 63, 2021-30. 
DAWES, C., O'MULLANE, D. & ADGAR, M. 2012. Saliva and oral health, Stephen 
Nancocks Ltd. 
DAYAN, M., ZINGER, H., KALUSH, F., MOR, G., AMIR-ZALTZMAN, Y., KOHEN, F., 
STHOEGER, Z. & MOZES, E. 1997. The beneficial effects of treatment with 
tamoxifen and anti-oestradiol antibody on experimental systemic lupus 
erythematosus are associated with cytokine modulations. Immunology, 90, 
101-8. 
DE TOGNI, P., GOELLNER, J., RUDDLE, N. H., STREETER, P. R., FICK, A., 
MARIATHASAN, S., SMITH, S. C., CARLSON, R., SHORNICK, L. P., 
STRAUSS-SCHOENBERGER, J. & ET AL. 1994. Abnormal development of 
peripheral lymphoid organs in mice deficient in lymphotoxin. Science, 264, 
703-7. 
DEL REY, M. J., FARE, R., IZQUIERDO, E., USATEGUI, A., RODRIGUEZ-
FERNANDEZ, J. L., SUAREZ-FUEYO, A., CANETE, J. D. & PABLOS, J. L. 
2014. Clinicopathological correlations of podoplanin (gp38) expression in 
rheumatoid synovium and its potential contribution to fibroblast platelet 
crosstalk. PLoS One, 9, e99607. 
DELOVITCH, T. L. & SINGH, B. 1997. The nonobese diabetic mouse as a model of 
autoimmune diabetes: immune dysregulation gets the NOD. Immunity, 7, 
727-38. 
DENTON, A. E., ROBERTS, E. W., LINTERMAN, M. A. & FEARON, D. T. 2014. 
Fibroblastic reticular cells of the lymph node are required for retention of 
resting but not activated CD8+ T cells. Proc Natl Acad Sci U S A, 111, 12139-
44. 
DETEIX, C., ATTUIL-AUDENIS, V., DUTHEY, A., PATEY, N., MCGREGOR, B., 
DUBOIS, V., CALIGIURI, G., GRAFF-DUBOIS, S., MORELON, E. & 
177 
 
THAUNAT, O. 2010. Intragraft Th17 infiltrate promotes lymphoid neogenesis 
and hastens clinical chronic rejection. J Immunol, 184, 5344-51. 
DIMITRIOU, I. D., KAPSOGEORGOU, E. K., MOUTSOPOULOS, H. M. & 
MANOUSSAKIS, M. N. 2002. CD40 on salivary gland epithelial cells: high 
constitutive expression by cultured cells from Sjogren's syndrome patients 
indicating their intrinsic activation. Clin Exp Immunol, 127, 386-92. 
DOHI, O., OHTANI, H., HATORI, M., SATO, E., HOSAKA, M., NAGURA, H., ITOI, E. 
& KOKUBUN, S. 2009. Histogenesis-specific expression of fibroblast 
activation protein and dipeptidylpeptidase-IV in human bone and soft tissue 
tumours. Histopathology, 55, 432-40. 
DOLZNIG, H., SCHWEIFER, N., PURI, C., KRAUT, N., RETTIG, W. J., 
KERJASCHKI, D. & GARIN-CHESA, P. 2005. Characterization of cancer 
stroma markers: In silico analysis of an mRNA expression database for 
fibroblast activation protein and endosialin. Cancer Immunity, 5, 1-9. 
DONG, C., JUEDES, A. E., TEMANN, U. A., SHRESTA, S., ALLISON, J. P., 
RUDDLE, N. H. & FLAVELL, R. A. 2001a. ICOS co-stimulatory receptor is 
essential for T-cell activation and function. Nature, 409, 97-101. 
DONG, C., TEMANN, U. A. & FLAVELL, R. A. 2001b. Cutting edge: critical role of 
inducible costimulator in germinal center reactions. J Immunol, 166, 3659-62. 
DRAYTON, D. L., YING, X., LEE, J., LESSLAUER, W. & RUDDLE, N. H. 2003. 
Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant 
expression of peripheral node addressin and a HEV-restricted 
sulfotransferase. J Exp Med, 197, 1153-63. 
DRUCKER, D. J. 2003. Therapeutic potential of dipeptidyl peptidase IV inhibitors for 
the treatment of type 2 diabetes. Expert Opin Investig Drugs, 12, 87-100. 
EBERL, G. & LOCHNER, M. 2009. The development of intestinal lymphoid tissues at 
the interface of self and microbiota. Mucosal Immunol, 2, 478-85. 
ECKERT, C., KIM, Y. O., JULICH, H., HEIER, E. C., KLEIN, N., KRAUSE, E., 
TSCHERNIG, T., KORNEK, M., LAMMERT, F., SCHUPPAN, D. & LUKACS-
KORNEK, V. 2016. Podoplanin discriminates distinct stromal cell populations 
and a novel progenitor subset in the liver. Am J Physiol Gastrointest Liver 
Physiol, 310, G1-G12. 
EKWALL, A. K., EISLER, T., ANDERBERG, C., JIN, C., KARLSSON, N., 
BRISSLERT, M. & BOKAREWA, M. I. 2011. The tumour-associated 
glycoprotein podoplanin is expressed in fibroblast-like synoviocytes of the 
hyperplastic synovial lining layer in rheumatoid arthritis. Arthritis Res Ther, 13, 
R40. 
ENDRES, R., ALIMZHANOV, M. B., PLITZ, T., FUTTERER, A., KOSCO-VILBOIS, 
M. H., NEDOSPASOV, S. A., RAJEWSKY, K. & PFEFFER, K. 1999. Mature 
follicular dendritic cell networks depend on expression of lymphotoxin beta 
receptor by radioresistant stromal cells and of lymphotoxin beta and tumor 
necrosis factor by B cells. J Exp Med, 189, 159-68. 
FAN, L., REILLY, C. R., LUO, Y., DORF, M. E. & LO, D. 2000. Cutting edge: ectopic 
expression of the chemokine TCA4/SLC is sufficient to trigger lymphoid 
neogenesis. J Immunol, 164, 3955-9. 
FARR, A. G., BERRY, M. L., KIM, A., NELSON, A. J., WELCH, M. P. & ARUFFO, A. 
1992. Characterization and cloning of a novel glycoprotein expressed by 
stromal cells in T-dependent areas of peripheral lymphoid tissues. The 
Journal of experimental medicine, 176, 1477-82. 
178 
 
FAZILLEAU, N., MCHEYZER-WILLIAMS, L. J., ROSEN, H. & MCHEYZER-
WILLIAMS, M. G. 2009. The function of follicular helper T cells is regulated by 
the strength of T cell antigen receptor binding. Nat Immunol, 10, 375-84. 
FEIG, C., JONES, J. O., KRAMAN, M., WELLS, R. J., DEONARINE, A., CHAN, D. 
S., CONNELL, C. M., ROBERTS, E. W., ZHAO, Q., CABALLERO, O. L., 
TEICHMANN, S. A., JANOWITZ, T., JODRELL, D. I., TUVESON, D. A. & 
FEARON, D. T. 2013. Targeting CXCL12 from FAP-expressing carcinoma-
associated fibroblasts synergizes with anti-PD-L1 immunotherapy in 
pancreatic cancer. Proc Natl Acad Sci U S A, 110, 20212-7. 
FILER, A., RAZA, K., SALMON, M. & BUCKLEY, C. D. 2007. Targeting stromal cells 
in chronic inflammation. Discov Med, 7, 20-6. 
FINKE, D., ACHA-ORBEA, H., MATTIS, A., LIPP, M. & KRAEHENBUHL, J. 2002. 
CD4+CD3- cells induce Peyer's patch development: role of alpha4beta1 
integrin activation by CXCR5. Immunity, 17, 363-73. 
FINNEY, B. A., SCHWEIGHOFFER, E., NAVARRO-NUNEZ, L., BENEZECH, C., 
BARONE, F., HUGHES, C. E., LANGAN, S. A., LOWE, K. L., POLLITT, A. Y., 
MOURAO-SA, D., SHEARDOWN, S., NASH, G. B., SMITHERS, N., REIS E 
SOUSA, C., TYBULEWICZ, V. L. & WATSON, S. P. 2012. CLEC-2 and Syk 
in the megakaryocytic/platelet lineage are essential for development. Blood, 
119, 1747-56. 
FITZGERALD-BOCARSLY, P., DAI, J. & SINGH, S. 2008. Plasmacytoid dendritic 
cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor 
Rev, 19, 3-19. 
FLEIGE, H., RAVENS, S., MOSCHOVAKIS, G. L., BOLTER, J., WILLENZON, S., 
SUTTER, G., HAUSSLER, S., KALINKE, U., PRINZ, I. & FORSTER, R. 2014. 
IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT 
in the absence of differentiated FDCs. J Exp Med, 211, 643-51. 
FLETCHER, A. L., ACTON, S. E. & KNOBLICH, K. 2015. Lymph node fibroblastic 
reticular cells in health and disease. Nat Rev Immunol, 15, 350-61. 
FLETCHER, A. L., ELMAN, J. S., ASTARITA, J., MURRAY, R., SAEIDI, N., 
D'ROZARIO, J., KNOBLICH, K., BROWN, F. D., SCHILDBERG, F. A., 
NIEVES, J. M., HENG, T. S., BOYD, R. L., TURLEY, S. J. & PAREKKADAN, 
B. 2014. Lymph node fibroblastic reticular cell transplants show robust 
therapeutic efficacy in high-mortality murine sepsis. Sci Transl Med, 6, 
249ra109. 
FLETCHER, A. L., LUKACS-KORNEK, V., REYNOSO, E. D., PINNER, S. E., 
BELLEMARE-PELLETIER, A., CURRY, M. S., COLLIER, A. R., BOYD, R. L. 
& TURLEY, S. J. 2010. Lymph node fibroblastic reticular cells directly present 
peripheral tissue antigen under steady-state and inflammatory conditions. J 
Exp Med, 207, 689-97. 
FORD, M. L., ADAMS, A. B. & PEARSON, T. C. 2014. Targeting co-stimulatory 
pathways: transplantation and autoimmunity. Nat Rev Nephrol, 10, 14-24. 
FOS, C., SALLES, A., LANG, V., CARRETTE, F., AUDEBERT, S., PASTOR, S., 
GHIOTTO, M., OLIVE, D., BISMUTH, G. & NUNES, J. A. 2008. ICOS ligation 
recruits the p50alpha PI3K regulatory subunit to the immunological synapse. 
J Immunol, 181, 1969-77. 
FOX, R. I. 2005. Sjogren's syndrome. Lancet, 366, 321-31. 
179 
 
FOX, R. I., TORNWALL, J. & MICHELSON, P. 1999. Current issues in the diagnosis 
and treatment of Sjogren's syndrome. Current opinion in rheumatology, 11, 
364-71. 
FREEMAN, G. J., LONG, A. J., IWAI, Y., BOURQUE, K., CHERNOVA, T., 
NISHIMURA, H., FITZ, L. J., MALENKOVICH, N., OKAZAKI, T., BYRNE, M. 
C., HORTON, H. F., FOUSER, L., CARTER, L., LING, V., BOWMAN, M. R., 
CARRENO, B. M., COLLINS, M., WOOD, C. R. & HONJO, T. 2000. 
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family 
member leads to negative regulation of lymphocyte activation. J Exp Med, 
192, 1027-34. 
FRUMAN, D. A. 2004. Phosphoinositide 3-kinase and its targets in B-cell and T-cell 
signaling. Curr Opin Immunol, 16, 314-20. 
FU, Y. X., HUANG, G., MATSUMOTO, M., MOLINA, H. & CHAPLIN, D. D. 1997a. 
Independent signals regulate development of primary and secondary follicle 
structure in spleen and mesenteric lymph node. Proc Natl Acad Sci U S A, 94, 
5739-43. 
FU, Y. X., MOLINA, H., MATSUMOTO, M., HUANG, G., MIN, J. & CHAPLIN, D. D. 
1997b. Lymphotoxin-alpha (LTalpha) supports development of splenic 
follicular structure that is required for IgG responses. J Exp Med, 185, 2111-
20. 
FURTADO, G. C., MARINKOVIC, T., MARTIN, A. P., GARIN, A., HOCH, B., 
HUBNER, W., CHEN, B. K., GENDEN, E., SKOBE, M. & LIRA, S. A. 2007. 
Lymphotoxin beta receptor signaling is required for inflammatory 
lymphangiogenesis in the thyroid. Proc Natl Acad Sci U S A, 104, 5026-31. 
FURUZAWA-CARBALLEDA, J., SANCHEZ-GUERRERO, J., BETANZOS, J. L., 
ENRIQUEZ, A. B., AVILA-CASADO, C., LLORENTE, L. & HERNANDEZ-
MOLINA, G. 2014. Differential cytokine expression and regulatory cells in 
patients with primary and secondary Sjogren's syndrome. Scand J Immunol, 
80, 432-40. 
GARIN-CHESA, P., BERESFORD, H. R., WALKER, S. & RETTIG, W. J. 1990a. 
Immunohistochemical analysis of the A4 and AO10 (gp110) cell-surface 
antigens of human astrocytoma. Am J Pathol, 136, 797-807. 
GARIN-CHESA, P., OLD, L. J. & RETTIG, W. J. 1990b. Cell surface glycoprotein of 
reactive stromal fibroblasts as a potential antibody target in human epithelial 
cancers. Proc Natl Acad Sci U S A, 87, 7235-9. 
GATUMU, M. K., SKARSTEIN, K., PAPANDILE, A., BROWNING, J. L., FAVA, R. A. 
& BOLSTAD, A. I. 2009. Blockade of lymphotoxin-beta receptor signaling 
reduces aspects of Sjogren's syndrome in salivary glands of non-obese 
diabetic mice. Arthritis Res Ther, 11, R24. 
GERLI, R., MUSCAT, C., GIANSANTI, M., DANIELI, M. G., SCIUTO, M., 
GABRIELLI, A., FIANDRA, E. & VITALI, C. 1997. Quantitative assessment of 
salivary gland inflammatory infiltration in primary Sjogren's syndrome: its 
relationship to different demographic, clinical and serological features of the 
disorder. British journal of rheumatology, 36, 969-75. 
GEURTSVANKESSEL, C. H., WILLART, M. A., BERGEN, I. M., VAN RIJT, L. S., 
MUSKENS, F., ELEWAUT, D., OSTERHAUS, A. D., HENDRIKS, R., 
RIMMELZWAAN, G. F. & LAMBRECHT, B. N. 2009. Dendritic cells are 
crucial for maintenance of tertiary lymphoid structures in the lung of influenza 
virus-infected mice. J Exp Med, 206, 2339-49. 
180 
 
GHERSI, G., DONG, H., GOLDSTEIN, L. A., YEH, Y., HAKKINEN, L., LARJAVA, H. 
S. & CHEN, W. T. 2002. Regulation of fibroblast migration on collagenous 
matrix by a cell surface peptidase complex. J Biol Chem, 277, 29231-41. 
GIGOUX, M., SHANG, J., PAK, Y., XU, M., CHOE, J., MAK, T. W. & SUH, W. K. 
2009. Inducible costimulator promotes helper T-cell differentiation through 
phosphoinositide 3-kinase. Proc Natl Acad Sci U S A, 106, 20371-6. 
GIOVELLI, R. A., SANTOS, M. C., SERRANO, E. V. & VALIM, V. 2015. Clinical 
characteristics and biopsy accuracy in suspected cases of Sjogren's 
syndrome referred to labial salivary gland biopsy. BMC musculoskeletal 
disorders, 16, 30. 
GOLDSTEIN, L. A., GHERSI, G., PINEIRO-SANCHEZ, M. L., SALAMONE, M., YEH, 
Y., FLESSATE, D. & CHEN, W. T. 1997. Molecular cloning of seprase: a 
serine integral membrane protease from human melanoma. Biochim Biophys 
Acta, 1361, 11-9. 
GOMMERMAN, J. L., GIZA, K., PERPER, S., SIZING, I., NGAM-EK, A., 
NICKERSON-NUTTER, C. & BROWNING, J. L. 2003. A role for surface 
lymphotoxin in experimental autoimmune encephalomyelitis independent of 
LIGHT. J Clin Invest, 112, 755-67. 
GONG, Y., ALSALEH,  GHADA, SIBILIA,  JEAN, GOTTENBERG,  JACQUES-ERIC 
2012. New Pathogenic Role of Salivary Gland Epithelial Cells in the 
Costimulation of T Lymphocytes in Primary Sjgren's Syndrome: 040 Ligand 
Expression, T-Cell Induction of OX40 and Promotion of T-Cell Survival, 
Proliferation and Activation. [abstract]. Arthritis Rheum 64. 
GONZALEZ, S., AGUILERA, S., ALLIENDE, C., URZUA, U., QUEST, A. F., 
HERRERA, L., MOLINA, C., HERMOSO, M., EWERT, P., BRITO, M., ROMO, 
R., LEYTON, C., PEREZ, P. & GONZALEZ, M. J. 2011. Alterations in type I 
hemidesmosome components suggestive of epigenetic control in the salivary 
glands of patients with Sjogren's syndrome. Arthritis and rheumatism, 63, 
1106-15. 
GOODMAN, J. D., ROZYPAL, T. L. & KELLY, T. 2003. Seprase, a membrane-bound 
protease, alleviates the serum growth requirement of human breast cancer 
cells. Clin Exp Metastasis, 20, 459-70. 
GOTTENBERG, J. E., CAGNARD, N., LUCCHESI, C., LETOURNEUR, F., MISTOU, 
S., LAZURE, T., JACQUES, S., BA, N., ITTAH, M., LEPAJOLEC, C., 
LABETOULLE, M., ARDIZZONE, M., SIBILIA, J., FOURNIER, C., 
CHIOCCHIA, G. & MARIETTE, X. 2006. Activation of IFN pathways and 
plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's 
syndrome. Proc Natl Acad Sci U S A, 103, 2770-5. 
GRABNER, R., LOTZER, K., DOPPING, S., HILDNER, M., RADKE, D., BEER, M., 
SPANBROEK, R., LIPPERT, B., REARDON, C. A., GETZ, G. S., FU, Y. X., 
HEHLGANS, T., MEBIUS, R. E., VAN DER WALL, M., KRUSPE, D., 
ENGLERT, C., LOVAS, A., HU, D., RANDOLPH, G. J., WEIH, F. & 
HABENICHT, A. J. 2009. Lymphotoxin beta receptor signaling promotes 
tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. 
J Exp Med, 206, 233-48. 
GREAVES, W. O. & WANG, S. A. 2011. Selected topics on lymphoid lesions in the 
head and neck regions. Head and neck pathology, 5, 41-50. 
181 
 
GREENSPAN, J. S., DANIELS, T. E., TALAL, N. & SYLVESTER, R. A. 1974. The 
histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral 
surgery, oral medicine, and oral pathology, 37, 217-29. 
GREETHAM, D., ELLIS, C. D., MEWAR, D., FEARON, U., AN ULTAIGH, S. N., 
VEALE, D. J., GUESDON, F. & WILSON, A. G. 2007. Functional 
characterization of NF-kappaB inhibitor-like protein 1 (NFkappaBIL1), a 
candidate susceptibility gene for rheumatoid arthritis. Hum Mol Genet, 16, 
3027-36. 
GRIMBACHER, B., HUTLOFF, A., SCHLESIER, M., GLOCKER, E., WARNATZ, K., 
DRAGER, R., EIBEL, H., FISCHER, B., SCHAFFER, A. A., MAGES, H. W., 
KROCZEK, R. A. & PETER, H. H. 2003. Homozygous loss of ICOS is 
associated with adult-onset common variable immunodeficiency. Nature 
immunology, 4, 261-8. 
GROGER, M., LOEWE, R., HOLNTHONER, W., EMBACHER, R., PILLINGER, M., 
HERRON, G. S., WOLFF, K. & PETZELBAUER, P. 2004. IL-3 induces 
expression of lymphatic markers Prox-1 and podoplanin in human endothelial 
cells. J Immunol, 173, 7161-9. 
HALDORSEN, K., MOEN, K., JACOBSEN, H., JONSSON, R. & BRUN, J. G. 2008. 
Exocrine function in primary Sjogren syndrome: natural course and prognostic 
factors. Annals of the rheumatic diseases, 67, 949-54. 
HALLAS, C., GREINER, A., PETERS, K. & MULLER-HERMELINK, H. K. 1998. 
Immunoglobulin VH genes of high-grade mucosa-associated lymphoid tissue 
lymphomas show a high load of somatic mutations and evidence of antigen-
dependent affinity maturation. Lab Invest, 78, 277-87. 
HAMEL, K. M., CAO, Y., OLALEKAN, S. A. & FINNEGAN, A. 2014. B cell-specific 
expression of inducible costimulator ligand is necessary for the induction of 
arthritis in mice. Arthritis Rheumatol, 66, 60-7. 
HARA, T. & FU, S. M. 1985. Human T cell activation. I. Monocyte-independent 
activation and proliferation induced by anti-T3 monoclonal antibodies in the 
presence of tumor promoter 12-o-tetradecanoyl phorbol-13 acetate. J Exp 
Med, 161, 641-56. 
HARRIS, N. L. 1999. Lymphoid proliferations of the salivary glands. American journal 
of clinical pathology, 111, S94-103. 
HAYNES, N. M., ALLEN, C. D., LESLEY, R., ANSEL, K. M., KILLEEN, N. & 
CYSTER, J. G. 2007. Role of CXCR5 and CCR7 in follicular Th cell 
positioning and appearance of a programmed cell death gene-1high germinal 
center-associated subpopulation. J Immunol, 179, 5099-108. 
HENRY, L. R., LEE, H. O., LEE, J. S., KLEIN-SZANTO, A., WATTS, P., ROSS, E. 
A., CHEN, W. T. & CHENG, J. D. 2007. Clinical implications of fibroblast 
activation protein in patients with colon cancer. Clin Cancer Res, 13, 1736-41. 
HERZOG, B. H., FU, J., WILSON, S. J., HESS, P. R., SEN, A., MCDANIEL, J. M., 
PAN, Y., SHENG, M., YAGO, T., SILASI-MANSAT, R., MCGEE, S., MAY, F., 
NIESWANDT, B., MORRIS, A. J., LUPU, F., COUGHLIN, S. R., MCEVER, R. 
P., CHEN, H., KAHN, M. L. & XIA, L. 2013. Podoplanin maintains high 
endothelial venule integrity by interacting with platelet CLEC-2. Nature, 502, 
105-9. 
HJELMSTROM, P. 2001. Lymphoid neogenesis: de novo formation of lymphoid 
tissue in chronic inflammation through expression of homing chemokines. J 
Leukoc Biol, 69, 331-9. 
182 
 
HOLSINGER, F. & BUI, D. 2007. Salivary Gland Disorders - Anatomy, Function, and 
Evaluation of the Salivary Glands, Springer Berlin Heidelberg. 
HONDA, K., NAKANO, H., YOSHIDA, H., NISHIKAWA, S., RENNERT, P., IKUTA, 
K., TAMECHIKA, M., YAMAGUCHI, K., FUKUMOTO, T., CHIBA, T. & 
NISHIKAWA, S. I. 2001. Molecular basis for hematopoietic/mesenchymal 
interaction during initiation of Peyer's patch organogenesis. J Exp Med, 193, 
621-30. 
HONDOWICZ, B. D., BATHEJA, A. O., METZGAR, M. H., CATON, A. J. & 
ERIKSON, J. 2010. ICOS expression by effector T cells influences the ability 
of regulatory T cells to inhibit anti-chromatin B cell responses in recipient 
mice. J Autoimmun, 34, 460-8. 
HONG, Y. K., HARVEY, N., NOH, Y. H., SCHACHT, V., HIRAKAWA, S., DETMAR, 
M. & OLIVER, G. 2002. Prox1 is a master control gene in the program 
specifying lymphatic endothelial cell fate. Developmental dynamics : an 
official publication of the American Association of Anatomists, 225, 351-7. 
HOU, T. Z., BYSTROM, J., SHERLOCK, J. P., QURESHI, O., PARNELL, S. M., 
ANDERSON, G., GILROY, D. W. & BUCKLEY, C. D. 2010. A distinct subset 
of podoplanin (gp38) expressing F4/80+ macrophages mediate phagocytosis 
and are induced following zymosan peritonitis. FEBS Lett, 584, 3955-61. 
HU, D., MOHANTA, S. K., YIN, C., PENG, L., MA, Z., SRIKAKULAPU, P., GRASSIA, 
G., MACRITCHIE, N., DEVER, G., GORDON, P., BURTON, F. L., IALENTI, 
A., SABIR, S. R., MCINNES, I. B., BREWER, J. M., GARSIDE, P., WEBER, 
C., LEHMANN, T., TEUPSER, D., HABENICHT, L., BEER, M., GRABNER, 
R., MAFFIA, P., WEIH, F. & HABENICHT, A. J. 2015. Artery Tertiary 
Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis 
via Vascular Smooth Muscle Cell Lymphotoxin beta Receptors. Immunity, 42, 
1100-15. 
HU, Y. L., METZ, D. P., CHUNG, J., SIU, G. & ZHANG, M. 2009. B7RP-1 blockade 
ameliorates autoimmunity through regulation of follicular helper T cells. J 
Immunol, 182, 1421-8. 
HUTLOFF, A., BUCHNER, K., REITER, K., BAELDE, H. J., ODENDAHL, M., 
JACOBI, A., DORNER, T. & KROCZEK, R. A. 2004. Involvement of inducible 
costimulator in the exaggerated memory B cell and plasma cell generation in 
systemic lupus erythematosus. Arthritis Rheum, 50, 3211-20. 
HUTLOFF, A., DITTRICH, A. M., BEIER, K. C., ELJASCHEWITSCH, B., KRAFT, R., 
ANAGNOSTOPOULOS, I. & KROCZEK, R. A. 1999. ICOS is an inducible T-
cell co-stimulator structurally and functionally related to CD28. Nature, 397, 
263-6. 
IIYAMA, R., KANAI, T., URAUSHIHARA, K., TOTSUKA, T., NAKAMURA, T., 
MIYATA, T., YAGITA, H., KUSHI, A., SUZUKI, K., TEZUKA, K. & 
WATANABE, M. 2003. The role of inducible co-stimulator (ICOS)/B7-related 
protein-1 (B7RP-1) interaction in the functional development of Peyer's 
patches. Immunol Lett, 88, 63-70. 
IWAI, H., KOZONO, Y., HIROSE, S., AKIBA, H., YAGITA, H., OKUMURA, K., 
KOHSAKA, H., MIYASAKA, N. & AZUMA, M. 2002. Amelioration of collagen-
induced arthritis by blockade of inducible costimulator-B7 homologous protein 
costimulation. J Immunol, 169, 4332-9. 
183 
 
IWANO, M., PLIETH, D., DANOFF, T. M., XUE, C., OKADA, H. & NEILSON, E. G. 
2002. Evidence that fibroblasts derive from epithelium during tissue fibrosis. 
The Journal of clinical investigation, 110, 341-50. 
IWASA, S., OKADA, K., CHEN, W. T., JIN, X., YAMANE, T., OOI, A. & MITSUMATA, 
M. 2005. 'Increased expression of seprase, a membrane-type serine 
protease, is associated with lymph node metastasis in human colorectal 
cancer'. Cancer Lett, 227, 229-36. 
JIN, L., YU, D., LI, X., YU, N., LI, X., WANG, Y. & WANG, Y. 2014. CD4+CXCR5+ 
follicular helper T cells in salivary gland promote B cells maturation in patients 
with primary Sjogren's syndrome. Int J Clin Exp Pathol, 7, 1988-96. 
JONES, G. W., BOMBARDIERI, M., GREENHILL, C. J., MCLEOD, L., NERVIANI, 
A., ROCHER-ROS, V., CARDUS, A., WILLIAMS, A. S., PITZALIS, C., 
JENKINS, B. J. & JONES, S. A. 2015. Interleukin-27 inhibits ectopic 
lymphoid-like structure development in early inflammatory arthritis. J Exp 
Med, 212, 1793-802. 
JONSSON, M. V., SALOMONSSON, S., OIJORDSBAKKEN, G. & SKARSTEIN, K. 
2005. Elevated serum levels of soluble E-cadherin in patients with primary 
Sjogren's syndrome. Scand J Immunol, 62, 552-9. 
KALLURI, R. & NEILSON, E. G. 2003. Epithelial-mesenchymal transition and its 
implications for fibrosis. The Journal of clinical investigation, 112, 1776-84. 
KATSIFIS, G. E., REKKA, S., MOUTSOPOULOS, N. M., PILLEMER, S. & WAHL, S. 
M. 2009. Systemic and local interleukin-17 and linked cytokines associated 
with Sjogren's syndrome immunopathogenesis. Am J Pathol, 175, 1167-77. 
KAWAMOTO, M., HARIGAI, M., HARA, M., KAWAGUCHI, Y., TEZUKA, K., 
TANAKA, M., SUGIURA, T., KATSUMATA, Y., FUKASAWA, C., ICHIDA, H., 
HIGAMI, S. & KAMATANI, N. 2006. Expression and function of inducible co-
stimulator in patients with systemic lupus erythematosus: possible 
involvement in excessive interferon-gamma and anti-double-stranded DNA 
antibody production. Arthritis Res Ther, 8, R62. 
KELLY, T., KECHELAVA, S., ROZYPAL, T. L., WEST, K. W. & KOROURIAN, S. 
1998. Seprase, a membrane-bound protease, is overexpressed by invasive 
ductal carcinoma cells of human breast cancers. Mod Pathol, 11, 855-63. 
KELLY, T., MUELLER, S. C., YEH, Y. & CHEN, W. T. 1994. Invadopodia promote 
proteolysis of a wide variety of extracellular matrix proteins. J Cell Physiol, 
158, 299-308. 
KHACHIGIAN, L. M. 2006. Early growth response-1 in cardiovascular pathobiology. 
Circ Res, 98, 186-91. 
KHAN, O., HEADLEY, M., GERARD, A., WEI, W., LIU, L. & KRUMMEL, M. F. 2011. 
Regulation of T cell priming by lymphoid stroma. PLoS One, 6, e26138. 
KIM, J. H., CHOI, Y. J., LEE, B. H., SONG, M. Y., BAN, C. Y., KIM, J., PARK, J., 
KIM, S. E., KIM, T. G., PARK, S. H., KIM, H. P., SUNG, Y. C., KIM, S. C. & 
SHIN, E. C. 2016. Programmed cell death ligand 1 alleviates psoriatic 
inflammation by suppressing IL-17A production from programmed cell death 
1-high T cells. J Allergy Clin Immunol. 
KIM, J. R., LIM, H. W., KANG, S. G., HILLSAMER, P. & KIM, C. H. 2005. Human 
CD57+ germinal center-T cells are the major helpers for GC-B cells and 
induce class switch recombination. BMC Immunol, 6, 3. 
184 
 
KLIMIUK, P. A., GORONZY, J. J., BJOR NSSON, J., BECKENBAUGH, R. D. & 
WEYAND, C. M. 1997. Tissue cytokine patterns distinguish variants of 
rheumatoid synovitis. Am J Pathol, 151, 1311-9. 
KRAMAN, M., BAMBROUGH, P. J., ARNOLD, J. N., ROBERTS, E. W., MAGIERA, 
L., JONES, J. O., GOPINATHAN, A., TUVESON, D. A. & FEARON, D. T. 
2010. Suppression of antitumor immunity by stromal cells expressing 
fibroblast activation protein-alpha. Science, 330, 827-30. 
KRAMER, J. M., KLIMATCHEVA, E. & ROTHSTEIN, T. L. 2013. CXCL13 is elevated 
in Sjogren's syndrome in mice and humans and is implicated in disease 
pathogenesis. Journal of leukocyte biology, 94, 1079-89. 
KRATZ, A., CAMPOS-NETO, A., HANSON, M. S. & RUDDLE, N. H. 1996. Chronic 
inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med, 
183, 1461-72. 
KROCZEK, R. A., GRAF, D., BRUGNONI, D., GILIANI, S., KORTHUER, U., 
UGAZIO, A., SENGER, G., MAGES, H. W., VILLA, A. & NOTARANGELO, L. 
D. 1994. Defective expression of CD40 ligand on T cells causes "X-linked 
immunodeficiency with hyper-IgM (HIGM1)". Immunol Rev, 138, 39-59. 
LATCHMAN, Y., WOOD, C. R., CHERNOVA, T., CHAUDHARY, D., BORDE, M., 
CHERNOVA, I., IWAI, Y., LONG, A. J., BROWN, J. A., NUNES, R., 
GREENFIELD, E. A., BOURQUE, K., BOUSSIOTIS, V. A., CARTER, L. L., 
CARRENO, B. M., MALENKOVICH, N., NISHIMURA, H., OKAZAKI, T., 
HONJO, T., SHARPE, A. H. & FREEMAN, G. J. 2001. PD-L2 is a second 
ligand for PD-1 and inhibits T cell activation. Nat Immunol, 2, 261-8. 
LEE, H. O., MULLINS, S. R., FRANCO-BARRAZA, J., VALIANOU, M., CUKIERMAN, 
E. & CHENG, J. D. 2011. FAP-overexpressing fibroblasts produce an 
extracellular matrix that enhances invasive velocity and directionality of 
pancreatic cancer cells. BMC Cancer, 11, 245. 
LEE, Y., CHIN, R. K., CHRISTIANSEN, P., SUN, Y., TUMANOV, A. V., WANG, J., 
CHERVONSKY, A. V. & FU, Y. X. 2006. Recruitment and activation of naive 
T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid 
structure. Immunity, 25, 499-509. 
LENSCHOW, D. J., WALUNAS, T. L. & BLUESTONE, J. A. 1996. CD28/B7 system 
of T cell costimulation. Annu Rev Immunol, 14, 233-58. 
LEVY, M. T., MCCAUGHAN, G. W., ABBOTT, C. A., PARK, J. E., CUNNINGHAM, A. 
M., MULLER, E., RETTIG, W. J. & GORRELL, M. D. 1999. Fibroblast 
activation protein: a cell surface dipeptidyl peptidase and gelatinase 
expressed by stellate cells at the tissue remodelling interface in human 
cirrhosis. Hepatology, 29, 1768-78. 
LI, X. Y., WU, Z. B., DING, J., ZHENG, Z. H., LI, X. Y., CHEN, L. N. & ZHU, P. 2012. 
Role of the frequency of blood CD4(+) CXCR5(+) CCR6(+) T cells in 
autoimmunity in patients with Sjogren's syndrome. Biochem Biophys Res 
Commun, 422, 238-44. 
LIANG, L., PORTER, E. M. & SHA, W. C. 2002. Constitutive expression of the B7h 
ligand for inducible costimulator on naive B cells is extinguished after 
activation by distinct B cell receptor and interleukin 4 receptor-mediated 
pathways and can be rescued by CD40 signaling. J Exp Med, 196, 97-108. 
LINDHOUT, E., VAN EIJK, M., VAN PEL, M., LINDEMAN, J., DINANT, H. J. & DE 
GROOT, C. 1999. Fibroblast-like synoviocytes from rheumatoid arthritis 
185 
 
patients have intrinsic properties of follicular dendritic cells. J Immunol, 162, 
5949-56. 
LINK, A., HARDIE, D. L., FAVRE, S., BRITSCHGI, M. R., ADAMS, D. H., SIXT, M., 
CYSTER, J. G., BUCKLEY, C. D. & LUTHER, S. A. 2011. Association of T-
zone reticular networks and conduits with ectopic lymphoid tissues in mice 
and humans. Am J Pathol, 178, 1662-75. 
LINK, A., VOGT, T. K., FAVRE, S., BRITSCHGI, M. R., ACHA-ORBEA, H., HINZ, B., 
CYSTER, J. G. & LUTHER, S. A. 2007. Fibroblastic reticular cells in lymph 
nodes regulate the homeostasis of naive T cells. Nat Immunol, 8, 1255-65. 
LIRA, S. A. 2005. A passport into the lymph node. Nat Immunol, 6, 866-8. 
LOCHNER, M., OHNMACHT, C., PRESLEY, L., BRUHNS, P., SI-TAHAR, M., 
SAWA, S. & EBERL, G. 2011. Microbiota-induced tertiary lymphoid tissues 
aggravate inflammatory disease in the absence of RORgamma t and LTi 
cells. J Exp Med, 208, 125-34. 
LUCAS, P. J., NEGISHI, I., NAKAYAMA, K., FIELDS, L. E. & LOH, D. Y. 1995. Naive 
CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific 
immune response. J Immunol, 154, 5757-68. 
LUKACS-KORNEK, V., MALHOTRA, D., FLETCHER, A. L., ACTON, S. E., ELPEK, 
K. G., TAYALIA, P., COLLIER, A. R. & TURLEY, S. J. 2011. Regulated 
release of nitric oxide by nonhematopoietic stroma controls expansion of the 
activated T cell pool in lymph nodes. Nat Immunol, 12, 1096-104. 
LUTHER, S. A., BIDGOL, A., HARGREAVES, D. C., SCHMIDT, A., XU, Y., 
PANIYADI, J., MATLOUBIAN, M. & CYSTER, J. G. 2002. Differing activities 
of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and 
dendritic cell recruitment and lymphoid neogenesis. Journal of immunology, 
169, 424-33. 
LUTHER, S. A., TANG, H. L., HYMAN, P. L., FARR, A. G. & CYSTER, J. G. 2000. 
Coexpression of the chemokines ELC and SLC by T zone stromal cells and 
deletion of the ELC gene in the plt/plt mouse. Proceedings of the National 
Academy of Sciences of the United States of America, 97, 12694-9. 
MA, J., ZHU, C., MA, B., TIAN, J., BAIDOO, S. E., MAO, C., WU, W., CHEN, J., 
TONG, J., YANG, M., JIAO, Z., XU, H., LU, L. & WANG, S. 2012. Increased 
frequency of circulating follicular helper T cells in patients with rheumatoid 
arthritis. Clin Dev Immunol, 2012, 827480. 
MACLENNAN, I. C. 1994. Germinal centers. Annu Rev Immunol, 12, 117-39. 
MAGLIONE, P. J., XU, J. & CHAN, J. 2007. B cells moderate inflammatory 
progression and enhance bacterial containment upon pulmonary challenge 
with Mycobacterium tuberculosis. J Immunol, 178, 7222-34. 
MAK, T. W., SHAHINIAN, A., YOSHINAGA, S. K., WAKEHAM, A., BOUCHER, L. M., 
PINTILIE, M., DUNCAN, G., GAJEWSKA, B. U., GRONSKI, M., ERIKSSON, 
U., ODERMATT, B., HO, A., BOUCHARD, D., WHORISKY, J. S., JORDANA, 
M., OHASHI, P. S., PAWSON, T., BLADT, F. & TAFURI, A. 2003. 
Costimulation through the inducible costimulator ligand is essential for both T 
helper and B cell functions in T cell-dependent B cell responses. Nature 
immunology, 4, 765-72. 
MALLADI, A. S., SACK, K. E., SHIBOSKI, S. C., SHIBOSKI, C. H., BAER, A. N., 
BANUSHREE, R., DONG, Y., HELIN, P., KIRKHAM, B. W., LI, M., SUGAI, S., 
UMEHARA, H., VIVINO, F. B., VOLLENWEIDER, C. F., ZHANG, W., ZHAO, 
Y., GREENSPAN, J. S., DANIELS, T. E. & CRISWELL, L. A. 2012. Primary 
186 
 
Sjogren's syndrome as a systemic disease: a study of participants enrolled in 
an international Sjogren's syndrome registry. Arthritis care & research, 64, 
911-8. 
MANZO, A., BUGATTI, S., CAPORALI, R., PREVO, R., JACKSON, D. G., 
UGUCCIONI, M., BUCKLEY, C. D., MONTECUCCO, C. & PITZALIS, C. 
2007. CCL21 expression pattern of human secondary lymphoid organ stroma 
is conserved in inflammatory lesions with lymphoid neogenesis. Am J Pathol, 
171, 1549-62. 
MANZO, A., PAOLETTI, S., CARULLI, M., BLADES, M. C., BARONE, F., YANNI, G., 
FITZGERALD, O., BRESNIHAN, B., CAPORALI, R., MONTECUCCO, C., 
UGUCCIONI, M. & PITZALIS, C. 2005. Systematic microanatomical analysis 
of CXCL13 and CCL21 in situ production and progressive lymphoid 
organization in rheumatoid synovitis. Eur J Immunol, 35, 1347-59. 
MARINKOVIC, T., GARIN, A., YOKOTA, Y., FU, Y. X., RUDDLE, N. H., FURTADO, 
G. C. & LIRA, S. A. 2006. Interaction of mature CD3+CD4+ T cells with 
dendritic cells triggers the development of tertiary lymphoid structures in the 
thyroid. J Clin Invest, 116, 2622-32. 
MARINKOVICH, M. P., KEENE, D. R., RIMBERG, C. S. & BURGESON, R. E. 1993. 
Cellular origin of the dermal-epidermal basement membrane. Developmental 
dynamics : an official publication of the American Association of Anatomists, 
197, 255-67. 
MATHEW, S., SCANLAN, M. J., MOHAN RAJ, B. K., MURTY, V. V. V. S., GARIN-
CHESA, P., OLD, L. J., RETTIG, W. J. & CHAGANTI, R. S. K. 1995. The 
Gene for Fibroblast Activation Protein (FAP), a Putative Cell Surface-Bound 
Serine Protease Expressed in Cancer Stroma and Wound Healing, Maps to 
Chromosome Band 2q23. Genomics, 25, 335-337. 
MCADAM, A. J., GREENWALD, R. J., LEVIN, M. A., CHERNOVA, T., 
MALENKOVICH, N., LING, V., FREEMAN, G. J. & SHARPE, A. H. 2001. 
ICOS is critical for CD40-mediated antibody class switching. Nature, 409, 
102-5. 
MCINDOE, R. A., BOHLMAN, B., CHI, E., SCHUSTER, E., LINDHARDT, M. & 
HOOD, L. 1999. Localization of non-Mhc collagen-induced arthritis 
susceptibility loci in DBA/1j mice. Proceedings of the National Academy of 
Sciences of the United States of America, 96, 2210-4. 
MEBIUS, R. E. 2003. Organogenesis of lymphoid tissues. Nature reviews. 
Immunology, 3, 292-303. 
MEBIUS, R. E. 2007. Lymphoid organogenesis: Educating stroma. Immunol Cell 
Biol, 85, 79-80. 
MEBIUS, R. E., RENNERT, P. & WEISSMAN, I. L. 1997. Developing lymph nodes 
collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and 
follicular cells but not T or B cells. Immunity, 7, 493-504. 
MEIER, D., BORNMANN, C., CHAPPAZ, S., SCHMUTZ, S., OTTEN, L. A., 
CEREDIG, R., ACHA-ORBEA, H. & FINKE, D. 2007. Ectopic lymphoid-organ 
development occurs through interleukin 7-mediated enhanced survival of 
lymphoid-tissue-inducer cells. Immunity, 26, 643-54. 
MERKENSCHLAGER, M. & BEVERLEY, P. C. 1989. Evidence for differential 
expression of CD45 isoforms by precursors for memory-dependent and 
independent cytotoxic responses: human CD8 memory CTLp selectively 
express CD45RO (UCHL1). Int Immunol, 1, 450-9. 
187 
 
MILNER, J. M., KEVORKIAN, L., YOUNG, D. A., JONES, D., WAIT, R., DONELL, S. 
T., BARKSBY, E., PATTERSON, A. M., MIDDLETON, J., CRAVATT, B. F., 
CLARK, I. M., ROWAN, A. D. & CAWSTON, T. E. 2006. Fibroblast activation 
protein alpha is expressed by chondrocytes following a pro-inflammatory 
stimulus and is elevated in osteoarthritis. Arthritis Res Ther, 8, R23. 
MITTAL, S., REVELL, M., BARONE, F., HARDIE, D. L., MATHARU, G. S., 
DAVENPORT, A. J., MARTIN, R. A., GRANT, M., MOSSELMANS, F., 
PYNSENT, P., SUMATHI, V. P., ADDISON, O., REVELL, P. A. & BUCKLEY, 
C. D. 2013. Lymphoid aggregates that resemble tertiary lymphoid organs 
define a specific pathological subset in metal-on-metal hip replacements. 
PLoS One, 8, e63470. 
MONSKY, W. L., LIN, C. Y., AOYAMA, A., KELLY, T., AKIYAMA, S. K., MUELLER, 
S. C. & CHEN, W. T. 1994. A potential marker protease of invasiveness, 
seprase, is localized on invadopodia of human malignant melanoma cells. 
Cancer Res, 54, 5702-10. 
MORI, Y., KONO, K., MATSUMOTO, Y., FUJII, H., YAMANE, T., MITSUMATA, M. & 
CHEN, W. T. 2004. The expression of a type II transmembrane serine 
protease (Seprase) in human gastric carcinoma. Oncology, 67, 411-9. 
MOUTSOPOULOS, H. M. 1994. Sjogren's syndrome: autoimmune epithelitis. Clinical 
immunology and immunopathology, 72, 162-5. 
MOUTSOPOULOS, H. M. & MANOUSSAKIS, M. N. 1998. Lumping or splitting 
autoimmune rheumatic disorders? Lessons from Sjogren's syndrome. British 
journal of rheumatology, 37, 1263-4. 
MOYRON-QUIROZ, J. E., RANGEL-MORENO, J., KUSSER, K., HARTSON, L., 
SPRAGUE, F., GOODRICH, S., WOODLAND, D. L., LUND, F. E. & 
RANDALL, T. D. 2004. Role of inducible bronchus associated lymphoid tissue 
(iBALT) in respiratory immunity. Nat Med, 10, 927-34. 
MUELLER, S. N. & GERMAIN, R. N. 2009. Stromal cell contributions to the 
homeostasis and functionality of the immune system. Nature reviews. 
Immunology, 9, 618-29. 
NAKAE, S., IWAKURA, Y., SUTO, H. & GALLI, S. J. 2007. Phenotypic differences 
between Th1 and Th17 cells and negative regulation of Th1 cell differentiation 
by IL-17. J Leukoc Biol, 81, 1258-68. 
NANJI, S. A., HANCOCK, W. W., LUO, B., SCHUR, C. D., PAWLICK, R. L., ZHU, L. 
F., ANDERSON, C. C. & SHAPIRO, A. M. 2006. Costimulation blockade of 
both inducible costimulator and CD40 ligand induces dominant tolerance to 
islet allografts and prevents spontaneous autoimmune diabetes in the NOD 
mouse. Diabetes, 55, 27-33. 
NAYLOR, A. J., FILER, A. & BUCKLEY, C. D. 2013. The role of stromal cells in the 
persistence of chronic inflammation. Clin Exp Immunol, 171, 30-5. 
NEYT, K., PERROS, F., GEURTSVANKESSEL, C. H., HAMMAD, H. & 
LAMBRECHT, B. N. 2012. Tertiary lymphoid organs in infection and 
autoimmunity. Trends Immunol, 33, 297-305. 
NGO, V. N., CORNALL, R. J. & CYSTER, J. G. 2001. Splenic T zone development is 
B cell dependent. J Exp Med, 194, 1649-60. 
NIEDERMEYER, J., ENENKEL, B., PARK, J. E., LENTER, M. C., RETTIG, W. J., 
DAMM, K. & SCHNAPP, A. 1998. Mouse fibroblast-activation protein - 
Conserved Fap gene organization and biochemical function as a serine 
protease. Eur. J. Biochem., 254, 650-654. 
188 
 
NIEDERMEYER, J., GARIN-CHESA, P., KRIZ, M., HILBERG, F., MUELLER, E., 
BAMBERGER, U., RETTIG, W. J. & SCHNAPP, A. 2001. Expression of the 
fibroblast activation protein during mouse embryo development. Int. J. Dev. 
Biol., 45. 
NIEDERMEYER, J., KRIZ, M., HILBERG, F., GARIN-CHESA, P., BAMBERGER, U., 
LENTER, M. C., PARK, J., VIERTEL, B., PÜSCHNER, H., MAUZ, M., 
RETTIG, W. J. & SCHNAPP, A. 2000. Targeted Disruption of Mouse 
Fibroblast Activation Protein. Mol. Cell. Biol., 20, 1089-1094. 
NIEDERMEYER, J., SCANLAN, M. J., GARIN-CHESA, P., DAIBER, C., FIEBIG, H. 
H., OLD, L. J., RETTIG, W. J. & SCHNAPP, A. 1997. Mouse Fibroblast 
Activation Protein: Molecular Cloning, Alternative Splicing and Expression in 
the Reactive Stroma of Epithelial Cancers. Int. J. Cancer, 71, 383-389. 
NISHIKAWA, S. I., HASHI, H., HONDA, K., FRASER, S. & YOSHIDA, H. 2000. 
Inflammation, a prototype for organogenesis of the 
lymphopoietic/hematopoietic system. Curr Opin Immunol, 12, 342-5. 
NURIEVA, R. I. 2005. Regulation of immune and autoimmune responses by ICOS-
B7h interaction. Clin Immunol, 115, 19-25. 
O'ROURKE, K. P., O'DONOGHUE, G., ADAMS, C., MULCAHY, H., MOLLOY, C., 
SILKE, C., MOLLOY, M., SHANAHAN, F. & O'GARA, F. 2008. High levels of 
Lymphotoxin-Beta (LT-Beta) gene expression in rheumatoid arthritis 
synovium: clinical and cytokine correlations. Rheumatol Int, 28, 979-86. 
OIKONOMIDOU, O., VLACHOYIANNOPOULOS, P. G., KOMINAKIS, A., 
KALOFOUTIS, A., MOUTSOPOULOS, H. M. & MOUTSATSOU, P. 2006. 
Glucocorticoid receptor, nuclear factor kappaB, activator protein-1 and C-jun 
N-terminal kinase in systemic lupus erythematosus patients. 
Neuroimmunomodulation, 13, 194-204. 
OKAMOTO, T., SAITO, S., YAMANAKA, H., TOMATSU, T., KAMATANI, N., 
OGIUCHI, H., UCHIYAMA, T. & YAGI, J. 2003. Expression and function of 
the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid 
arthritis. J Rheumatol, 30, 1157-63. 
PARK, J. E., LENTER, M. C., ZIMMERMANN, R. N., GARIN-CHESA, P., OLD, L. J. 
& RETTIG, W. J. 1999. Fibroblast activation protein, a dual specificity serine 
protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem, 
274, 36505-12. 
PARRY, R. V., RUMBLEY, C. A., VANDENBERGHE, L. H., JUNE, C. H. & RILEY, J. 
L. 2003. CD28 and inducible costimulatory protein Src homology 2 binding 
domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and 
IL-2 expression in primary human CD4 T lymphocytes. J Immunol, 171, 166-
74. 
PARSONAGE, G., FILER, A. D., HAWORTH, O., NASH, G. B., RAINGER, G. E., 
SALMON, M. & BUCKLEY, C. D. 2005. A stromal address code defined by 
fibroblasts. Trends Immunol, 26, 150-6. 
PEACH, R. J., BAJORATH, J., BRADY, W., LEYTZE, G., GREENE, J., NAEMURA, 
J. & LINSLEY, P. S. 1994. Complementarity determining region 1 (CDR1)- 
and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to 
B7-1. J Exp Med, 180, 2049-58. 
PEDUTO, L., DULAUROY, S., LOCHNER, M., SPATH, G. F., MORALES, M. A., 
CUMANO, A. & EBERL, G. 2009. Inflammation recapitulates the ontogeny of 
lymphoid stromal cells. J Immunol, 182, 5789-99. 
189 
 
PENA, A. S. & PENATE, M. 2002. Genetic susceptibility and regulation of 
inflammation in Crohn's disease. Relationship with the innate immune system. 
Rev Esp Enferm Dig, 94, 351-60. 
PETERS, A., PITCHER, L. A., SULLIVAN, J. M., MITSDOERFFER, M., ACTON, S. 
E., FRANZ, B., WUCHERPFENNIG, K., TURLEY, S., CARROLL, M. C., 
SOBEL, R. A., BETTELLI, E. & KUCHROO, V. K. 2011. Th17 cells induce 
ectopic lymphoid follicles in central nervous system tissue inflammation. 
Immunity, 35, 986-96. 
PICARELLA, D. E., KRATZ, A., LI, C. B., RUDDLE, N. H. & FLAVELL, R. A. 1993. 
Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets 
leads to insulitis, not diabetes. Distinct patterns of inflammation in TNF-alpha 
and TNF-beta transgenic mice. J Immunol, 150, 4136-50. 
PIKOR, N. B., ASTARITA, J. L., SUMMERS-DELUCA, L., GALICIA, G., QU, J., 
WARD, L. A., ARMSTRONG, S., DOMINGUEZ, C. X., MALHOTRA, D., 
HEIDEN, B., KAY, R., CASTANOV, V., TOUIL, H., BOON, L., O'CONNOR, 
P., BAR-OR, A., PRAT, A., RAMAGLIA, V., LUDWIN, S., TURLEY, S. J. & 
GOMMERMAN, J. L. 2015. Integration of Th17- and Lymphotoxin-Derived 
Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate 
Neuroinflammation. Immunity, 43, 1160-73. 
PILLEMER, S. R., MATTESON, E. L., JACOBSSON, L. T., MARTENS, P. B., 
MELTON, L. J., 3RD, O'FALLON, W. M. & FOX, P. C. 2001. Incidence of 
physician-diagnosed primary Sjogren syndrome in residents of Olmsted 
County, Minnesota. Mayo Clinic proceedings, 76, 593-9. 
PINEIRO-SANCHEZ, M. L., GOLDSTEIN, L. A., DODT, J., HOWARD, L., YEH, Y., 
TRAN, H., ARGRAVES, W. S. & CHEN, W. T. 1997. Identification of the 170-
kDa melanoma membrane-bound gelatinase (seprase) as a serine integral 
membrane protease. The Journal of biological chemistry, 272, 7595-601. 
PITT, J. M., STAVROPOULOS, E., REDFORD, P. S., BEEBE, A. M., BANCROFT, 
G. J., YOUNG, D. B. & O'GARRA, A. 2012. Blockade of IL-10 signaling during 
bacillus Calmette-Guerin vaccination enhances and sustains Th1, Th17, and 
innate lymphoid IFN-gamma and IL-17 responses and increases protection to 
Mycobacterium tuberculosis infection. J Immunol, 189, 4079-87. 
PITZALIS, C., JONES, G. W., BOMBARDIERI, M. & JONES, S. A. 2014. Ectopic 
lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev 
Immunol, 14, 447-62. 
POWELL, N., WALKER, A. W., STOLARCZYK, E., CANAVAN, J. B., GOKMEN, M. 
R., MARKS, E., JACKSON, I., HASHIM, A., CURTIS, M. A., JENNER, R. G., 
HOWARD, J. K., PARKHILL, J., MACDONALD, T. T. & LORD, G. M. 2012. 
The transcription factor T-bet regulates intestinal inflammation mediated by 
interleukin-7 receptor+ innate lymphoid cells. Immunity, 37, 674-84. 
QIN, Y., GREINER, A., HALLAS, C., HAEDICKE, W. & MULLER-HERMELINK, H. K. 
1997. Intraclonal offspring expansion of gastric low-grade MALT-type 
lymphoma: evidence for the role of antigen-driven high-affinity mutation in 
lymphomagenesis. Lab Invest, 76, 477-85. 
RAMIREZ, M. I., MILLIEN, G., HINDS, A., CAO, Y., SELDIN, D. C. & WILLIAMS, M. 
C. 2003. T1alpha, a lung type I cell differentiation gene, is required for normal 
lung cell proliferation and alveolus formation at birth. Dev Biol, 256, 61-72. 
RAMOS-CASALS, M., SOLANS, R., ROSAS, J., CAMPS, M. T., GIL, A., DEL PINO-
MONTES, J., CALVO-ALEN, J., JIMENEZ-ALONSO, J., MICO, M. L., 
190 
 
BELTRAN, J., BELENGUER, R. & PALLARES, L. 2008. Primary Sjogren 
syndrome in Spain: clinical and immunologic expression in 1010 patients. 
Medicine, 87, 210-9. 
RANDALL, T. D., CARRAGHER, D. M. & RANGEL-MORENO, J. 2008. Development 
of secondary lymphoid organs. Annu Rev Immunol, 26, 627-50. 
RANGEL-MORENO, J., CARRAGHER, D. M., DE LA LUZ GARCIA-HERNANDEZ, 
M., HWANG, J. Y., KUSSER, K., HARTSON, L., KOLLS, J. K., KHADER, S. 
A. & RANDALL, T. D. 2011. The development of inducible bronchus-
associated lymphoid tissue depends on IL-17. Nat Immunol, 12, 639-46. 
RANGEL-MORENO, J., MOYRON-QUIROZ, J. E., HARTSON, L., KUSSER, K. & 
RANDALL, T. D. 2007. Pulmonary expression of CXC chemokine ligand 13, 
CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local 
immunity to influenza. Proc Natl Acad Sci U S A, 104, 10577-82. 
RASMUSSEN, A., ICE, J. A., LI, H., GRUNDAHL, K., KELLY, J. A., RADFAR, L., 
STONE, D. U., HEFNER, K. S., ANAYA, J. M., ROHRER, M., 
GOPALAKRISHNAN, R., HOUSTON, G. D., LEWIS, D. M., CHODOSH, J., 
HARLEY, J. B., HUGHES, P., MAIER-MOORE, J. S., MONTGOMERY, C. G., 
RHODUS, N. L., FARRIS, A. D., SEGAL, B. M., JONSSON, R., LESSARD, C. 
J., SCOFIELD, R. H. & SIVILS, K. L. 2014. Comparison of the American-
European Consensus Group Sjogren's syndrome classification criteria to 
newly proposed American College of Rheumatology criteria in a large, 
carefully characterised sicca cohort. Annals of the rheumatic diseases, 73, 
31-8. 
RETTIG, W. J., GARIN-CHESA, P., BERESFORD, H. R., FEICKERT, H., 
JENNINGS, M. T., COHEN, J., OETTGEN, H. F. & OLD, L. J. 1986. 
Differential Expression of Cell Surface Antigens and Glial Fibrillary Acidic 
Protein in Human Astrocytoma Subsets. Cancer Research, 46, 6406-6412. 
RETTIG, W. J., GARIN-CHESA, P., BERESFORD, H. R., OETTGEN, H. F., 
MELAMED, M. R. & OLD, L. J. 1988. Cell-surface glycoproteins of human 
sarcomas: differential expression in normal and malignant tissues and 
cultured cells. Proc Natl Acad Sci U S A, 85, 3110-4. 
RETTIG, W. J., GARIN-CHESA, P., HEALEY, J. H., SU, S. L., OZER, H. L., 
SCHWAB, M., ALBINO, A. P. & OLD, L. J. 1993. Regulation and heteromeric 
structure of the fibroblast activation protein in normal and transformed cells of 
mesenchymal and neuroectodermal origin. Cancer Res, 53, 3327-35. 
RISHI, A. K., JOYCE-BRADY, M., FISHER, J., DOBBS, L. G., FLOROS, J., 
VANDERSPEK, J., BRODY, J. S. & WILLIAMS, M. C. 1995. Cloning, 
characterization, and development expression of a rat lung alveolar type I cell 
gene in embryonic endodermal and neural derivatives. Dev Biol, 167, 294-
306. 
RISSELADA, A. P., KRUIZE, A. A. & BIJLSMA, J. W. 2013a. Clinical features 
distinguishing lymphoma development in primary Sjogren's Syndrome--a 
retrospective cohort study. Seminars in arthritis and rheumatism, 43, 171-7. 
RISSELADA, A. P., LOOIJE, M. F., KRUIZE, A. A., BIJLSMA, J. W. & VAN ROON, J. 
A. 2013b. The role of ectopic germinal centers in the immunopathology of 
primary Sjogren's syndrome: a systematic review. Seminars in arthritis and 
rheumatism, 42, 368-76. 
191 
 
ROBAK, T., GLADALSKA, A. & STEPIEN, H. 1998. The tumour necrosis factor 
family of receptors/ligands in the serum of patients with rheumatoid arthritis. 
Eur Cytokine Netw, 9, 145-54. 
ROBERTS, E. W., DEONARINE, A., JONES, J. O., DENTON, A. E., FEIG, C., 
LYONS, S. K., ESPELI, M., KRAMAN, M., MCKENNA, B., WELLS, R. J., 
ZHAO, Q., CABALLERO, O. L., LARDER, R., COLL, A. P., O'RAHILLY, S., 
BRINDLE, K. M., TEICHMANN, S. A., TUVESON, D. A. & FEARON, D. T. 
2013. Depletion of stromal cells expressing fibroblast activation protein-alpha 
from skeletal muscle and bone marrow results in cachexia and anemia. J Exp 
Med, 210, 1137-51. 
SABATELLI, P., BONALDO, P., LATTANZI, G., BRAGHETTA, P., BERGAMIN, N., 
CAPANNI, C., MATTIOLI, E., COLUMBARO, M., OGNIBENE, A., PEPE, G., 
BERTINI, E., MERLINI, L., MARALDI, N. M. & SQUARZONI, S. 2001. 
Collagen VI deficiency affects the organization of fibronectin in the 
extracellular matrix of cultured fibroblasts. Matrix biology : journal of the 
International Society for Matrix Biology, 20, 475-86. 
SACCA, R., KRATZ, A., CAMPOS-NETO, A., HANSON, M. S. & RUDDLE, N. H. 
1995. Lymphotoxin: from chronic inflammation to lymphoid organs. J Inflamm, 
47, 81-4. 
SALOMONSSON, S., JONSSON, M. V., SKARSTEIN, K., BROKSTAD, K. A., 
HJELMSTROM, P., WAHREN-HERLENIUS, M. & JONSSON, R. 2003. 
Cellular basis of ectopic germinal center formation and autoantibody 
production in the target organ of patients with Sjogren's syndrome. Arthritis 
and rheumatism, 48, 3187-201. 
SALOMONSSON, S., LARSSON, P., TENGNER, P., MELLQUIST, E., 
HJELMSTROM, P. & WAHREN-HERLENIUS, M. 2002. Expression of the B 
cell-attracting chemokine CXCL13 in the target organ and autoantibody 
production in ectopic lymphoid tissue in the chronic inflammatory disease 
Sjogren's syndrome. Scand J Immunol, 55, 336-42. 
SANTOS, A. M., JUNG, J., AZIZ, N., KISSIL, J. L. & PURE, E. 2009. Targeting 
fibroblast activation protein inhibits tumor stromagenesis and growth in mice. 
J Clin Invest, 119, 3613-25. 
SARIGUL, M., YAZISIZ, V., BASSORGUN, C. I., ULKER, M., AVCI, A. B., 
ERBASAN, F., GELEN, T., GORCZYNSKI, R. M. & TERZIOGLU, E. 2010. 
The numbers of Foxp3 + Treg cells are positively correlated with higher grade 
of infiltration at the salivary glands in primary Sjogren's syndrome. Lupus, 19, 
138-45. 
SATO, M., HIRAYAMA, S., MATSUDA, Y., WAGNETZ, D., HWANG, D. M., GUAN, 
Z., LIU, M. & KESHAVJEE, S. 2011. Stromal activation and formation of 
lymphoid-like stroma in chronic lung allograft dysfunction. Transplantation, 91, 
1398-405. 
SATOH, J., ILLES, Z., PETERFALVI, A., TABUNOKI, H., ROZSA, C. & YAMAMURA, 
T. 2007. Aberrant transcriptional regulatory network in T cells of multiple 
sclerosis. Neurosci Lett, 422, 30-3. 
SCANLAN, M. J., RAJ, B. K., CALVO, B., GARIN-CHESA, P., SANZ-MONCASI, M. 
P., HEALEY, J. H., OLD, L. J. & RETTIG, W. J. 1994. Molecular cloning of 
fibroblast activation protein alpha, a member of the serine protease family 
selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl 
Acad Sci U S A, 91, 5657-61. 
192 
 
SCHACHT, V., RAMIREZ, M. I., HONG, Y. K., HIRAKAWA, S., FENG, D., HARVEY, 
N., WILLIAMS, M., DVORAK, A. M., DVORAK, H. F., OLIVER, G. & 
DETMAR, M. 2003. T1alpha/podoplanin deficiency disrupts normal lymphatic 
vasculature formation and causes lymphedema. EMBO J, 22, 3546-56. 
SCHAERLI, P., WILLIMANN, K., LANG, A. B., LIPP, M., LOETSCHER, P. & 
MOSER, B. 2000. CXC chemokine receptor 5 expression defines follicular 
homing T cells with B cell helper function. J Exp Med, 192, 1553-62. 
SCHMUTZ, S., BOSCO, N., CHAPPAZ, S., BOYMAN, O., ACHA-ORBEA, H., 
CEREDIG, R., ROLINK, A. G. & FINKE, D. 2009. Cutting edge: IL-7 regulates 
the peripheral pool of adult ROR gamma+ lymphoid tissue inducer cells. J 
Immunol, 183, 2217-21. 
SCHOLL, F. G., GAMALLO, C., VILARO, S. & QUINTANILLA, M. 1999. Identification 
of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that 
induces plasma membrane extensions and increased motility in 
keratinocytes. J Cell Sci, 112 ( Pt 24), 4601-13. 
SCHREIBER, H. & ROWLEY, D. A. 2010. Cancer. Awakening immunity. Science, 
330, 761-2. 
SHARPE, A. H. & FREEMAN, G. J. 2002. The B7-CD28 superfamily. Nat Rev 
Immunol, 2, 116-26. 
SHEN, L., SURESH, L., WU, J., XUAN, J., LI, H., ZHANG, C., PANKEWYCZ, O. & 
AMBRUS, J. L., JR. 2010. A role for lymphotoxin in primary Sjogren's 
disease. J Immunol, 185, 6355-63. 
SHI, M., YU, D. H., CHEN, Y., ZHAO, C. Y., ZHANG, J., LIU, Q. H., NI, C. R. & ZHU, 
M. H. 2012. Expression of fibroblast activation protein in human pancreatic 
adenocarcinoma and its clinicopathological significance. World J 
Gastroenterol, 18, 840-6. 
SHIBOSKI, S. C., SHIBOSKI, C. H., CRISWELL, L., BAER, A., CHALLACOMBE, S., 
LANFRANCHI, H., SCHIODT, M., UMEHARA, H., VIVINO, F., ZHAO, Y., 
DONG, Y., GREENSPAN, D., HEIDENREICH, A. M., HELIN, P., KIRKHAM, 
B., KITAGAWA, K., LARKIN, G., LI, M., LIETMAN, T., LINDEGAARD, J., 
MCNAMARA, N., SACK, K., SHIRLAW, P., SUGAI, S., VOLLENWEIDER, C., 
WHITCHER, J., WU, A., ZHANG, S., ZHANG, W., GREENSPAN, J. & 
DANIELS, T. 2012. American College of Rheumatology classification criteria 
for Sjogren's syndrome: a data-driven, expert consensus approach in the 
Sjogren's International Collaborative Clinical Alliance cohort. Arthritis care & 
research, 64, 475-87. 
SIEGERT, S., HUANG, H. Y., YANG, C. Y., SCARPELLINO, L., CARRIE, L., 
ESSEX, S., NELSON, P. J., HEIKENWALDER, M., ACHA-ORBEA, H., 
BUCKLEY, C. D., MARSLAND, B. J., ZEHN, D. & LUTHER, S. A. 2011. 
Fibroblastic reticular cells from lymph nodes attenuate T cell expansion by 
producing nitric oxide. PLoS One, 6, e27618. 
SIMPSON, T. R., QUEZADA, S. A. & ALLISON, J. P. 2010. Regulation of CD4 T cell 
activation and effector function by inducible costimulator (ICOS). Curr Opin 
Immunol, 22, 326-32. 
SONG, G., OUYANG, G. & BAO, S. 2005. The activation of Akt/PKB signaling 
pathway and cell survival. J Cell Mol Med, 9, 59-71. 
SPORICI, R. A., BESWICK, R. L., VON ALLMEN, C., RUMBLEY, C. A., HAYDEN-
LEDBETTER, M., LEDBETTER, J. A. & PERRIN, P. J. 2001. ICOS ligand 
193 
 
costimulation is required for T-cell encephalitogenicity. Clinical immunology, 
100, 277-88. 
STUART, R. W. & RACKE, M. K. 2002. Targeting T cell costimulation in autoimmune 
disease. Expert Opin Ther Targets, 6, 275-89. 
SUEMATSU, S. & WATANABE, T. 2004. Generation of a synthetic lymphoid tissue-
like organoid in mice. Nat Biotechnol, 22, 1539-45. 
SUN, S., ALBRIGHT, C. F., FISH, B. H., GEORGE, H. J., SELLING, B. H., HOLLIS, 
G. F. & WYNN, R. 2002. Expression, purification, and kinetic characterization 
of full-length human fibroblast activation protein. Protein Expr Purif, 24, 274-
81. 
SUZUKI-INOUE, K., INOUE, O., DING, G., NISHIMURA, S., HOKAMURA, K., ETO, 
K., KASHIWAGI, H., TOMIYAMA, Y., YATOMI, Y., UMEMURA, K., SHIN, Y., 
HIRASHIMA, M. & OZAKI, Y. 2010. Essential in vivo roles of the C-type lectin 
receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by 
blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-
deficient platelets. The Journal of biological chemistry, 285, 24494-507. 
SWALLOW, M. M., WALLIN, J. J. & SHA, W. C. 1999. B7h, a novel costimulatory 
homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity, 11, 423-32. 
SZABO, K., PAPP, G., DEZSO, B. & ZEHER, M. 2014. The histopathology of labial 
salivary glands in primary Sjogren's syndrome: focusing on follicular helper T 
cells in the inflammatory infiltrates. Mediators Inflamm, 2014, 631787. 
SZODORAY, P., ALEX, P., JONSSON, M. V., KNOWLTON, N., DOZMOROV, I., 
NAKKEN, B., DELALEU, N., JONSSON, R. & CENTOLA, M. 2005. Distinct 
profiles of Sjogren's syndrome patients with ectopic salivary gland germinal 
centers revealed by serum cytokines and BAFF. Clinical immunology, 117, 
168-76. 
TAKAHASHI, N., MATSUMOTO, K., SAITO, H., NANKI, T., MIYASAKA, N., 
KOBATA, T., AZUMA, M., LEE, S. K., MIZUTANI, S. & MORIO, T. 2009. 
Impaired CD4 and CD8 effector function and decreased memory T cell 
populations in ICOS-deficient patients. J Immunol, 182, 5515-27. 
TAKEMURA, S., BRAUN, A., CROWSON, C., KURTIN, P. J., COFIELD, R. H., 
O'FALLON, W. M., GORONZY, J. J. & WEYAND, C. M. 2001. Lymphoid 
neogenesis in rheumatoid synovitis. J Immunol, 167, 1072-80. 
TAN, A. H., GOH, S. Y., WONG, S. C. & LAM, K. P. 2008. T helper cell-specific 
regulation of inducible costimulator expression via distinct mechanisms 
mediated by T-bet and GATA-3. J Biol Chem, 283, 128-36. 
TAN, A. H., WONG, S. C. & LAM, K. P. 2006. Regulation of mouse inducible 
costimulator (ICOS) expression by Fyn-NFATc2 and ERK signaling in T cells. 
J Biol Chem, 281, 28666-78. 
TANGYE, S. G., MA, C. S., BRINK, R. & DEENICK, E. K. 2013. The good, the bad 
and the ugly - TFH cells in human health and disease. Nat Rev Immunol, 13, 
412-26. 
TARIN, D. & CROFT, C. B. 1969. Ultrastructural features of wound healing in mouse 
skin. J Anat, 105, 189-90. 
THEANDER, E., HENRIKSSON, G., LJUNGBERG, O., MANDL, T., MANTHORPE, 
R. & JACOBSSON, L. T. 2006. Lymphoma and other malignancies in primary 
Sjogren's syndrome: a cohort study on cancer incidence and lymphoma 
predictors. Annals of the rheumatic diseases, 65, 796-803. 
194 
 
THEANDER, E., VASAITIS, L., BAECKLUND, E., NORDMARK, G., WARFVINGE, 
G., LIEDHOLM, R., BROKSTAD, K., JONSSON, R. & JONSSON, M. V. 2011. 
Lymphoid organisation in labial salivary gland biopsies is a possible predictor 
for the development of malignant lymphoma in primary Sjogren's syndrome. 
Annals of the rheumatic diseases, 70, 1363-8. 
THOMPSON, C. B., LINDSTEN, T., LEDBETTER, J. A., KUNKEL, S. L., YOUNG, H. 
A., EMERSON, S. G., LEIDEN, J. M. & JUNE, C. H. 1989. CD28 activation 
pathway regulates the production of multiple T-cell-derived 
lymphokines/cytokines. Proc Natl Acad Sci U S A, 86, 1333-7. 
TOMITA, T., NAKASE, T., KANEKO, M., SHI, K., TAKAHI, K., OCHI, T. & 
YOSHIKAWA, H. 2002. Expression of extracellular matrix metalloproteinase 
inducer and enhancement of the production of matrix metalloproteinases in 
rheumatoid arthritis. Arthritis and rheumatism, 46, 373-8. 
TRUNEH, A., REDDY, M., RYAN, P., LYN, S. D., EICHMAN, C., COUEZ, D., 
HURLE, M. R., SEKALY, R. P., OLIVE, D. & SWEET, R. 1996. Differential 
recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 
(B7.2): analysis by site directed mutagenesis. Mol Immunol, 33, 321-34. 
TUMANOV, A., KUPRASH, D., LAGARKOVA, M., GRIVENNIKOV, S., ABE, K., 
SHAKHOV, A., DRUTSKAYA, L., STEWART, C., CHERVONSKY, A. & 
NEDOSPASOV, S. 2002. Distinct role of surface lymphotoxin expressed by B 
cells in the organization of secondary lymphoid tissues. Immunity, 17, 239-50. 
TUMANOV, A. V., KUPRASH, D. V., MACH, J. A., NEDOSPASOV, S. A. & 
CHERVONSKY, A. V. 2004. Lymphotoxin and TNF produced by B cells are 
dispensable for maintenance of the follicle-associated epithelium but are 
required for development of lymphoid follicles in the Peyer's patches. Journal 
of immunology, 173, 86-91. 
UHRIN, P., ZAUJEC, J., BREUSS, J. M., OLCAYDU, D., CHRENEK, P., 
STOCKINGER, H., FUERTBAUER, E., MOSER, M., HAIKO, P., FASSLER, 
R., ALITALO, K., BINDER, B. R. & KERJASCHKI, D. 2010. Novel function for 
blood platelets and podoplanin in developmental separation of blood and 
lymphatic circulation. Blood, 115, 3997-4005. 
VAN BERKEL, M. E. & OOSTERWEGEL, M. A. 2006. CD28 and ICOS: similar or 
separate costimulators of T cells? Immunology letters, 105, 115-22. 
VAN DAMME, J., STRUYF, S., WUYTS, A., VAN COILLIE, E., MENTEN, P., 
SCHOLS, D., SOZZANI, S., DE MEESTER, I. & PROOST, P. 1999. The role 
of CD26/DPP IV in chemokine processing. Chem Immunol, 72, 42-56. 
VINUESA, C. G., COOK, M. C., ANGELUCCI, C., ATHANASOPOULOS, V., RUI, L., 
HILL, K. M., YU, D., DOMASCHENZ, H., WHITTLE, B., LAMBE, T., 
ROBERTS, I. S., COPLEY, R. R., BELL, J. I., CORNALL, R. J. & 
GOODNOW, C. C. 2005. A RING-type ubiquitin ligase family member 
required to repress follicular helper T cells and autoimmunity. Nature, 435, 
452-8. 
VINUESA, C. G., SANZ, I. & COOK, M. C. 2009. Dysregulation of germinal centres in 
autoimmune disease. Nature reviews. Immunology, 9, 845-57. 
VITALI, C., BOMBARDIERI, S., JONSSON, R., MOUTSOPOULOS, H. M., 
ALEXANDER, E. L., CARSONS, S. E., DANIELS, T. E., FOX, P. C., FOX, R. 
I., KASSAN, S. S., PILLEMER, S. R., TALAL, N. & WEISMAN, M. H. 2002. 
Classification criteria for Sjogren's syndrome: a revised version of the 
195 
 
European criteria proposed by the American-European Consensus Group. 
Annals of the rheumatic diseases, 61, 554-8. 
VITALI, C., BOMBARDIERI, S., MOUTSOPOULOS, H. M., COLL, J., GERLI, R., 
HATRON, P. Y., KATER, L., KONTTINEN, Y. T., MANTHORPE, R., MEYER, 
O., MOSCA, M., OSTUNI, P., PELLERITO, R. A., PENNEC, Y., PORTER, S. 
R., RICHARDS, A., SAUVEZIE, B., SCHIODT, M., SCIUTO, M., 
SHOENFELD, Y., SKOPOULI, F. N., SMOLEN, J. S., SOROMENHO, F., 
TISHLER, M., WATTIAUX, M. J. & ET AL. 1996. Assessment of the 
European classification criteria for Sjogren's syndrome in a series of clinically 
defined cases: results of a prospective multicentre study. The European 
Study Group on Diagnostic Criteria for Sjogren's Syndrome. Annals of the 
rheumatic diseases, 55, 116-21. 
VON FREEDEN-JEFFRY, U., VIEIRA, P., LUCIAN, L. A., MCNEIL, T., BURDACH, 
S. E. & MURRAY, R. 1995. Lymphopenia in interleukin (IL)-7 gene-deleted 
mice identifies IL-7 as a nonredundant cytokine. J Exp Med, 181, 1519-26. 
VOULGARELIS, M., DAFNI, U. G., ISENBERG, D. A. & MOUTSOPOULOS, H. M. 
1999. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, 
retrospective, clinical study by the European Concerted Action on Sjogren's 
Syndrome. Arthritis and rheumatism, 42, 1765-72. 
VU, F., DIANZANI, U., WARE, C. F., MAK, T. & GOMMERMAN, J. L. 2008. ICOS, 
CD40, and lymphotoxin beta receptors signal sequentially and 
interdependently to initiate a germinal center reaction. J Immunol, 180, 2284-
93. 
WALDELE, S., KOERS-WUNRAU, C., BECKMANN, D., KORB-PAP, A., 
WEHMEYER, C., PAP, T. & DANKBAR, B. 2015. Deficiency of fibroblast 
activation protein alpha ameliorates cartilage destruction in inflammatory 
destructive arthritis. Arthritis Res Ther, 17, 12. 
WANG, X. M., YU, D. M., MCCAUGHAN, G. W. & GORRELL, M. D. 2005. Fibroblast 
activation protein increases apoptosis, cell adhesion, and migration by the 
LX-2 human stellate cell line. Hepatology, 42, 935-45. 
WARE, C. F., CROWE, P. D., GRAYSON, M. H., ANDROLEWICZ, M. J. & 
BROWNING, J. L. 1992. Expression of surface lymphotoxin and tumor 
necrosis factor on activated T, B, and natural killer cells. J Immunol, 149, 
3881-8. 
WARNATZ, K., BOSSALLER, L., SALZER, U., SKRABL-BAUMGARTNER, A., 
SCHWINGER, W., VAN DER BURG, M., VAN DONGEN, J. J., ORLOWSKA-
VOLK, M., KNOTH, R., DURANDY, A., DRAEGER, R., SCHLESIER, M., 
PETER, H. H. & GRIMBACHER, B. 2006. Human ICOS deficiency abrogates 
the germinal center reaction and provides a monogenic model for common 
variable immunodeficiency. Blood, 107, 3045-52. 
WATSON, S. P., HERBERT, J. M. & POLLITT, A. Y. 2010. GPVI and CLEC-2 in 
hemostasis and vascular integrity. Journal of thrombosis and haemostasis : 
JTH, 8, 1456-67. 
WELT, S., DIVGI, C. R., SCOTT, A. M., GARIN-CHESA, P., FINN, R. D., GRAHAM, 
M., CARSWELL, E. A., COHEN, A., LARSON, S. M., OLD, L. J. & ET AL. 
1994. Antibody targeting in metastatic colon cancer: a phase I study of 
monoclonal antibody F19 against a cell-surface protein of reactive tumor 
stromal fibroblasts. J Clin Oncol, 12, 1193-203. 
196 
 
WENGNER, A. M., HOPKEN, U. E., PETROW, P. K., HARTMANN, S., SCHURIGT, 
U., BRAUER, R. & LIPP, M. 2007. CXCR5- and CCR7-dependent lymphoid 
neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis 
Rheum, 56, 3271-83. 
WETTERWALD, A., HOFFSTETTER, W., CECCHINI, M. G., LANSKE, B., 
WAGNER, C., FLEISCH, H. & ATKINSON, M. 1996. Characterization and 
cloning of the E11 antigen, a marker expressed by rat osteoblasts and 
osteocytes. Bone, 18, 125-32. 
WEYAND, C. M. & GORONZY, J. J. 2003. Ectopic germinal center formation in 
rheumatoid synovitis. Ann N Y Acad Sci, 987, 140-9. 
WEYAND, C. M., KLIMIUK, P. A. & GORONZY, J. J. 1998. Heterogeneity of 
rheumatoid arthritis: from phenotypes to genotypes. Springer Semin 
Immunopathol, 20, 5-22. 
WHITE, A., CARRAGHER, D., PARNELL, S., MSAKI, A., PERKINS, N., LANE, P., 
JENKINSON, E., ANDERSON, G. & CAAMANO, J. H. 2007. Lymphotoxin a-
dependent and -independent signals regulate stromal organizer cell 
homeostasis during lymph node organogenesis. Blood, 110, 1950-9. 
WILDENBERG, M. E., VAN HELDEN-MEEUWSEN, C. G., VAN DE MERWE, J. P., 
DREXHAGE, H. A. & VERSNEL, M. A. 2008. Systemic increase in type I 
interferon activity in Sjogren's syndrome: a putative role for plasmacytoid 
dendritic cells. Eur J Immunol, 38, 2024-33. 
WILLIAMS, M. C., CAO, Y., HINDS, A., RISHI, A. K. & WETTERWALD, A. 1996. T1 
alpha protein is developmentally regulated and expressed by alveolar type I 
cells, choroid plexus, and ciliary epithelia of adult rats. Am J Respir Cell Mol 
Biol, 14, 577-85. 
WINTER, S., LODDENKEMPER, C., AEBISCHER, A., RABEL, K., HOFFMANN, K., 
MEYER, T. F., LIPP, M. & HOPKEN, U. E. 2010. The chemokine receptor 
CXCR5 is pivotal for ectopic mucosa-associated lymphoid tissue neogenesis 
in chronic Helicobacter pylori-induced inflammation. J Mol Med (Berl), 88, 
1169-80. 
WONG, S. C., OH, E., NG, C. H. & LAM, K. P. 2003. Impaired germinal center 
formation and recall T-cell-dependent immune responses in mice lacking the 
costimulatory ligand B7-H2. Blood, 102, 1381-8. 
WU, W. M., SUEN, J. L., LIN, B. F. & CHIANG, B. L. 2000. Tamoxifen alleviates 
disease severity and decreases double negative T cells in autoimmune MRL-
lpr/lpr mice. Immunology, 100, 110-8. 
YANG, C. Y., VOGT, T. K., FAVRE, S., SCARPELLINO, L., HUANG, H. Y., 
TACCHINI-COTTIER, F. & LUTHER, S. A. 2014. Trapping of naive 
lymphocytes triggers rapid growth and remodeling of the fibroblast network in 
reactive murine lymph nodes. Proc Natl Acad Sci U S A, 111, E109-18. 
YAZISIZ, V., BEHLUL, A., BASAK, S. T. & BORLU, F. 2013. Expression of 
podoplanin in minor salivary glands increases in primary Sjogren syndrome. J 
Rheumatol, 40, 2100-2. 
YOSHIDA, H., HONDA, K., SHINKURA, R., ADACHI, S., NISHIKAWA, S., MAKI, K., 
IKUTA, K. & NISHIKAWA, S. I. 1999. IL-7 receptor alpha+ CD3(-) cells in the 
embryonic intestine induces the organizing center of Peyer's patches. Int 
Immunol, 11, 643-55. 
YOSHINAGA, S. K., WHORISKEY, J. S., KHARE, S. D., SARMIENTO, U., GUO, J., 
HORAN, T., SHIH, G., ZHANG, M., COCCIA, M. A., KOHNO, T., TAFURI-
197 
 
BLADT, A., BRANKOW, D., CAMPBELL, P., CHANG, D., CHIU, L., DAI, T., 
DUNCAN, G., ELLIOTT, G. S., HUI, A., MCCABE, S. M., SCULLY, S., 
SHAHINIAN, A., SHAKLEE, C. L., VAN, G., MAK, T. W. & SENALDI, G. 
1999. T-cell co-stimulation through B7RP-1 and ICOS. Nature, 402, 827-32. 
YOSHINAGA, S. K., ZHANG, M., PISTILLO, J., HORAN, T., KHARE, S. D., MINER, 
K., SONNENBERG, M., BOONE, T., BRANKOW, D., DAI, T., DELANEY, J., 
HAN, H., HUI, A., KOHNO, T., MANOUKIAN, R., WHORISKEY, J. S. & 
COCCIA, M. A. 2000. Characterization of a new human B7-related protein: 
B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int Immunol, 12, 
1439-47. 
YU, D., TAN, A. H., HU, X., ATHANASOPOULOS, V., SIMPSON, N., SILVA, D. G., 
HUTLOFF, A., GILES, K. M., LEEDMAN, P. J., LAM, K. P., GOODNOW, C. 
C. & VINUESA, C. G. 2007. Roquin represses autoimmunity by limiting 
inducible T-cell co-stimulator messenger RNA. Nature, 450, 299-303. 
YUSUF, I., STERN, J., MCCAUGHTRY, T. M., GALLAGHER, S., SUN, H., GAO, C., 
TEDDER, T., CARLESSO, G., CARTER, L., HERBST, R. & WANG, Y. 2014. 
Germinal center B cell depletion diminishes CD4+ follicular T helper cells in 
autoimmune mice. PLoS One, 9, e102791. 
ZAMOYSKA, R., BASSON, A., FILBY, A., LEGNAME, G., LOVATT, M. & SEDDON, 
B. 2003. The influence of the src-family kinases, Lck and Fyn, on T cell 
differentiation, survival and activation. Immunol Rev, 191, 107-18. 
ZHANG, J., VALIANOU, M. & CHENG, J. D. 2010. Identification and characterization 
of the promoter of fibroblast activation protein. Front Biosci (Elite Ed), 2, 
1154-63. 
ZHENG, Y., CHAUDHRY, A., KAS, A., DEROOS, P., KIM, J. M., CHU, T. T., 
CORCORAN, L., TREUTING, P., KLEIN, U. & RUDENSKY, A. Y. 2009. 
Regulatory T-cell suppressor program co-opts transcription factor IRF4 to 
control T(H)2 responses. Nature, 458, 351-6. 
 
